


## **Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation**

A Boland  
Y Dunder  
A Bagust  
A Haycox  
R Hill  
R Mujica Mota  
T Valley  
R Dickson

**Health Technology Assessment  
NHS R&D HTA Programme**





**INAHTA**

### **How to obtain copies of this and other HTA Programme reports.**

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (<http://www.hta.ac.uk>). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

- fax (with **credit card** or **official purchase order**)
- post (with **credit card** or **official purchase order** or **cheque**)
- phone during office hours (**credit card** only).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

### **Contact details are as follows:**

HTA Despatch  
c/o Direct Mail Works Ltd  
4 Oakwood Business Centre  
Downley, HAVANT PO9 2NP, UK

Email: [orders@hta.ac.uk](mailto:orders@hta.ac.uk)  
Tel: 02392 492 000  
Fax: 02392 478 555  
Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

### **Payment methods**

#### *Paying by cheque*

If you pay by cheque, the cheque must be in **pounds sterling**, made payable to *Direct Mail Works Ltd* and drawn on a bank with a UK address.

#### *Paying by credit card*

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

#### *Paying by official purchase order*

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

### **How do I get a copy of HTA on CD?**

Please use the form on the HTA website ([www.hta.ac.uk/htacd.htm](http://www.hta.ac.uk/htacd.htm)). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

---

The website also provides information about the HTA Programme and lists the membership of the various committees.

# Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation

A Boland  
Y Dundar  
A Bagust  
A Haycox  
R Hill  
R Mujica Mota  
T Walley  
R Dickson\*

Liverpool Reviews and Implementation Group, New Medical School,  
Liverpool, UK

\* Corresponding author

**Declared competing interests of the authors:** none

Published April 2003

---

This report should be referenced as follows:

Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. *Health Technol Assess* 2003;**7**(15).

*Health Technology Assessment* is indexed in *Index Medicus/MEDLINE* and *Excerpta Medica/EMBASE*. Copies of the Executive Summaries are available from the NCCHTA website (see opposite).

# NHS R&D HTA Programme

The NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.

The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.

The research reported in this monograph was funded as project number 01/27/01.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.

## Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA Programme Director: Professor Kent Woods  
Series Editors: Professor Andrew Stevens, Dr Ken Stein, Professor John Gabbay,  
Dr Ruairidh Milne and Dr Chris Hyde  
Managing Editors: Sally Bailey and Sarah Llewellyn Lloyd

The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report.

ISSN 1366-5278

© Queen's Printer and Controller of HMSO 2003

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, University of Southampton, Southampton, SO16 7PX, UK.

Published by Core Research, Alton, on behalf of the NCCHTA.  
Printed on acid-free paper in the UK by The Basingstoke Press, Basingstoke.



# Contents

<b>Glossary and list of abbreviations</b> .....	i	<b>7 Discussion</b> .....	79
<b>Executive summary</b> .....	v	<b>8 Conclusions</b> .....	81
<b>1 Introduction</b> .....	1	Clinical effectiveness.....	81
Aim of the review .....	1	Economic evaluation .....	81
Background .....	1	Implementation .....	81
<b>2 Methods</b> .....	7	<b>Acknowledgements</b> .....	83
Methods for reviewing clinical effectiveness.....	7	<b>References</b> .....	85
Methods for reviewing cost-effectiveness ...	8	<b>Appendix 1</b> In-hospital thrombolysis assessment, Countess of Chester Hospital NHS Trust, 2001 .....	91
<b>3 Results: clinical effectiveness – hospital</b> ..	11	<b>Appendix 2</b> Pre-hospital thrombolysis assessment, East Midlands Ambulance Service NHS Trust.....	93
Selection and characteristics of included studies .....	11	<b>Appendix 3</b> Search for clinical studies .....	95
Analysis of results .....	19	<b>Appendix 4</b> Search strategy MEDLINE (1980–2001) .....	97
Discussion .....	26	<b>Appendix 5</b> Search strategy EMBASE (1980–2001) .....	99
Conclusions .....	32	<b>Appendix 6</b> Quality assessment checklist for clinical studies.....	101
<b>4 Results: clinical effectiveness – pre-hospital</b> .....	33	<b>Appendix 7</b> Search for cost-effectiveness studies .....	103
Included studies .....	33	<b>Appendix 8</b> Quality assessment checklist for cost-effectiveness studies .....	105
Characteristics of pre-hospital studies.....	33	<b>Appendix 9</b> Current contraindications to thrombolysis .....	107
Discussion .....	35	<b>Appendix 10</b> Derivation of ‘preferred method’ efficacy parameters .....	109
Conclusions .....	38	<b>Appendix 11</b> Supplementary references ..	113
<b>5 Results: economic analysis</b> .....	39	<b>Health Technology Assessment reports published to date</b> .....	127
Introduction .....	39	<b>Health Technology Assessment Programme</b> .....	133
Review of economic literature .....	39		
Detailed analysis of major sources of economic evidence .....	47		
Discussion of key issues highlighted by reviews of economic evidence .....	52		
Summary from review of economic evidence.....	52		
Critique and re-analysis of industry- submitted economic models .....	53		
Defining a preferred baseline .....	62		
Cost-effectiveness comparisons .....	63		
Conclusions .....	67		
<b>6 Implementation</b> .....	69		
Introduction .....	69		
Time to thrombolysis .....	69		
Choice of drug .....	70		
Models of care.....	72		
Costs associated with the implementation of early thrombolysis models of care.....	75		





## Glossary and list of abbreviations

Technical terms and abbreviations are used throughout this report. The meaning is usually clear from the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the literature, but the term has a constant meaning throughout this review.

### Glossary

**Arrhythmias** Irregular heart rhythms.

**Door-to-needle time** Time from arrival of patient in hospital to delivery of thrombolysis.

**Ejection fraction** The percentage of blood pumped out of the ventricle with each contraction.

**Haemorrhage** The escape of blood from the vessels, bleeding.

**Ischaemia** Lack of oxygen (usually from blockage of blood vessel).

**Infarct** Death of tissue due to ischaemia.

**Killip class** Classification of severity of heart failure.

**Recanalisation** Joining of capillaries within a thrombus establishing a way for blood to traverse the thrombus.

**Reinfarction** Any new myocardial infarction occurring after the index infarct, irrespective of the mechanism and location of infarction.

**Reperfusion** The restoration of blood flow in a blocked artery.

**Thrombosis** Process of clotting.

**Thrombus** Blood clot.

**Time to treatment** Time from onset of symptoms of acute myocardial infarction (AMI) until delivery of thrombolysis.

**TIMI flow rate** A measure of coronary blood flow.



**List of abbreviations**

A&E	Accident and Emergency	FDA	Food and Drug Administration, US Department of Health and Human Services
ACCP	American College of Chest Physicians	FTT	Fibrinolytic Therapy Trialists
Acct-PA	accelerated alteplase	GISSI-2	Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico
AMI	acute myocardial infarction	GP	general practitioner
APPT	activated partial thromboplastin time	GRACE	Global Registry of Acute Coronary Events
APSAC	anisoylated plasminogen streptokinase activator complex	GREAT	Grampian Region Early Anistreplase Trial
ASSENT	Assessment of the Safety of a New Thrombolytic	GUSTO	Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
<i>BNF</i>	<i>British National Formulary</i>	i.c.	intracoronary
BP	blood pressure	ICER	incremental cost-effectiveness ratio
CCU	coronary care unit	INJECT	International Joint Efficacy Comparison for Thrombolytics
C-E	cost-effectiveness	ISG	International Study Group
CEEU	Clinical Effectiveness and Evaluation Unit (Royal College of Physicians and British Cardiac Society)	ISIS	International Study of Infarct Survival
CHD	coronary heart disease	ITT	intention-to-treat
CHF	congestive heart failure	i.v.	intravenous
CI	confidence interval	IU	international unit
CNS	central nervous system	JRCALC	Joint Royal Colleges Ambulance Liaison Committee
COBALT	Continuous Infusion versus Double-Bolus Administration of Alteplase	KAMIT	Kentucky Acute Myocardial Infarction Trial
DARE	Database of Abstracts of Reviews of Effectiveness	LVF	left ventricular function
df	degrees of freedom	MI	myocardial infarction
ECG	electrocardiogram	MINAP	Myocardial Infarction National Audit Project
ECSG	European Cooperative Study Group	MITI	Myocardial Infarction Triage and Intervention trial
EMIP	European Myocardial Infarction Project	NA	not available

*continued*



**List of abbreviations contd**

na	not applicable	RAPID-1	Reteplase Angiographic Phase II International Dose-Finding trial
NAOMI	National Audit of Myocardial Infarction	RAPID-2	Reteplase versus Alteplase Patency Investigation during Myocardial Infarction trial
NHS CRD	NHS Centre for Reviews and Dissemination	RCT	randomised controlled trial
NHS EED	NHS Economic Evaluation Database	r-PA	reteplase: recombinant plasminogen activator
NICE	National Institute for Clinical Excellence	QALY	quality-adjusted life-year
NS	not significant	SA	sensitivity analysis
ns	not stated	s.c.	subcutaneous
NSF	National Service Framework	SD	standard deviation
OR	odds ratio	SK	streptokinase
OXMIS	Oxford Myocardial Infarction Incidence Study	TIMI	Thrombolysis in Myocardial Infarction
PAIMS	Plasminogen Activator Italian Multicentre Study	TNK	tenecteplase
RAAMI	Randomised Angiographic trial of recombinant tissue-type plasminogen Activator (alteplase) in Myocardial Infarction	t-PA/rt-PA	alteplase: tissue plasminogen activator/recombinant tissue plasminogen activator
		U	unit

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.





## Executive summary

### Background

Coronary heart disease (CHD) is a major cause of morbidity and mortality in the UK accounting for around 125,000 deaths a year. Acute myocardial infarction (AMI) affects an estimated 274,000 people each year. Of these, approximately 50% (137,000) die within 30 days of AMI and over half these deaths occur prior to reaching hospital or other medical assistance.

The development and introduction of new pharmacological agents has made it necessary to review the clinical and cost-effectiveness of older and newer agents used for early thrombolysis. Those reviewed in this document include streptokinase, alteplase, reteplase and tenecteplase.

### Objectives

To examine the clinical and cost-effectiveness of available drugs for early thrombolysis in the treatment of AMI in hospital and pre-hospital settings.

### Methods

The search incorporated a number of strategies for clinical effectiveness and economic evaluation. The search strategy covered the period from 1980 to 2001 and included the following electronic databases: MEDLINE, EMBASE, Science Citation Index/Web of Science, Cochrane Trials Register, NHS Centre for Reviews and Dissemination Health Technology Assessment (NHS CRD HTA), Database of Abstracts of Reviews of Effectiveness (DARE) and NHS Economic Evaluation Database (NHS EED). Search terms included were **myocardial infarction/heart infarction** combined with specific drug terms including **alteplase, reteplase, streptokinase, tenecteplase, anistreplase** and **urokinase**. Reference lists of included studies and pharmaceutical company submissions to the National Institute for Clinical Excellence (NICE) were searched to identify other relevant studies.

In addition, a number of medical journals were handsearched to identify any newly published papers that might not yet have been indexed in electronic databases.

### Study selection

Randomised controlled trials (RCTs) that included comparison of the specified drugs (alteplase, reteplase, streptokinase and tenecteplase) in the early stages of AMI delivered in the pre-hospital or hospital setting were included in the review. Studies that examined the use of anistreplase or urokinase were identified but not included in the analysis. Data on the following outcome measures were included in the review: mortality, bleeding, stroke, reinfarction, allergy and anaphylaxis.

Economic evaluation included studies reporting efficacy data primarily based on drug versus drug randomised controlled clinical evidence, explicit synthesis of costs and outcomes in a cost-effectiveness ratio, full economic evaluation.

### Quality assessment

The methodological quality of studies for clinical effectiveness was assessed using the criteria based on the NHS CRD Report No. 4 (University of York, 1996).

The quality of cost-effectiveness was assessed using a checklist updated from that produced by Drummond and colleagues.\*

## Results

### Clinical effectiveness

#### *Hospital*

A total of 162 references were identified to which the inclusion criteria were applied. Of these, 20 studies reported in 50 articles fulfilled the inclusion criteria. These included 14 comparative studies involving a total study population of 142,907 patients. Data from two studies were combined in the study reports and this combination of data is maintained in the review.

\* Drummond M, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications; 1987.

Definitive conclusions on efficacy (30–35-day mortality) are that streptokinase is as effective as non-accelerated alteplase, that tenecteplase is as effective as accelerated alteplase, and that reteplase is at least as effective as streptokinase.

Some conclusions require interpretation of data, i.e. whether streptokinase is as effective as, or inferior to accelerated alteplase; and whether reteplase is as effective as accelerated alteplase or not.

Depending on these, two further conclusions on indirect comparisons arise, whether tenecteplase is superior to streptokinase or not, and whether reteplase is as effective as tenecteplase or not.

That these questions remain to be resolved illustrates that any differences in mortality between drugs is small.

There seem to be significant differences between drugs in incidence of stroke, with streptokinase having the lowest rate.

Streptokinase causes more allergic reactions than other drugs.

### **Pre-hospital**

The search failed to identify any studies conducted in the pre-hospital setting that compared the effectiveness of different drugs. There is no reason to believe that the effectiveness of a drug will be altered by administration in the pre-hospital setting.

Nine RCTs that examined the efficacy and safety of pre-hospital thrombolysis were identified and are discussed. The required use of heparin with either of the bolus products does not seem to provide any practical barrier to their widespread use.

### **Cost-effectiveness and modelling**

A detailed review of the economic literature was undertaken. Of the 107 articles assessed, only eight met the quality criteria that led them to be evaluated in detail. The general quality of economic analyses undertaken in this area was disappointing and largely focused on evaluating cost-effectiveness in healthcare environments outside the NHS.

A critique and re-analysis were also undertaken of the two detailed economic models contained in the industry submissions to NICE. Both models

were rerun using the assumptions contained in the competitor model. In addition, they were re-analysed using a preferred set of coefficients that reflected, as far as possible, the weight of the available evidence.

Variations in quality-adjusted life-years (QALYs) gained between the individual drugs were small. Supposed advantages presented in the industry submissions to NICE largely related to comparatively minor variations in efficacy or minor improvements in aspects of the side-effect profile associated with each individual drug. Streptokinase was clearly the most cost-effective drug and other drugs were compared to it. Costs per QALY for newer drugs compared to streptokinase ranged up to £17,000. Given the similarity in outcome, cost-effectiveness becomes largely determined by the acquisition costs of the drug. This conclusion was robust to a range of variations in assumptions. In contrast to this robust conclusion, differences between alteplase, tenecteplase and reteplase were small and their relative ranking in cost-effectiveness changed according to the assumptions used.

### **Implementation**

There are substantial opportunities for refining hospital thrombolysis procedures to meet National Service Framework (NSF) targets. Changing drugs is a very minor element in achieving improved door-to-needle time.

Pre-hospital thrombolysis will be necessary in some areas to allow NSF targets to be met. The choice of drug for pre-hospital thrombolysis is determined by acquisition cost and by convenience. Our experts did not wish to consider the use of infusion products (e.g. alteplase or streptokinase) but preferred bolus administration (reteplase and tenecteplase).

The cost-impact of switching to the more expensive bolus drugs could be as much as £50 million per year, over and above existing costs of approximately £30–40 million for the NHS in England and Wales.

## **Conclusions**

### **Clinical effectiveness**

The decision regarding which agent to use is therefore a balance of the risks and benefits related to mortality and stroke. No clear conclusion, based on statistical comparison, can be drawn.

### **Economic evaluation**

Given the similarity in outcome, cost-effectiveness becomes largely determined by the acquisition

costs of the drug. This conclusion was robust to a range of variations in assumptions. Streptokinase was therefore the most cost-effective drug.



# Chapter 1

## Introduction

### Aim of the review

The aim of the review was to examine the comparative clinical and cost effectiveness of available drugs for early thrombolysis in the treatment of acute myocardial infarction (AMI) in hospital and pre-hospital settings.

### Background

#### Description of underlying health problem

Coronary heart disease (CHD) is a major cause of morbidity and mortality in the UK accounting for more than 125,000 deaths per year.<sup>1</sup> Although rates of CHD have been decreasing over the past three decades, this has not been consistent across age groups, gender or socio-economic class. A more rapid reduction has been seen in younger age groups (45–54 years), in men and in higher socio-economic groups. In addition, the rate of decline in the UK has been slower than that in other developed countries (e.g. Denmark, Norway, Australia).<sup>1</sup>

CHD is usually due to atherosclerotic narrowing of the coronary arteries supplying the muscle of the heart (the myocardium). It may be silent or manifest itself as angina pectoris (typically chest pain on exertion, when the myocardial oxygen demands rise above the ability of the narrowed arteries to deliver). Its first presentation can be an AMI. AMI is the result of a thrombus or clot forming on top of a ruptured atherosclerotic plaque, blocking the blood flow through the artery. Unless the blood flow can be quickly restored, the muscle supplied by that artery ‘infarcts’, or dies because of lack of oxygen (ischaemia). This muscle damage weakens the heart, and may cause heart failure either early (within a matter of hours) or later (over a period of months or years). It may also lead to other events such as fatal heart rhythm disturbances and death.

Typical symptoms of AMI include chest pain (often described as crushing), pallor and shortness of breath. Pain is often severe enough for the sufferer to seek help. Older patients or diabetics

may experience atypical symptoms and relatively little or less severe pain.<sup>2</sup>

In the UK, AMI affects an estimated 274,000 people each year (237,000 in England and Wales). Of these, approximately 50% (137,000) die within 30 days of AMI and over half of these deaths occur prior to the patient reaching hospital or other medical assistance. Onset of symptoms of AMI is usually sudden and the highest risk of death is within the first hour of experiencing an AMI. International data show a 28-day case fatality rate for all AMI of about 50% and about a third of patients experiencing AMI die within the first hour of the onset of their symptoms.<sup>3,4</sup>

The Oxford Myocardial Infarction Incidence Study (OXMIS) has provided an analysis of fatality rates (at one month) for all cases, hospitalised cases and sudden death (i.e. ‘coronary deaths before patient was seen by a doctor’).<sup>5</sup> For males, ‘all cases’ fatality rates were 41 per 100,000, ‘hospitalised cases’ 15, and ‘sudden death’ 27. For females, the corresponding figures were 44, 22 and 26. The OXMIS survey also indicated an incidence:mortality ratio of 2.43:1 in males and 2.14:1 in females when mortality is defined by non-survival to 28 days. The British Heart Foundation summary indicates that of those dying within 28 days, three-quarters die within 24 hours. The British Regional Heart Study data checked on 198 persons who had heart attacks between 1978 and 1985 but survived 28 days. Of these, 77% survived 5 years and 63% 10 years (controls surviving 96% and 91% over the same period).<sup>6</sup> Approximately one-third of all AMIs remain clinically unrecognised at the time of the acute event.<sup>7</sup>

#### Diagnosis

According to the WHO, the diagnosis of AMI requires that at least two of the following three criteria be met:

- a clinical history of ischaemic-type chest discomfort
- changes on repeated electrocardiogram (ECG) tracings usually over 2–3 days
- a rise and fall in serum cardiac markers (typically over 1–2 days but new sensitive markers may allow a diagnosis within 6–12 hours).

However, these criteria may not be suitable for the diagnosis of AMI, within the first 6 hours when interventions to restore blood flow, such as drugs to dissolve the thrombus, may be of most value. Changes in ECG readings are useful in the diagnosis of AMI and ST segment elevation is very specific in identifying patients requiring reperfusion therapy. These changes may occur in the 'anterior' ECG leads (generally indicating an occlusion in the left coronary artery, the main supply to the myocardium, and hence affecting more myocardium with a worse prognosis), or in the 'inferior' (generally implying a smaller infarct with a better outlook, possibly due to obstruction in the right coronary artery or some smaller branches of the left artery) ECG leads. However, as many as 50% of patients with AMI may not exhibit ST elevation in the early stages<sup>2</sup> and assessment of change in ST abnormalities has been proposed as a more sensitive diagnostic marker. Changes in traditional serum cardiac markers also often occur too slowly to be of immediate value. Newer, more rapidly available tests are being evaluated.

Current practice for early identification of patients experiencing an AMI, and who might benefit from reperfusion therapy, therefore includes a combination of clinical symptoms and ECG changes. Serial ECG changes are monitored if initial readings appear normal but clinical symptoms persist or become worse. Serial readings may also be needed if initial readings are abnormal but not diagnostic of AMI.

### **Treatment**

Medical care for patients experiencing AMI has changed over the past 40 years. Care in the 1960s and 1970s focused on the treatment of life-threatening arrhythmias. This included the development of specialist coronary care units (CCUs) to monitor these patients. The 1980s saw the conduction of large clinical trials to assess the effectiveness of drugs that broke down the clot causing the infarct (thrombolysis).

If the clot blocking the artery can be dissolved, then the ischaemic tissue can be reperfused and death of muscle (infarct) avoided. The earlier this can be done, the more muscle can be salvaged. Reperfusion can be achieved by mechanical means (physically disrupting the clot) or by chemical means, by using drugs which hasten the dissolution of the clot. If reperfusion is delayed, then the muscle will infarct and die before it can be reperfused. The time without reperfusion to cause infarction can be as little as 1 hour, but

there is still benefit from reperfusion therapy for up to at least 12 hours, decreasing as time goes by.

The first reports of the use of thrombolysis in AMI (e.g. with streptokinase) appeared in the late 1950s. However, the first meta-analysis of studies comparing the use of thrombolysis to placebo and indicating its positive impact on mortality was not published until 1985.<sup>8</sup> This analysis indicated the highly significant 22% ( $\pm$  5%) reduction in odds of death. In addition it revealed somewhat larger decreases in reinfarction rates and only small numbers of adverse events.

Clinical practice in the use of these drugs did not change until the results of some key large studies were published in the late 1980s.<sup>9,10</sup> These trials showed a reduction in 30-day mortality of around 20%, which was a decrease in actual mortality rates from 10% to 8%. This is lower than the 25% case fatality rate typically reported around this time, and reflected perhaps the effects of selection criteria for the clinical trials. Nevertheless, this was a considerable improvement in outcome, and thrombolytic therapy for patients seen within 12 hours of onset of AMI became the expected standard of care.

Some adjunctive therapies are also beneficial, in particular the antiplatelet agent aspirin. The Second International Study of Infarct Survival (ISIS-2)<sup>10</sup> showed a reduction in mortality of around 3% in patients treated with streptokinase alone, but of 6% in those treated with both streptokinase and aspirin. Other studies and meta-analyses have confirmed the benefits of aspirin,<sup>11,12</sup> which has become standard recommended therapy. Studies of other antiplatelet agents are ongoing and suggest a cumulative benefit with that of aspirin in certain settings.

Treatment regimes for patients experiencing AMI have been presented in evidence-based clinical guidelines established through a combination of professional and voluntary bodies.<sup>2,3,13,14</sup> Not all patients are suitable for thrombolytic treatment. In the first instance, delay on the part of the patient following the onset of symptoms may mean that they are not eligible for treatment. Even patients seeking help early may not be suitable for treatment. The increased risk of bleeding means that all patients need to be screened. Appendices 1 and 2 include current criteria used in this screening process. However, even those appropriately screened who receive treatment may bleed. One of the most severe bleeds can be



within the brain perhaps causing a catastrophic intracranial haemorrhage. Thrombolysis is therefore a balance of the benefits and risks, each of which must be carefully weighed.

### Description of new intervention

The list of thrombolytic agents licensed for use in the UK, their method of administration and listed costs are presented in *Table 1*. Two other

drugs, not available in the UK, are also described. Some key clinical features of these drugs are described here<sup>13</sup> but differences in their *in vitro* clot specificity are omitted. These drugs activate plasminogen, a naturally occurring protein in the blood, to form plasmin, which breaks down fibrin. Fibrin is a key structural protein in a thrombus and hence the drugs 'dissolve' the clot. All of these drugs are delivered intravenously.

**TABLE 1** Characteristics of drugs included in the review

Generic name	Proprietary name	Supplier	Dosage	Adminis- tration	Heparin dose <sup>17-20</sup>	Approximate cost* (£)
Alteplase (t-PA), or recombinant tissue plasminogen activator (rt-PA)	Actilyse <sup>®</sup>	Boehringer Ingelheim, Bracknell, UK	<b>Standard:</b> 100 mg over 3 h (10 mg i.v. followed by 50 mg over 60 minutes then 4 infusions of 10 mg over 30 minutes)  <b>Accelerated:</b> 15 mg bolus 50 mg over 30 minutes 35 mg over 60 minutes	i.v. bolus/ infusion	5000 U bolus followed by 1000 U/h	600
Retepase (r-PA)	Rapilysin <sup>®</sup>	Roche Products Ltd., Welwyn Garden City, UK	10 U followed by further 10 U in 30 minutes	i.v. bolus	5000 U bolus followed by 1000 U/h	720
Streptokinase (SK)	Streptase <sup>®</sup>	Aventis Behring, Haywards Heath, UK	1.5 x 10 <sup>6</sup> U over 60 minutes	i.v. infusion	5000 U bolus followed by 1000 U/h	80–85
	Kabikinase <sup>®</sup> (no longer produced)	Pharmacia Ltd., Milton Keynes, UK			12500 U s.c. twice daily	
Tenecteplase (TNK) TNK-tPA	Non-proprietary (to be withdrawn) Metalyse <sup>®</sup>	B. Braun, Sheffield, UK Boehringer Ingleheim	30–50 mg over 10 s	i.v. bolus	5000 U bolus followed by 1000 U/h	700–800
<b>Agents no longer available</b>						
Anistreplase, anisoylated plasminogen streptokinase activator complex (APSAC)	na	na	30 U	i.v. bolus		495 (1995)
Urokinase	na	na	2.0 x 10 <sup>6</sup> U	i.v. bolus		460 (1995)

\* Based on list prices stated in the British National Formulary<sup>21</sup>

**Streptokinase**

This was the first widely used fibrinolytic agent. It has a short half-life and is delivered in a continuous infusion over 1 hour. It is derived from group A streptococci. Patients may have antibodies to these common microorganisms or may develop antibodies following administration of this agent. If a patient has antibodies, they are at increased risk of an allergic reaction (including the most severe form, anaphylaxis) to streptokinase. Alternatively the presence of antibodies may diminish the thrombolytic effect of streptokinase. These effects mean that streptokinase is used only once in any given patient, and repeated administration is discouraged. In some areas, up to 50% of patients presenting with AMI have already received streptokinase once and are therefore not suitable for this drug.

**Alteplase**

Alteplase is essentially the same as the naturally occurring activator of plasminogen (t-PA) in the human body, produced by recombinant DNA technology (rt-PA). As a human product, it does not cause antibody formation and is therefore less far less likely than streptokinase to cause allergic reactions. It can also be administered on more than one occasion. Initially it was delivered in an infusion over 3 hours. Further investigation suggested that it might be more effective when delivered in what has come to be known as an accelerated manner, which includes a bolus dose, followed by infusion over 90 minutes.<sup>15,16</sup> This is the currently recommended treatment protocol.

**Retepase**

This is a more recent drug, a recombinant plasminogen activator (r-PA) similar to alteplase, but with a prolonged half-life. It is delivered through two intravenous bolus injections 30 minutes apart.

**Tenecteplase**

This drug is newly available in the UK. It is also a recombinant plasminogen activator similar to alteplase but with a prolonged half-life, increased fibrin specificity and increased resistance to inhibition by plasminogen activator inhibitors. Administration is through a single intravenous bolus injection. Tenecteplase is currently listed as a black triangle drug indicating that the Committee on Safety of Medicines is monitoring it to assess the frequency of adverse reactions.

**Anistreplase**

This drug was a derivative of streptokinase that could be administered as a single bolus injection

instead of an infusion. This made it acceptable in particular for pre-hospital thrombolysis. The drug is no longer available in the UK since sales were inadequate to justify its continued manufacture.

**Urokinase**

This drug was similar to alteplase but had been subjected to less evaluation. Its manufacture was also abandoned for commercial reasons.

All these currently available drugs are administered with aspirin and with heparin, as shown in *Table 1*. Although it is not within the remit of this review to assess the effectiveness of heparin therapy, it will be discussed briefly later.

These drugs may differ in their beneficial and in their adverse effects, and the benefits and risks have to be considered in each patient. There are guidelines for the identification of the appropriate population of patients to receive treatment.<sup>2,13,14,22</sup> These guidelines have been transferred into checklists to be used to screen patients prior to administration of treatment. Examples of such lists for use in the hospital and pre-hospital setting are presented in appendices 1 and 2.

**Current service provision**

The exact number of patients treated with thrombolysis in England and Wales is uncertain: the number is probably between 80,000 and 100,000 per year, at a current cost of around £35 million (see chapter 6). Although thrombolysis is standard treatment for patients presenting with AMI in the NHS, there is evidence that many patients are receiving suboptimal therapy with variation in the delivery of thrombolysis treatment in hospital settings in the UK. In relation to the use of thrombolysis, data from 39 UK hospitals (1992–95) revealed that a range of 49–85% of patients with a confirmed diagnosis of AMI received thrombolysis.<sup>23</sup> In relation to timing of treatment, survey data from three British health districts in 1994–95 indicated that 2% of patients had received thrombolysis within 60 minutes of presentation while 25% received treatment within 2 hours.<sup>24,25</sup>

Thrombolysis is almost always delivered to patients after arriving in hospital, possibly losing valuable time (and hence heart muscle). Meta-analysis of trials has shown that early thrombolysis is more effective and that the treatment is of limited value once irreversible myocardial damage has occurred.<sup>26–28</sup> Advances in the speed of action and ease of administration of newer drugs combined with recognition of improved outcomes with

earlier administration, have prompted further attempts to decrease the time from symptom onset to treatment delivery.

The period of greatest risk for patients experiencing AMI is in the first few hours after onset of symptoms and delays in this time period are a result of a number of factors.<sup>29</sup> The major delay is in patients seeking help. However other delays occur after this and require attention. Directions to address this in England are outlined in the National Service Framework (NSF) for Coronary Heart Disease<sup>30</sup> and the NHS Plan.<sup>31</sup> Specifically, in the NSF, standards five and six, stipulate that:

“People with symptoms of a possible heart attack should receive help from an individual equipped with and appropriately trained in the use of a defibrillator within eight minutes of calling for help, to maximise the benefits of resuscitation should it be necessary and...people thought to be suffering from heart attack should be assessed professionally and, if indicated, receive aspirin. Thrombolysis should be given within 60 minutes of calling for professional help.”

There has been recognition that a goal of providing thrombolysis within this 60 minute time window may be difficult when transport distances (or times) are long. To address this issue the NSF states:

“...usually hospital will be the best place to give thrombolysis. However, where the ‘call to hospital’ time cannot be reduced below 30 minutes, it may be more appropriate to plan to give thrombolysis before admission to hospital.”

The NHS Plan therefore has stipulated that:

“There will be a 3 year programme to train and equip ambulance paramedics to provide thrombolysis an hour sooner than if they were taken to hospital first, saving up to 3000 lives a year once fully implemented.”

The implementation of these standards of care requires the assessment of current service provision by both hospitals and ambulance services. It requires an assessment of patient populations, geography, transport times, pre-hospital service equipment and expertise and in-hospital services for the delivery of thrombolysis.

#### **The Myocardial Infarction National Audit Project and hospital care**

The establishment of the NSF prompted the Royal College of Physicians to develop the Myocardial Infarction National Audit Project

(MINAP) in late 1998.<sup>32</sup> This is a joint project of the Clinical Effectiveness and Evaluation Unit (CEEU) of the Royal College of Physicians and the British Cardiac Society. The working group overseeing this project has been tasked with:

“developing a mechanism that would allow clinicians to examine the management of myocardial infarction within their hospitals in order to meet the standards specified by the National Service Framework for Coronary Heart Disease”.

The MINAP project aims to have all hospitals in England and Wales collecting data by 2002.<sup>33</sup> By the end of 2001, 70% of hospitals had begun transmitting data to the project.

The core data set of the MINAP project comprises all aspects of “the process and outcome of the management of patients admitted to hospital with myocardial infarction”. However, those aspects related to early thrombolysis include demography, delay to treatment, cardiac arrest and resuscitation, and thrombolytic and anti-thrombotic therapy. The data collection method was pilot-tested in nine sites in 2000.<sup>34</sup> Initial data quality assessment from ten hospitals is now available.<sup>33</sup>

#### **Variation in service**

Initial work of the CEEU also included a baseline survey of UK facilities that provide care to patients with AMI.<sup>35</sup> Ninety-seven per cent of hospitals had a written policy regarding the use of thrombolysis. The location of delivery of treatment varied. Approximately 25% of 211 hospitals had a fast-track system to transfer patients from Accident and Emergency (A&E) to the CCU to receive treatment. Over half provided treatment primarily in the A&E department, transferring patients to the CCU, while half of all hospitals had a mechanism whereby AMI patients could be admitted directly to the CCU without assessment anywhere else in the hospital. In those hospitals that provided thrombolysis in the A&E department, 16% used the services of specially trained nurses.

#### **Drug choice in thrombolysis**

Accurate cumulative reports of the proportion of patients receiving various agents in the UK and Wales do not exist. As mentioned previously, the work by the Royal College of Physicians<sup>35</sup> identified that almost all hospitals have a written policy regarding the use of thrombolysis. Overall, 82% stated that streptokinase was used for eligible patients experiencing their first AMI. However,

additional data indicated that approximately half of the hospitals recommend the use of alteplase for younger patients. Almost 60% of hospitals indicated that their choice of drug was limited by cost. Data in pharmaceutical company submissions to the National Institute for Clinical Excellence (NICE) suggested that in the NHS, streptokinase was used in 55% of thrombolysis episodes, alteplase in 33% and reteplase in 11%.

### **Pre-hospital care in AMI**

At present, pre-hospital care is often limited to getting the patient quickly to hospital. The Department of Health Emergency Services Report for 2000–2001<sup>36</sup> indicates that there is a variation in the ability of the ambulance services to meet the NSF standards. Although performance is improving, this report indicates that only three services responded to 75% of category A (immediately life-threatening, including probable AMI) calls within 8 minutes.

Pre-hospital thrombolysis may increasingly be provided where NSF targets on speed of thrombolysis cannot be met using only hospital administration. It is currently available in two (out of 30) ambulance trusts in England (East Midlands and Staffordshire).<sup>37,38</sup> The 2001 report of NHS Wales includes mention of provision of aspirin to patients with AMI by members of the ambulance service but makes no mention of the delivery of pre-hospital thrombolysis.<sup>39</sup>

A recent survey conducted in 2001 by the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) indicates that a number of other ambulance trusts are considering implementing pre-hospital thrombolysis. A larger group indicated

that they would be moving towards paramedics performing ECGs, and transmission of this data to alert receiving hospitals and reduce delay after arrival at hospital (Chamberlain D, JRCALC: personal communication, 2002). This is consistent with other information provided to the review group regarding implementation of independent projects in eight different ambulance trusts. The aim of these projects will be to reduce time to thrombolysis through the transmission of preadmission ECG data (Quinn T, Cardiac Care Advisor, University of Coventry: personal communication, 2002). Draft reports and presentation of the findings of these projects are beginning to appear.<sup>40</sup>

### **Summary**

The primary purpose of this review is to examine the effectiveness and cost-effectiveness of various drugs used in early thrombolysis for AMI. It therefore includes evaluation of the clinical studies of drug-effectiveness and the evaluation of existing economic evaluations. It goes on to present the results of the analysis of the economic models submitted to NICE.

The economic conclusions are based on an assumption that the clinical environment (hospital and pre-hospital) is currently able to provide appropriate treatment. This of course is not the case. Hospital care currently includes thrombolytic treatment but treatment times are not optimal and variations in provision exist. Provision of pre-hospital care in the UK is limited. Although outside the remit of this review, the authors provide a discussion regarding the factors influential in the implementation of appropriate treatment.

# Chapter 2

## Methods

### Methods for reviewing clinical effectiveness

#### Search strategy

The search incorporated a number of strategies. Search terms for electronic databases included were: **myocardial infarction**, **heart infarction** and **thrombolysis** combined with specific drug terms (e.g. **alteplase** (t-PA), **reteplase**, **streptokinase**, **tenecteplase**, **anistreplase** and **urokinase**)

Electronic searches included the following databases:

- MEDLINE (1980–2001)
- EMBASE (1980–2001)
- Science Citation Index/Web of Science (1988–2001)
- Cochrane Trials Register (2001, Issue 4)
- NHS Centre for Reviews and Dissemination Health Technology Assessment (NHS CRD HTA) (1992–2001)
- Database of Abstracts of Reviews of Effectiveness (DARE) (1982–2001).

Specific search strategies and the number of references retrieved for each search are provided in appendices 3, 4 and 5.

Searching was limited to English language reports.

Reference lists of included studies and pharmaceutical company submissions to NICE were searched to identify other relevant studies. In addition, handsearching of *American Heart Journal*, *Circulation*, *American Journal of Cardiology*, *British Medical Journal*, *Circulation*, *European Heart Journal*, *Heart*, *Emergency Medicine Journal*, *International Journal of Cardiology*, *Journal of the American College of Cardiology*, *Journal of the American Medical Association*, *Lancet*, *New England Journal of Medicine* and *Stroke* was carried out for the period from January 2001 to January 2002 to identify any newly published papers that might not yet have been indexed in electronic databases.

All the references were exported to Endnote reference database, ISI Research Soft, CA, USA, version 5.

#### Inclusion criteria

The identified citations were assessed for inclusion through two stages and disagreements were settled by discussion at each stage. Two reviewers independently scanned all the titles and abstracts and identified the potentially relevant articles to be retrieved (YD, ABol). Full text copies of the selected papers were obtained and assessed independently by two reviewers for inclusion (YD, RD). Studies were considered eligible for inclusion if they met the following criteria:

#### Study design

Randomised controlled trials (RCTs) that included comparison of included drugs and any or all of the listed outcomes.

#### Interventions

Comparison of currently available intravenous thrombolytic therapies administered in the early stages of AMI in the hospital or pre-hospital setting. Drugs included in the review were: alteplase, reteplase, streptokinase and tenecteplase. Studies that examined the use of anistreplase (not currently available) or urokinase (not currently licensed for use in thrombolysis in the UK) were also identified and used to inform the background of the review but were not included in the analysis.

#### Participants

Patients with recent onset AMI without contraindications to thrombolytic therapy; diagnosis of AMI was made through clinical assessment or ECG.

#### Outcomes

Data on the following outcome measures were included:

- mortality
- patency of coronary arteries
- left ventricular function
- stroke
- reinfarction
- bleeding
- allergy
- anaphylaxis.

## Data extraction

### Hospital

Data extraction was carried out by three reviewers (YD, RD, RH). Data were independently extracted by one reviewer and checked by a second into a pre-designed data extraction form. Data from multiple reports of single trials were extracted onto a single data extraction form.

### Pre-hospital

Data for information tables were extracted by one reviewer (RD) and checked by a second (YD).

## Quality assessment

### Hospital

Three reviewers (YD, RD, RH) independently evaluated the included primary studies for methodological quality. This involved methodological assessment for clinical effectiveness based on the NHS CRD, York, Report No. 4<sup>41</sup> (see appendix 6). Any discrepancies were resolved through consensus.

### Pre-hospital

Since no studies comparing drugs used in the pre-hospital setting were identified, there were no studies to be assessed. Descriptive comment is provided regarding trials that evaluated pre-hospital care.

## Methods for reviewing cost-effectiveness

### Search strategy

The following databases were searched for English language papers:

- MEDLINE (1985–2001)
- EMBASE (1988–2001)
- NHS Economic Evaluation Database (NHS EED) (1995–2001)
- DARE (1995–2001)
- Science Citation Index/Web of Science (1984–2001)
- Cochrane Trials Register (2001, Issue 3)
- NHS CRD HTA (1995–2001).

Search strategies and results of the searches undertaken are presented in appendix 7.

### Inclusion and exclusion criteria

Using explicit, predetermined criteria, two reviewers (ABol, AH) independently identified studies for inclusion in the cost-effectiveness review process. Decisions were compared. Where there was disagreement, both reviewers discussed the

paper together and a final decision was made. The inclusion and exclusion criteria used in the review are presented below.

### Inclusion criteria

- active comparator (streptokinase, alteplase, reteplase or tenecteplase)
- efficacy data primarily based on published drug versus drug RCT evidence
- explicit synthesis of costs and outcomes in a cost-effectiveness ratio
- full economic evaluation
- primary paper.

### Exclusion criteria

- non-drug comparator (e.g. placebo or conservative therapy) or aspirin, urokinase, anistreplase
- source of clinical efficacy data from non-RCT or not explicitly stated
- no attempt to synthesise costs and benefits
- letters, editorials, reviews, commentaries or methodological papers.

All the references were exported to Endnote reference database.

### Data extraction

All cost-effectiveness data were abstracted by a single reviewer (ABol) and then checked by a second reviewer (RM). Both reviewers are health economists with expertise in economic evaluation. Given that several of the cost-effectiveness papers included in the review incorporated the use of modelling techniques, it was appropriate to extract additional data from these papers.

The data extracted from the published cost-effectiveness analyses are presented in four sections (see pages 39–47).

Firstly, there is a section on study design where the following information is stated:

- type of economic evaluation and measure of synthesis
- intervention
- study population
- time period of analysis and extrapolation details.

The second section summarises the key cost and cost data sources used in the studies:

- cost items
- cost data sources
- country, currency and year.

The third section summarises the range of outcomes and efficacy data sources used in the studies:

- range of outcomes
- efficacy data sources
- utility values and data sources
- modelling method and data sources.

Finally, the fourth section explores the results of the cost-effectiveness studies:

- cost-effectiveness ratio
- subgroup analysis and results
- sensitivity analysis and results
- authors' conclusions.

### **Quality assessment**

The quality assessment of cost-effectiveness analyses was based on the Drummond 10-point checklist.<sup>42</sup> All studies were scored (ABol, RM) according to the checklist detailed in appendix 8.





## Chapter 3

### Results: clinical effectiveness – hospital

#### Selection and characteristics of included studies

##### Selection

A total of 162 references were identified to which the inclusion criteria were applied. Of these, 20 studies reported in 50 articles fulfilled the inclusion criteria (see appendix 11, page 113). A total of 21 papers were reports of studies examining the effectiveness of thrombolytic agents not currently available in the UK. These were excluded on this basis and are listed (by drug) in appendix 11 (page 117).

No studies that compared thrombolytic agents in the pre-hospital care met the inclusion criteria. A list of 31 references to studies conducted in the pre-hospital environment is available in appendix 11 (page 119). Chapter 4 includes a discussion of studies reporting the use of thrombolysis in the pre-hospital setting.

Reports of studies relating to agents under consideration in this review (*Table 1*), utilised within hospital, but which did not fulfil the inclusion criteria are detailed in appendix 11 (page 122). The reason for exclusion is given for each of these excluded references.

Details of the hospital studies included in the review follow below.

##### Hospital-based studies:

Twenty studies reported in 50 articles met the inclusion criteria (see *Table 2*). These

included 14 studies comparing two or more drugs,<sup>17–20,43–52,59</sup> four dose-ranging trials<sup>53–56</sup> and two trials of various regimes of the same drug.<sup>57,58</sup> Dose-ranging trial is defined as a clinical trial in which two or more doses of an agent are tested against each other to determine which dose works best and is least harmful. Data from two included studies, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) and the International Study Group (ISG)<sup>46,47</sup> were combined in the study reports and this combination of data was maintained in this review.

##### Quality assessment

Methodological quality of studies is summarised in *Table 3* using the criteria based on CRD Report No. 4 (see appendix 6).<sup>41</sup> The CRD checklist includes key aspects of RCT design and quality. However, this is a recently developed tool and when used to assess studies that pre-date it, it provides some challenges to reviewers in interpretation of the terminology (e.g. double-blind, concealment of allocation). A discussion of these issues has been published by Schulz and Grimes.<sup>60</sup>

Of the 14 included studies, nine reported a truly random method of sequence generation (i.e. use of centralised or computerised random numbers), in all other trials the method was not stated. Eight studies appeared to have adequately concealed allocation of treatment.

All studies reported the number of randomised participants and presented the participant

**TABLE 2** Summary of included clinical studies

Alteplase/streptokinase	Alteplase/tenecteplase	Alteplase/reteplase	Streptokinase/reteplase	Dose-ranging and mixed regimes
GUSTO I <sup>18</sup> Central Illinois <sup>43</sup> Cherng <i>et al.</i> <sup>44</sup> ECSG <sup>45</sup> GISSI-2/ISG <sup>46,47</sup> ISIS-3 <sup>48</sup> KAMIT <sup>49</sup> PAIMS <sup>50</sup> TIMI 1 <sup>51</sup> White <i>et al.</i> <sup>59</sup>	ASSENT-2 <sup>20*</sup>	GUSTO III <sup>19*</sup> RAPID-2 <sup>17*</sup>	INJECT <sup>52</sup>	COBALT <sup>57</sup> (t-PA)* Xu <i>et al.</i> <sup>58</sup> (SK) Six <i>et al.</i> <sup>53</sup> (SK) ASSENT-1 <sup>54</sup> (TNK) TIMI 10B <sup>55</sup> (TNK)* RAPID-1 <sup>56</sup> (r-PA)
* Involved accelerated alteplase				

TABLE 3 Quality assessment of included clinical studies

Checklist items: <sup>*</sup>	Randomisation:		Baseline comparability:		Eligibility criteria specified	Co-interventions identified	Blinding:			Withdrawals:		Intention-to-treat		
	Truly random	Allocation concealment	Presented	Achieved			Assessors	Administration	Participants	Procedure assessed	> 80% randomised in final analysis		Reasons stated	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14
<b>Alteplase/streptokinase:</b>														
GUSTO I <sup>16</sup>	✓	✓	✓	✓	✓	✓	✓	✓	X	X	ns	✓	✓	✓
Central Illinois <sup>43</sup>	ns	ns	✓	✓	✓	✓	✓	✓	X	✓	ns	✓	✓	✓
Cherng et al. <sup>44</sup>	ns	ns	✓	✓	✓	✓	✓	ns	X	X	ns	✓	✓	✓
ECSG <sup>45</sup>	✓	✓	✓	✓	✓	✓	✓	✓	ns	ns	ns	✓	✓	✓
GISSI-2/ <sup>46,47</sup> ISG	✓	✓	✓	✓	✓	✓	✓	X	X	X	ns	✓	✓	✓
ISIS-3 <sup>48</sup>	✓	✓	✓	ns	ns	✓	✓	✓/X	✓/X	✓/X	ns	✓	✓	✓
KAMIT <sup>49</sup>	✓	✓	✓	✓	✓	✓	✓	✓	ns	ns	ns	✓	✓	✓
PAIMS <sup>50</sup>	ns	ns	✓	✓	✓	✓	✓	✓	ns	ns	ns	✓	✓	✓
TIMI 1 <sup>51</sup>	✓	ns	✓	✓	✓	✓	✓	✓	✓	✓	ns	✓	✓	✓
White et al. <sup>59</sup>	ns	ns	✓	✓	✓	✓	✓	✓	✓	✓	ns	✓	✓	✓
<b>Alteplase/tenecteplase:</b>														
ASSENT-2 <sup>20</sup>	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	ns	✓	✓	✓
<b>Alteplase/reteplase:</b>														
GUSTO III <sup>19</sup>	✓	✓	✓	✓	✓	✓	✓	✓	X	X	ns	✓	✓	✓
RAPID-2 <sup>17</sup>	ns	ns	✓	✓	✓	✓	✓	✓	X	X	ns	✓	✓	✓
<b>Streptokinase/reteplase:</b>														
INJECT <sup>32</sup>	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	ns	✓	✓	✓

Items graded: ✓, yes (item adequately addressed), X, no (item not adequately addressed), ✓/X, partially (item partially addressed) or ns, not stated

\* Quality assessment checklist items in are described in full in appendix 6

eligibility criteria. The co-interventions for each treatment group were identified in all studies.

The baseline comparability for each treatment group was presented and achieved in 13 trials, whereas in one study (ISIS-3<sup>48</sup>) it was not presented.

Eleven studies reported the blinding of outcome assessors. None of the studies reported the assessment of the blinding procedure. All studies appeared to include an intention-to-treat (ITT) analysis and reported the number of and reason for withdrawals.

Overall methodological quality of included studies was excellent. The three large studies that compared accelerated alteplase (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I),<sup>18</sup> Assessment of the Safety of a New Thrombolytic (ASSENT-2)<sup>20</sup>, GUSTO III<sup>19</sup>) and the single large study comparing streptokinase and reteplase (International Joint Efficacy Comparison for Thrombolytics (INJECT))<sup>52</sup> were international studies that scored well on all criteria except assessment of their blinding techniques. Two of these large studies (GUSTO I<sup>18</sup> and GUSTO III<sup>19</sup>) were open-label studies, and therefore those administering the drugs, and presumably also the patients, were aware of the treatment being administered. However, in each, treatment allocation was randomised, the outcome assessors were blind to the treatment allocation, and the treatment outcome (death at 30 days) was objective. Follow-up of patients in all studies was excellent.

### Characteristics of trials

The 14 included trials involved a total study population of 142,907 patients. Characteristics of these studies are presented in *Table 4*. In addition, six were dose-ranging trials and trials of various regimes of the same drug, involving in total 12,189 patients. These are listed in appendix 11 (page 116).

The size of studies varied from the smallest with 122 patients to the largest involving 41,299 patients. Six trials had fewer than 300 patients in total whereas five trials had more than 10,000 patients in total.

Eight trials were carried out in more than one country. The remainder were conducted in a single country (Taiwan, New Zealand, Italy and USA – three trials).

Ten studies compared alteplase with streptokinase. Seven studies used the standard doses of streptokinase (1.5 MU) and alteplase (100 mg). One of

these utilised accelerated administration of alteplase. Two studies compared accelerated alteplase with reteplase. One study compared streptokinase to reteplase, and one alteplase with tenecteplase.

Inclusion criteria were consistent across the trials and were based on age, ECG changes and duration of AMI symptoms. Patients presenting up to 6 hours after the onset of AMI symptoms with duration of at least 30 minutes were included in seven trials. Eleven trials excluded patients with current contraindications to thrombolysis comparable to those described by the European Society of Cardiology (see appendix 9). Other criteria for exclusion included shock, hypotension, history of previous myocardial infarction (MI), malignancy and childbearing age or pregnancy.

The primary end-points used in the trials included 30–35-day mortality, efficacy, 90-minute artery patency/flow rates and left ventricular function. A range of secondary outcomes have been reported in trials such as bleeding, stroke, reinfarction, allergy and anaphylaxis.

All trials used various adjunct treatments. Of these, eleven studies reported the use of aspirin and heparin, two studies used a combination of heparin and nitroglycerine and one further study used a combination of heparin, aspirin and nitroglycerine.

### Participant characteristics

The baseline characteristics of the participants are presented in *Table 5*. Five studies reported the proportion of participants aged over 70–75 years, ranging between 11.6% and 26.1%. The Thrombolysis in Myocardial Infarction (TIMI 1)<sup>51</sup> study reported the proportion of participants over 65 years of age (alteplase 22%, streptokinase 28%). The proportion of females among the studies varied between 8.5% and 28.2%. In nine studies the proportion of females was at least 19%. The proportion of patients with an anterior infarct varied from 32% to 61.9%. Two studies reported time to treatment in intervals (recording proportions of people treated within various time bands over 0–24 hours in ISIS-3<sup>48</sup> and 0–6 hours in GISSI-2<sup>46,47</sup>). The other studies reported median or mean time to treatment, ranging from 2.1 (Plasminogen Activator Italian Multi-centre Study (PAIMS)<sup>50</sup>) to 5.2 hours.<sup>44</sup> Time to treatment varied somewhat between the treatment arms. The proportion of participants with a history of previous MI was between 6% and 18.4%. Follow-up was within hospital in six studies, and 30–35 days in the others.

TABLE 4 Characteristics of clinical studies

Study	Interventions	Number randomised	Location	Participant inclusion	Participant exclusion	Primary end-point	Other outcomes	Adjunct treatment(s)
<b>Alteplase/streptokinase</b> GUSTO I <sup>18*</sup>	Accelerated alteplase	10,396	International 1081 hospitals 15 countries	AMI symptoms within previous 6 h; chest pain for 20 minutes; ECG changes	Contraindications to thrombolysis; previous treatment with streptokinase or anistreplase; previous participation in the trial; non-compressible vascular punctures	Mortality 30-day	Combined 30-day mortality; non-fatal stroke, or non-fatal haemorrhagic stroke; combined 30-day mortality or non-fatal disabling stroke	Aspirin; heparin
	Streptokinase	20,251						
	Streptokinase + alteplase Streptokinase 1.0 MU/h, alteplase 1.0 mg/kg/h	10,374						
Central Illinois <sup>43</sup>	Alteplase 10 mg bolus, followed by 50 mg in the first hour, and 20 mg/h for the next 2 h	123	USA 30 hospitals	Treatment within 4 h of onset of chest pain; ECG changes; age $\leq$ 75 years with first AMI	Contraindications to thrombolysis; ST segment depression or non-Q-wave infarction, or both; left bundle branch block; prior coronary artery bypass surgery	Not stated	LVF; mortality; bleeding; stroke; allergic reactions	Aspirin; i.v. heparin
	Streptokinase 375,000 IU bolus, followed by 1,125,000 IU/h	130						
Cherng <i>et al.</i> <sup>44</sup>	Alteplase	59	Taiwan	Chest pain $\geq$ 30 minutes; $<$ 6 h, ECG changes; age $<$ 70 years	Contraindications to thrombolysis; shock (BP $<$ 80 mmHg); childbearing age	Unclear	Patency; LVF; bleeding; mortality	Aspirin; i.v. nitroglycerine; i.v. heparin
	Streptokinase	63						
ECSSG <sup>45</sup>	Alteplase 0.75 mg/kg/90 minutes	64	Europe 7 hospitals	Severe chest pain 30 minutes; randomisation within 6 h of onset of symptoms; ECG changes; age 20–70 years; no previous AMI	Contraindications to thrombolysis; hypotension (systolic BP $<$ 90 mmHg); heart rate $>$ 110/minute; previous infarction; major hepatic or renal disease, cancer or proliferate diabetic retinopathy; pregnancy	Not stated	Patency; mortality; adverse events – used their own criteria	i.v. heparin; streptokinase group also got aspirin
	Streptokinase	65						
GISSI-2/ISG <sup>46,47</sup>	Alteplase	10,372	International 14 countries	AMI admitted to CCU within 6 h from symptom onset; ECG changes	Contraindications to thrombolysis; uncontrolled hypertension (systolic $\geq$ 200 mmHg, diastolic $\geq$ 110 mmHg); previous treatment with streptokinase within past 6 months	Mortality in-hospital	Mortality – (discharge + 6 months); major adverse events	Aspirin; heparin (50%)
	Streptokinase 1.5 MU/30–60 minutes	10,396						

continued

TABLE 4 contd Characteristics of clinical studies

Study	Interventions	Number randomised	Location	Participant inclusion	Participant exclusion	Primary end-point	Other outcomes	Adjunct treatment(s)
Alteplase/streptokinase contd ISIS-3 <sup>48</sup>	Alteplase	13,746	International 914 hospitals 17 countries	Symptoms of AMI within previous 24 h	Contraindications to thrombolysis	Mortality 35-day	Allergy; reduced BP; stroke; shock; pulmonary embolism; ventricular fibrillation; cardiac arrest; reinfarction	Aspirin (all patients); heparin (half of patients)
	Streptokinase	13,780						
	APSAC 30 U over 3 minutes	13,773						
PAIMS <sup>50</sup>	Alteplase	86	Italy 8 hospitals	Chest pain for 30 minutes, unrelieved by nitroglycerine; < 3 h from onset of symptoms to recruit- ment; ECG changes; age 20–70 years	Contraindications to thrombolysis; previous MI; cardiogenic shock; left bundle branch block; uncontrolled hypertension (diastolic $\geq$ 110 mmHg; systolic $\geq$ 200 mmHg); major liver or renal disease; childbearing age	Thrombolytic efficacy and effects on LVF	Time to reperfusion; ECG output; intensity of chest pain; adverse events	Heparin; nitroglycerine
	Streptokinase	85						
TIMI 1 <sup>51</sup>	Alteplase	157	USA 13 hospitals	Chest pain 30 minutes; ECG changes; age < 75 years	Contraindications to thrombolysis; pain > 7 h, patients with less than 50% reduction in artery post-i.c. nitroglycerine	Recanalisation at 90 minutes	LVF; ejection fraction; adverse events	i.v. heparin; i.c. nitroglycerine
	Streptokinase	159						
White et al. <sup>59</sup>	Alteplase	135	New Zealand 4 hospitals	Chest pain 30 minutes; ECG changes; first AMI	Age > 70 years; Q-wave infarction; hypertension (systolic pressure > 200 mmHg)	LVF	Patency rates at 3 weeks; reinfarction; adverse events; mortality	Aspirin; i.v. heparin
	Streptokinase 1.5 MU/ 30 minutes	135						
Alteplase/alteplase and streptokinase KAMIT <sup>49</sup>	Alteplase	107	USA	Chest pain within previous 6 h; ECG changes; age < 75 years	Contraindications to thrombolysis	Patency at 90 minutes	In-hospital reocclusion; LVF; bleeding; recurrent ischaemic events	Aspirin; heparin
	Alteplase (half dose – 10 mg bolus then 40 mg/h) + streptokinase (1.5 MU)	109						

continued

TABLE 4 contd Characteristics of clinical studies

Study	Interventions	Number randomised	Location	Participant inclusion	Participant exclusion	Primary end-point	Other outcomes	Adjunct treatment(s)
<b>Alteplase/alteplase and streptokinase contd</b> ASSENT-2 <sup>20</sup>	Accelerated alteplase	8,488	International 29 countries 1021 hospitals	AMI symptoms within previous 6 h; ECG changes; age $\geq$ 18 years	Contraindications to thrombolysis; use of abciximab or other glycoprotein IIb/IIIa antagonists within preceding 12 h; biopsy of a parenchymal organ, transient ischaemic attack, or dementia; any structural damage to CNS	Mortality 30-day	Non-fatal stroke; major non-fatal cardiac events stroke	Aspirin; i.v. heparin
	Tenecteplase 30–50 mg, single bolus, weight-adjusted	8,461						
<b>Alteplase/reteplase</b> GUSTO III <sup>98</sup>	Accelerated alteplase	4,921	International 20 countries 807 hospitals	Chest pain $>$ 30 minutes; symptoms $<$ 6 h	Contraindications to thrombolysis; systolic BP $>$ 200 mmHg, diastolic BP 110 mmHg, recent non-compressible vascular pressure	Mortality 30-day	Net clinical benefit (freedom from death or disabling stroke); death or stroke; adverse events	Aspirin; heparin
	Reteplase	10,138						
<b>RAPID-2<sup>17*</sup></b>	Accelerated alteplase	155	USA 20 hospitals	Chest pain $\geq$ 30 minutes, not relieved by nitroglycerine; presenting within $\leq$ 12 h of symptom onset; ECG changes; age $>$ 18 years	Prior coronary angioplasty within 2 weeks; previous Q-wave MI in the same anatomic region; women with childbearing potential; contraindications to thrombolysis	Patency at 90 minutes	Patency rates; LVF; stroke; reinfarction; bleeding; death	Aspirin; i.v. heparin
	Reteplase	169	Germany 5 hospitals					
<b>Streptokinase/reteplase</b> INJECT <sup>32</sup>	Streptokinase	3,006	Europe 9 countries 208 hospitals	Chest pain $\geq$ 30 minutes; treatment within 12 h of onset of symptoms; ECG changes or bundle branch block	Intracranial neoplasm, arteriovenous malformation, or aneurysm; pregnancy or breastfeeding; contra-indication to streptokinase; treatment with streptokinase or anistreplase within 12 months; administration of any other investigational drug within 30 days; previous enrolment in the study	Mortality 35-day	Intracerebral events; bleeding; cerebrovascular events; allergic reactions; reinfarction	Aspirin; i.v. heparin
	Reteplase	3,004						

\* Involved accelerated alteplase. Current contraindications to thrombolysis<sup>3</sup> are detailed in appendix 9

TABLE 5 Characteristics of clinical study participants

Study	Number randomised	Age (years)	> 70-75 years (%)	Sex (female %)	Systolic BP (mmHg)	Anterior infarct (%)	Time from symptom onset to treatment (h)	Previous AMI (%)	Follow-up
<b>Alteplase/streptokinase</b>									
GUSTO I <sup>18</sup>	41,021	Median Acc t-PA 62 (52-70) SK 62 (52-70) SK + t-PA 61 (52-70)		25	Median Acc t-PA + i.v. heparin 130 (113-144) SK + s.c. heparin 130 (111-144) SK + i.v. heparin 129 (112-144) SK + t-PA + i.v. heparin 130 (112-143)	t-PA 44 SK 36	Median (minutes) Acc t-PA + i.v. heparin 165 (120-230) SK + s.c. heparin 164 (115-232) SK + i.v. heparin 165 (120-230) SK + t-PA + i.v. heparin 170 (121-237)	Acc t-PA 17 SK 16.5 SK + t-PA 6	30 days
Central Illinois <sup>43</sup>	253	Mean t-PA 59 (10) SK 59 (11)		t-PA 28 SK 28			Mean (minutes) t-PA 146 (61) SK 148 (59)		Hospital
Cherng et al. <sup>44</sup>	122	Mean t-PA 57.3 (9.6) SK 57.8 (9.5)	0.0*	t-PA 8.5 SK 20.6		t-PA 57.6 SK 61.9	Mean t-PA 5.2 (3.7) SK 4.9 (2.3)		30 days
ECSCG <sup>45</sup>	129	Median t-PA 55.1 (32.4-70.7) SK 54.3 (36.2-70.4)		t-PA 9.3 SK 8.5	Median t-PA 130 (70-195) SK 130 (90-195)	t-PA 53 SK 48	Median t-PA 3.0 (1.1-5.5) SK 2.6 (0.8-5.9)		Hospital
GISSI-2/ISG <sup>46,47</sup>	20,891	Not reported	t-PA 22.9 SK 23.0	t-PA 21.7 SK 21.1			≤ 1 t-PA 14.4 SK 14.9	t-PA 17.4 SK 16.9	Hospital
ISIS-3 <sup>48</sup>	41,299	Not reported	26.1 (> 70 years)	27.1		34.9	≤ 3 t-PA 63.9 SK 63.7		
							> 3-6 t-PA 34.5 SK 34.7		
							(%) t-PA 78.2 SK 14.4 13-24 7.4	21.7	35 days
									continued

TABLE 5 contd Characteristics of clinical study participants

Study	Number randomised	Age (years)	> 70–75 years (%)	Sex female %	Systolic BP (mmHg)	Anterior infarct (%)	Time from symptom onset to treatment (h)	Previous AMI (%)	Follow-up
<b>Alteplase/streptokinase contd</b> PAIMS <sup>50</sup>	171	Mean			Mean		Mean (minutes)		Hospital
		t-PA 57 (8) SK 58 (8)	t-PA 12.8 SK 22.3	t-PA 133 (22) SK 135 (21)	t-PA 1.2 SK 43.5	t-PA 124 (40) SK 127 (41)			
TIMI 1 <sup>51</sup>	316	Mean			Mean		Mean (minutes)		Hospital
		t-PA 56 SK 57	t-PA 20 SK 21	t-PA 132 SK 134	t-PA 45 SK 52	t-PA 286 SK 287			
White et al. <sup>59</sup>	270	Mean t-PA 55 (9) SK 56 (9)			Mean t-PA 132 (27) SK 133 (26)	t-PA 36 SK 32	Mean t-PA 2.5 (0.6) SK 2.5 (0.6)		30 days
<b>Alteplase/alteplase and streptokinase</b> KAMIT <sup>49</sup>	216	Mean			Mean		Mean		Hospital
		t-PA 55 (11) t-PA/SK 53 (11)	t-PA 17 t-PA/SK 17	t-PA 130 (21) t-PA/SK 129 (26)	t-PA 42 t-PA/SK 42	t-PA 3.0 (1.2) t-PA/SK 2.9 (1.2)			
<b>Alteplase/tecteplase</b> ASSENT-2 <sup>20*</sup>	16,949	Median			Median		Median		30 days
		t-PA 61 (51–70) TNK 62 (52–70)	t-PA 23.3 TNK 22.9	t-PA 133 (119–150) TNK 133 (120–150)	t-PA 40.2 TNK 39.4	t-PA 2.8 (1.9–3.8) TNK 2.7 (1.9–3.8)			
<b>Alteplase/reteplase</b> GUSTO III <sup>19*</sup>	15,059	Median			Median		Median		30 days
		t-PA 63.0 (53–72) r-PA 62.9 (53–71)	t-PA 27.2 r-PA 27.5	t-PA 134 (119–150) r-PA 135 (119–150)	t-PA 47.7 r-PA 47.4	t-PA 2.7 (1.9–3.9) r-PA 2.7 (1.8–3.8)			
RAPID-2 <sup>17*</sup>	324	Median t-PA 62 (30–89) r-PA 58 (24–87)			Unclear	t-PA 37 r-PA 39	Median t-PA 2.4 r-PA 2.5		35 days
<b>Streptokinase/reteplase</b> INJECT <sup>52</sup>	6,010	Mean SK 61.9 (11.7) r-PA 61.8 (11.5)	SK 12.1 r-PA 11.6	Mean SK 134.7 (23.4) r-PA 135.8 (23.1)	SK 44.0 r-PA 41.4	Mean SK 4.1 (2.4) r-PA 4.2 (2.8)		SK 14.7 r-PA 14.5	35 days

Values given are mean (SD) or median (range)

\* Patients over 70 years of age excluded from study



## Thrombolytic drug comparisons

Data on selected clinical outcomes from studies comparing thrombolytic agents are detailed in *Table 6*. Outcomes include mortality up to 35 days, any stroke, haemorrhagic stroke, reinfarction, bleeding, allergy and anaphylaxis.

All of the 14 included studies presented data on mortality up to 35 days, although there was variation in the timescale underpinning the mortality values. Only three of the studies did not report stroke data, although a total of six studies did not give figures for haemorrhagic stroke. Again, the majority of studies (10/14) reported numbers of study participants found to have experienced reinfarction. Information on major bleeding was provided in most trials (13/14), however, the categorisation and reporting of bleeding events varied. The review team was unable to confidently match the description of bleeds in the GUSTO I<sup>18</sup> report with the bleeding categories used in this review. Therefore, bleed data are only presented for 12 studies. Incidences of allergy and anaphylaxis were less frequently reported. Eight studies reported on allergy. With the exception of the INJECT study,<sup>52</sup> these were all trials investigating alteplase/streptokinase. Five reports provided data on anaphylaxis. This included three studies comparing alteplase/streptokinase and one for each of the alteplase/tenecteplase and alteplase/reteplase studies.

Where available, data on the compared outcomes were used in the meta-analyses presented next.

## Analysis of results

### Meta-analysis

The primary end-points and major secondary end-points of the trials comparing at least two drugs in particular, related to hazards of drugs, are presented here and a meta-analysis undertaken. The trials compare: alteplase to streptokinase (*Table 7* for all alteplase and *Table 8* for alteplase other than in accelerated infusions), accelerated alteplase to tenecteplase (*Table 9*, based only on one study, ASSENT-2<sup>20</sup>), accelerated alteplase to reteplase (*Table 10*), and reteplase to streptokinase (*Table 11*, one study, INJECT<sup>52</sup>).

The meta-analysis was carried out using the RevMan 4.1 made available through the Cochrane Collaboration. The data are presented in the tables using odds ratios (ORs) with 95% confidence intervals (CIs) and, as appropriate, using a random

effects model. Data extracted and included in the analysis are mortality (30–35-day), stroke (total and haemorrhagic), major bleed and reinfarction. Data related to congestive heart failure (CHF) did not lend itself to meta-analysis and was extracted for use in the economic model; it is presented in chapter 5.

There has been extensive debate over the evaluation of the effectiveness of alteplase provided as an infusion and accelerated alteplase which is provided as a bolus followed by an infusion.<sup>11</sup> We expand on this controversy in the discussion. We therefore present the analysis in two tables, one including the GUSTO I trial<sup>18</sup> and one not. There is no statistical evidence of heterogeneity between trials in either table. The data for GUSTO I is the more commonly presented comparison of the two streptokinase-only arms compared to the accelerated alteplase arm.

These provide direct comparisons where they are available: however not all the possible drug comparisons have been made in RCTs and it is necessary to draw indirect comparisons. The justifications for and conclusions of the direct and indirect comparisons are given in the discussion (see page 26).

The main results are as follows:

- **All alteplase versus streptokinase:** no difference in mortality or reinfarction (see *Table 7*). Total stroke and haemorrhagic stroke rates were lower in streptokinase grouping.
- **Alteplase excluding accelerated alteplase versus streptokinase:** no difference in mortality (see *Table 8*). In the streptokinase group there was a lower incidence of total stroke and haemorrhagic stroke. Major bleed and reinfarction rates were lower in the alteplase group.
- **Accelerated alteplase versus tenecteplase:** no differences in mortality, total stroke, haemorrhagic stroke or reinfarction. Fewer major bleeds with tenecteplase (see *Table 9*).
- **Accelerated alteplase versus reteplase:** no difference in mortality, total stroke, haemorrhagic stroke, major bleed or reinfarction (see *Table 10*).
- **reteplase versus streptokinase:** no difference in mortality, total stroke, major bleeds. There was a lower incidence of haemorrhagic strokes in the streptokinase group (see *Table 11*).

TABLE 6 Thrombolytic drug comparisons

Study	Interventions	Number randomised	Mortality 0–35 days	Stroke any	Haemorrhagic stroke	Reinfarction	Bleeding total	Bleeding major	Allergy any	Anaphylaxis
<b>Alteplase/streptokinase</b> GUSTO 1 <sup>18</sup>	SK s.c. heparin	9,841	705/9796 (7.2) <sup>a</sup>	118/9709 (1.2)	46/9709 (0.5)	295/8669 (3.4)	Unclear	Unclear	494/8669 (5.7)	61/8669 (0.7)
	SK i.v. heparin	10,410	767/10377 (7.4) <sup>a</sup>	144/10314 (1.4)	56/10314 (0.5)	370/9260 (4.0)	Unclear	Unclear	537/9260 (5.8)	56/9260 (0.6)
Central Illinois <sup>43</sup>	Acc t-PA	10,396	652/10344 (6.3) <sup>a</sup>	159/10268 (1.6)	74/10268 (0.7)	369/9235 (4.0)	Unclear	Unclear	148/9235 (1.6)	18/9235 (0.2)
	SK + t-PA	10,374	723/10328 (7.0) <sup>a</sup>	168/10248 (1.6)	96/10248 (0.9)	368/9193 (4.0)	Unclear	Unclear	496/9193 (5.4)	55/9193 (0.6)
Cherng et al. <sup>44</sup>	t-PA	123	6/123 (4.9)				26/123 (2.11)	18/123 (14.6)	0/123 (0)	0/123 (0)
	SK	130	9/130 (6.9)				36/130 (27.7)	25/130 (19.2)	3/130 (2.3)	0/130 (0)
ECSCG <sup>45</sup>	t-PA	59	2/59 (3.4)				8/59 (13.6)	3/59 (5.1)		
	SK	63	5/63 (7.9)				7/63 (11.1)	3/63 (4.8)		
GISSI-2/ISG <sup>46,47</sup>	t-PA	64	3/64 (4.7) <sup>b</sup>	0/64 (0)		2/64 (3.1)		4/64 (6.3)	0/64 (0)	
	SK	65	3/65 (4.6) <sup>b</sup>	1/65 (1.5)		4/65 (6.1)		5/65 (7.7)	1/65 (1.5)	
ISIS-3 <sup>48</sup>	t-PA	10,372	929/10372 (9.0) <sup>c</sup>	138/10372 (1.3)	44/10372 (0.4)	274/10372 (2.6)	64/10372 (0.6)	64/10372 (0.6)		
	SK	10,396	887/10396 (8.5) <sup>c</sup>	98/10396 (0.9)	30/10396 (0.3)	314/10396 (3.0)	96/10396 (0.9)	96/10396 (0.9)		
PAIMS <sup>50</sup>	t-PA	13,746	1418/13746 (10.3)	188/13569 (1.4)	76/13569 (0.56) <sup>d</sup>	397/13569 (2.9)	109/13569 (0.8)	109/13569 (0.8)	109/13569 (0.8)	
	SK	13,780	1455/13780 (10.6)	141/13607 (1.0)	25/13607 (0.18) <sup>d</sup>	472/13607 (3.5)	118/13607 (0.8)	118/13607 (0.8)	490/13607 (3.6)	
TIMI 1 <sup>51</sup>	t-PA	86 <sup>e</sup>	4/86 (4.7)			0/86 (0)	10/86 (11.6)	0/86 (0)	0/86 (0)	
	SK	85 <sup>e</sup>	7/85 (8.2)			2/85 (2.4)	6/85 (7.1)	1/85 (1.2)	4/85 (4.7)	
White et al. <sup>59</sup>	t-PA	143–157	7/143 (4.9) <sup>e</sup>	0/290 (0)		19/143 (13.3) <sup>f</sup>	47/143 (32.9)	22/143 (15.4)	7/143 (4.9)	0/290 (0)
	SK	147–159	12/147 (8.2) <sup>e</sup>			17/147 (11.6) <sup>f</sup>	46/147 (31.3)	23/147 (15.6)	25/147 (17.0)	
<b>Alteplase/alteplase and streptokinase</b> KAMIT <sup>19</sup>	t-PA/SK	109	6/109 (5.5) <sup>e</sup>	2/109 (1.8)	1/109 (0.9)	0/109 (0)	13/109 (11.9)	13/109 (11.9)		
	SK	107	4/107 (3.7) <sup>e</sup>	2/107 (1.9)	0/107 (0)	4/107 (3.7)	11/107 (10.3)	11/107 (10.3)		
<b>Alteplase/tenecteplase</b> ASSENT-2 <sup>20</sup>	Acc t-PA	8,488	522/8488 (6.1) <sup>ab</sup>	141/8488 (1.7)	80/8488 (0.9)	323/8488 (3.8)	2457/8488 (28.9)	504/8488 (5.9)		17/8488 (0.2)
	TNK	8,461	523/8461 (6.2) <sup>ab</sup>	151/8461 (1.8)	79/8461 (0.9)	347/8461 (4.1)	2236/8461 (26.4)	394/8461 (4.7)		8/8461 (0.1)
<b>Alteplase/reteplase</b> GUSTO III <sup>19</sup>	Acc t-PA	4,921	356/4921 (7.2) <sup>ab</sup>	88/4921 (1.8)	42/4921 (0.9)	207/4921 (4.2)	59/4921 (1.2)	59/4921 (1.2)		3/4921 (0.06)
	r-PA	10,138	757/10138 (7.5) <sup>ab</sup>	166/10138 (1.6)	92/10138 (0.9)	426/10138 (4.2)	96/10138 (0.9)	96/10138 (0.9)		5/10138 (0.05)
RAPID-2 <sup>17</sup>	t-PA	155	13/155 (8.4)	4/155 (2.6)						
	r-PA	169	7/169 (4.1)	3/169 (1.8)						

continued

**TABLE 6 contd** Thrombolytic drug comparisons

Study	Interventions	Number randomised	Mortality 0-35 days	Stroke any	Haemorrhagic stroke	Reinfarction	Bleeding total	Bleeding major	Allergy any	Anaphylaxis
<b>Streptokinase/reteplase</b> INJECT <sup>52</sup>	SK	3,004	285/2992 (9.5)	30/2992 (1.0)	11/2992 (0.4)		458/2992 (15.3)	141/2992 (4.7)	54/2992 (1.8)	
	r-PA	3,006	270/2994 (9.0)	37/2994 (1.2)	23/2994 (0.8)		449/2994 (15.0)	138/2994 (4.6)	33/2994 (1.1)	
Percentages are shown in parentheses										
<sup>a</sup> Data for 30 days										
<sup>b</sup> Events from third day until discharge										
<sup>c</sup> In-hospital data, with and without heparin										
<sup>d</sup> Definite only										
<sup>e</sup> In-hospital stay										
<sup>f</sup> 21 days data; 6 months t-PA 24/143, SK 19/147; 12 months t-PA 26/143, SK 21/147										

TABLE 7 All alteplase versus streptokinase

Outcome	Study	Alteplase	Streptokinase	OR random effect (95% CI)
Mortality up to 35 days	Central Illinois <sup>43</sup>	6/123	9/130	0.69 (0.24 to 2.00)
	Cherng et al. <sup>44</sup>	2/59	5/63	0.41 (0.08 to 2.18)
	ECSG <sup>45</sup>	3/64	3/65	1.02 (0.20 to 5.23)
	GISSI-2/ISG <sup>46,47</sup>	929/10,372	887/10,396	1.05 (0.96 to 1.16)
	GUSTO I <sup>18</sup>	652/10,344	1,472/20,173	0.85 (0.78 to 0.94)
	ISIS-3 <sup>48</sup>	1,418/13,746	1,455/13,780	0.97 (0.90 to 1.05)
	PAIMS <sup>50</sup>	4/86	7/85	0.54 (0.15 to 1.93)
	TIMI 1 <sup>51</sup>	7/143	12/147	0.58 (0.22 to 1.52)
	White et al. <sup>59</sup>	5/135	10/135	0.48 (0.16 to 1.45)
<b>Total</b>	<b>3,026/35,072</b>	<b>3,860/44,974</b>	<b>0.94 (0.85 to 1.04)</b>	<b>Test for heterogeneity <math>\chi^2 = 13.96</math>, df = 8, p = 0.083</b>
Stroke (total)	ECSG <sup>45</sup>	0/64	1/165	0.33 (0.01 to 8.34)
	GISSI-2/ISG <sup>46,47</sup>	138/10,372	98/10,396	1.42 (1.09 to 1.84)
	GUSTO I <sup>18</sup>	159/10,268	262/20,023	1.19 (0.97 to 1.45)
	ISIS-3 <sup>48</sup>	188/13,569	141/13,607	1.34 (1.08 to 1.67)
<b>Total</b>	<b>485/34,273</b>	<b>502/44,091</b>	<b>1.29 (1.13 to 1.46)</b>	<b>Test for heterogeneity <math>\chi^2 = 1.99</math>, df = 3, p = 0.58</b>
Haemorrhagic stroke	GISSI-2/ISG <sup>46,47</sup>	44/10,372	30/10,396	1.47 (0.92 to 2.34)
	GUSTO I <sup>18</sup>	74/10,268	102/20,023	1.42 (1.05 to 1.91)
	ISIS-3 <sup>48</sup>	76/13,569	25/13,607	3.06 (1.95 to 4.81)
<b>Total</b>	<b>194/34,209</b>	<b>157/44,026</b>	<b>1.83 (1.14 to 2.93)</b>	<b>Test for heterogeneity <math>\chi^2 = 8.30</math>, df = 2, p = 0.016</b>
Reinfarction	ECSG <sup>45</sup>	2/64	4/65	0.49 (0.09 to 2.79)
	GISSI-2/ISG <sup>46,47</sup>	274/10,372	314/10,396	0.87 (0.74 to 1.03)
	GUSTO I <sup>18</sup>	369/9,235	665/17,929	1.08 (0.95 to 1.23)
	ISIS-3 <sup>48</sup>	397/13,569	472/13,607	0.84 (0.73 to 0.96)
	PAIMS <sup>50</sup>	0/86	2/85	0.19 (0.01 to 4.08)
	TIMI 1 <sup>51</sup>	19/143	17/147	1.17 (0.58 to 2.36)
	White et al. <sup>59</sup>	7/135	7/135	1.00 (0.34 to 2.93)
<b>Total</b>	<b>1,068/33,604</b>	<b>1,481/42,364</b>	<b>0.93 (0.81 to 1.07)</b>	<b>Test for heterogeneity <math>\chi^2 = 9.91</math>, df = 6, p = 0.13</b>

### Other adverse effects reported

Several studies reported rates of allergy or anaphylaxis. Reported rates for allergy were often different suggesting different diagnostic criteria, but in general the rates of allergy and anaphylaxis on streptokinase were approximately 3–4 times those on alteplase (e.g. GUSTO I<sup>18</sup> reported 5.7% allergy and 0.7% anaphylaxis on streptokinase compared to 1.6% and 0.2% respectively on alteplase). The differential rates with reteplase were not so large – INJECT<sup>52</sup>

reported 1.8% allergy on streptokinase compared to 1.1% on reteplase. There seems to be little difference in rates of allergy between the newer drugs in comparative studies.

### Subgroup analysis of included studies

Six included studies<sup>18–20,46–48,52</sup> conducted subgroup analysis of mortality at 30–35 days. The three most common subgroups of patients were identified according to age, location of

**TABLE 8** Alteplase, excluding accelerated alteplase, versus streptokinase (GUSTO I<sup>18</sup> omitted)

Outcome	Study	Alteplase	Streptokinase	OR random effect (95% CI)
Mortality up to 35 days	Central Illinois <sup>43</sup>	6/123	9/130	0.69 (0.24 to 2.00)
	Cherng <i>et al.</i> <sup>44</sup>	2/59	5/63	0.41 (0.08 to 2.18)
	ECSG <sup>45</sup>	3/64	3/65	1.02 (0.20 to 5.23)
	GISSI-2/ISG <sup>46,47</sup>	929/10,372	887/10,396	1.05 (0.96 to 1.16)
	GUSTO I <sup>18</sup>	1,418/13,746	1,455/13,780	0.97 (0.90 to 1.05)
	ISIS-3 <sup>48</sup>	4/86	7/85	0.54 (0.15 to 1.93)
	PAIMS <sup>50</sup>	7/143	12/147	0.58 (0.22 to 1.52)
	TIMI 1 <sup>51</sup>	5/135	10/135	0.48 (0.16 to 1.45)
	<b>Total</b>	<b>2,374/24,728</b>	<b>2,388/224,801</b>	<b>1.00 (0.94 to 1.06)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 6.87, df = 7, p = 0.44$
Stroke (total)	ECSG <sup>45</sup>	0/64	1/165	0.33 (0.01 to 8.34)
	GISSI-2/ISG <sup>46,47</sup>	138/10,372	98/10,396	1.42 (1.09 to 1.84)
	ISIS-3 <sup>48</sup>	188/13,569	141/13,607	3.06 (1.95 to 4.81)
	<b>Total</b>	<b>326/24,005</b>	<b>240/24,068</b>	<b>1.37 (1.16 to 1.62)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 0.84, df = 2, p = 0.66$
Haemorrhagic stroke	GISSI-2/ISG <sup>46,47</sup>	44/10,372	30/10,396	1.47 (0.92 to 2.34)
	ISIS-3 <sup>48</sup>	76/13,569	25/13,607	3.06 (1.95 to 4.81)
	<b>Total</b>	<b>120/23,941</b>	<b>55/24,003</b>	<b>2.13 (1.04 to 4.36)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 4.91, df = 1, p = 0.027$
Major bleed	Central Illinois <sup>43</sup>	18/123	25/130	0.72 (0.37 to 1.40)
	Cherng <i>et al.</i> <sup>44</sup>	3/59	3/63	1.07 (0.21 to 5.53)
	ECSG <sup>45</sup>	4/64	5/65	0.80 (0.20 to 3.13)
	GISSI-2/ISG <sup>46,47</sup>	64/10,372	96/10,396	0.67 (0.48 to 0.92)
	ISIS-3 <sup>48</sup>	109/13,569	118/13,607	0.93 (0.71 to 1.20)
	PAIMS <sup>50</sup>	0/86	1/85	0.33 (0.01 to 8.11)
	TIMI 1 <sup>51</sup>	22/143	23/147	0.98 (0.52 to 1.85)
	White <i>et al.</i> <sup>59</sup>	0/135	3/135	0.14 (0.01 to 2.73)
	<b>Total</b>	<b>220/24,551</b>	<b>274/24,628</b>	<b>0.81 (0.68 to 0.97)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 4.69, df = 7, p = 0.7$
Reinfarction	ECSG <sup>45</sup>	2/64	4/65	0.49 (0.09 to 2.79)
	GISSI-2/ISG <sup>46,47</sup>	274/10,372	314/10,396	0.87 (0.74 to 1.03)
	ISIS-3 <sup>48</sup>	397/13,569	472/13,607	0.84 (0.73 to 0.96)
	PAIMS <sup>50</sup>	0/86	2/85	0.19 (0.01 to 4.08)
	TIMI 1 <sup>51</sup>	19/143	17/147	1.17 (0.58 to 2.36)
	White <i>et al.</i> <sup>59</sup>	7/135	7/135	1.00 (0.34 to 2.93)
	<b>Total</b>	<b>699/24,369</b>	<b>816/24,435</b>	<b>0.86 (0.77 to 0.95)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 2.29, df = 5, p = 0.81$

**TABLE 9** Accelerated alteplase versus tenecteplase

Outcome	Study	Accelerated alteplase	Tenecteplase	OR random effect (95% CI)
Mortality up to 35 days	ASSENT-2 <sup>20</sup>	522/8,488	523/8,461	0.99 (0.88 to 1.13)
Stroke	ASSENT-2	141/8,488	151/8,461	0.93 (0.74 to 1.17)
Haemorrhagic stroke	ASSENT-2	80/8,488	79/8,461	1.01 (0.74 to 1.38)
Major bleed	ASSENT-2	504/8,488	394/8,461	1.29 (1.13 to 1.48)
Reinfarction	ASSENT-2	323/8,488	347/8,461	0.93 (0.79 to 1.08)

**TABLE 10** Accelerated alteplase versus reteplase

Outcome	Study	Accelerated alteplase	Reteplase	OR random effect (95% CI)
Mortality up to 35 days	GUSTO III <sup>19</sup>	356/4,921	757/10,138	0.97 (0.85 to 1.10)
	RAPID-2 <sup>17</sup>	13/155	7/169	2.12 (0.82 to 5.46)
	<b>Total</b>	<b>369/5,076</b>	<b>764/10,307</b>	<b>1.24 (0.61 to 2.53)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 2.60, df = 1, p = 0.11$
Stroke (total)	GUSTO III	88/4,921	166/10,138	1.09 (0.84 to 1.42)
	RAPID-2	4/155	3/169	1.47 (0.32 to 6.66)
	<b>Total</b>	<b>92/5,076</b>	<b>169/10,307</b>	<b>1.10 (0.85 to 1.43)</b>
				<b>Test for heterogeneity</b> $\chi^2 = 0.14, df = 1, p = 0.71$
Haemorrhagic stroke	GUSTO III	42/4,921	92/10,138	0.94 (0.65 to 1.36)
Major bleed	GUSTO III	59/4,921	96/10,138	1.27 (0.92 to 1.76)
Reinfarction	GUSTO III	207/4,921	426/10,138	1.00 (0.84 to 1.19)

**TABLE 11** Reteplase versus streptokinase

Outcome	Study	Reteplase	Streptokinase	OR random effect (95% CI)
Mortality up to 35 days	INJECT <sup>52</sup>	270/2,994	285/2,992	0.94 (0.79 to 1.12)
Stroke (total)	INJECT	37/2,994	30/2,992	1.24 (0.76 to 2.00)
Haemorrhagic stroke	INJECT	23/2,994	11/2,992	2.10 (1.02 to 4.31)
Major bleed	INJECT	138/2,994	141/2,992	0.98 (0.77 to 1.24)

infarction and time from onset of symptoms to treatment. Thrombolytic drug comparisons by subgroups are presented in *Table 12*.

There were no differences in the comparative efficacy of different drugs at different ages. Older patients typically had higher mortality rates regardless of drug. The GUSTO I study<sup>18</sup> which showed an advantage of accelerated alteplase

over streptokinase showed the advantage consistently in all age groups.

When the time to treatment was categorised at different time intervals, the GUSTO I study seemed to show a better outcome with accelerated alteplase in those treated within 6 hours, but a better outcome with streptokinase in those treated after 6 hours.<sup>18</sup> On re-analysis, this was not

TABLE 12 Thrombolytic drug comparisons by subgroups

Study	Number randomised	Age (years)	Infarct location	Time from symptom onset to treatment (h)
<b>Alteplase/streptokinase</b>				
GUSTO I <sup>18*</sup>	41,021	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>
		< 65 t-PA 2.7 SK 3.3	Anterior t-PA 8.6 SK 10.5	0–2 t-PA 4.3 SK 5.4
		65–74 t-PA 8.3 SK 10.4	Inferior t-PA 4.7 SK 5.3	2–4 t-PA 5.5 SK 6.7
		75–85 t-PA 18.2 SK 19.7		4–6 t-PA 8.9 SK 9.3
		> 85 t-PA 30.0 SK 29.2		> 6 t-PA 10.4 SK 8.3
GISSI-2/ISG <sup>46,47</sup>	20,891	<b>In-hospital mortality (%)</b>	Not reported	<b>In-hospital mortality (%)</b>
		≤ 70 t-PA 5.8 SK 5.4		
		> 70 t-PA 19.4 SK 19.1		
		≤ 3 t-PA 8.2 SK 7.9		
		> 3 t-PA 10.2 r-PA 9.5		
ISIS-3 <sup>48</sup>	41,299	Not reported	Not reported	<b>35-day mortality (%)</b>
				0–6 t-PA 9.6 SK 10.0
<b>Alteplase/tenecteplase</b>				
ASSENT-2 <sup>20*</sup>	16,949	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>
		≤ 75 t-PA 4.3 TNK 4.6	Anterior t-PA 8.2 TNK 8.0	0–2 t-PA 4.9 TNK 5.0
		> 75 t-PA 19.3 TNK 17.4	Other t-PA 4.8 TNK 5.0	2–4 t-PA 5.5 TNK 6.3
				> 4 t-PA 9.2 TNK 7.0
<b>Alteplase/reteplase</b>				
GUSTO III <sup>19*</sup>	15,059	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>	<b>30-day mortality (%)</b>
		≤ 75 t-PA 5.2 r-PA 5.5	Anterior t-PA 9.4 r-PA 10.1	0–2 t-PA 6.1 r-PA 5.8
		> 75 t-PA 20.2 r-PA 21.6	Inferior t-PA 5.2 r-PA 4.8	2–4 t-PA 6.9 r-PA 7.2
			Other t-PA 7.5 r-PA 9.7	> 4 t-PA 7.9 r-PA 9.7
<b>Streptokinase/reteplase</b>				
INJECT <sup>52</sup>	6,010	<b>35-day mortality (%)</b>	Not reported	<b>35-day mortality (%)</b>
		< 51 r-PA 1.7 SK 2.9		< 3 r-PA 6.7 SK 7.5
		51–65 r-PA 5.3 SK 6.4		3–6 r-PA 9.1 SK 9.4
		> 65 r-PA 16.4 SK 15.4		> 6 h r-PA 13.2 SK 13.6

\* Involved accelerated alteplase

statistically significant.<sup>61</sup> In ASSENT-2,<sup>20</sup> the 30-day mortality in patients treated after 4 hours from symptom onset was significantly lower with tenecteplase than with alteplase (absolute difference 2%) and in GUSTO III,<sup>19</sup> alteplase showed a significantly better mortality benefit in late-treated patients (greater than 4 hours) than reteplase.

In GUSTO I,<sup>18</sup> although statistically not significant, 30-day mortality benefit from accelerated alteplase was consistent compared with streptokinase regardless of location of infarct. However, the absolute benefit was greater in patients with anterior wall infarctions.

## Discussion

### Equivalence and non-equivalence

Before discussing the results and their interpretation, and the indirect comparisons, it is important to consider how we may determine whether two drugs are similar in their efficacy, and how clinical trials are designed to prove that drugs are either different or equivalent. This is a key issue with which appraisers of this evidence must be familiar.

Broadly, non-equivalence studies (often referred to as superiority studies) are powered to demonstrate a difference between two treatments. They are based on a null hypothesis that there is no difference, which may then be disproved. It is standard in such studies to use an ITT analysis (i.e. to analyse all patients according to their randomised allocation to treatment, and not according to whether they ever received the therapy or whether they perhaps changed at some point to the alternative therapy). The ITT analysis is by its nature conservative and tends to demonstrate **no difference** rather than **difference**,<sup>62</sup> and is the most rigorous analysis.

Equivalence trials are used when the existing standard therapy is considered effective and a placebo controlled trial would not be appropriate. One might then wish to prove that a new therapy is at least as good as the existing standard. Equivalence studies are also used to assess frequency of side-effect, cost, or the ease of administration of one drug versus another. Equivalence studies aim therefore to demonstrate that the treatment effects are equal, not different. However, the two drugs are unlikely to produce exactly the same results (this would be the case even if we compared exactly the same drug in two arms of a study); so we must define *a priori* what we mean by equivalence – e.g. what is the

range of difference in efficacy between two therapies, within which the therapies may be considered clinically equivalent?

A key question therefore is what is this range of difference in efficacy (i.e. in 30-day mortality) between two thrombolytic agents within which we may consider them equivalent? There is the view held by some research groups<sup>63</sup> and presented in the American College of Chest Physicians' (ACCP) guidelines that the range of difference (i.e. the 95% CIs of any difference) must be less than 1% absolute difference in mortality at 30 days.<sup>13</sup> This means that the CIs of any difference in efficacy must lie within –1% and +1% if the two drugs are to be considered clinically equivalent. This is based on the extent of the difference seen in the GUSTO I study<sup>18</sup> between alteplase and streptokinase, where a difference greater than this is considered to indicate that alteplase and streptokinase are clinically different.

Other studies have used other criteria: for instance, the Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) study,<sup>57</sup> examining two methods of dosing with alteplase, used an extremely rigorous level of not more than 0.4% difference based on the lower confidence interval (CI) of the difference seen in GUSTO I.<sup>18</sup> This was subsequently considered excessively rigorous by many, and Ware and Antman<sup>62</sup> suggest a difference of up to 1.5%. Other studies have used no more than 50% relative mortality difference compared to streptokinase (an interval that could equate to roughly 1% in absolute mortality, on the basis that streptokinase shows a 2% reduction compared to placebo).

The American drug licensing agency, the Food and Drugs Administration (FDA) proposes a boundary based on the relative risk ratio between two drugs, where the upper 95% CI should not exceed 14.3% relative difference (also based on the relative difference in GUSTO I).<sup>64</sup> The European Medicines Evaluation Agency (responsible for licensing thrombolytic drugs in Europe) has not yet determined what it considers equivalence but it seems likely to be similar to the ACCP guidance (Rotblat F, Medicines Control Agency, London: personal communication, 2002).

This definition of equivalence relates only to efficacy in 30-day mortality. Some argue that the correct figures on which to base equivalence should also include a measure of adverse effects such as stroke.<sup>65</sup> However, there is no consensus around this, nor any consensus on what the limits



for equivalence for any end-point other than 30-day mortality should be.

### Analysing equivalence trials

Even if there was agreement on the definition of equivalence, there remain issues regarding how we analyse equivalence trial data. It can be argued that ITT analysis (essential in superiority trials where it is deliberately conservative in tending to reject a difference between therapies) is less appropriate in equivalence studies where it might hide true differences. The more conservative approach would be a 'per protocol' analysis (i.e. analysing only those patients who received a particular therapy and who continued on it) which tends to emphasise differences. An ideal would be to consider both forms of analysis (as is done in the report of the INJECT study).<sup>66</sup>

Problems that may produce differences between ITT and 'per protocol' analyses include loss of data (e.g. due to patient drop-outs) and of handling crossovers (where patients originally assigned to one arm actually switch at some point to the alternative). Fortunately, these problems do not apply in studies of thrombolytic drugs: data ascertainment for 30-day mortality are usually of very high standard, and the nature of the acute treatment means that there is rarely any crossover.

We therefore believe it is methodologically sound to interpret the CIs produced in superiority studies of thrombolytic therapies as if they had been produced in true equivalence studies, with both ITT and 'per protocol' analysis. This is a view supported by others.<sup>67,68</sup> The results of the INJECT study<sup>52</sup> also lend confidence to this approach where the results of the ITT analysis are similar to those of the 'per protocol' analysis.

### Direct comparisons between drugs

The evidence base is dominated by a small number of large clinical trials and these require careful critical review. In addition the previous discussion regarding the establishment of criteria for judging equivalence will be included here.

Data presented in this section are combinations of the odds ratio (OR) data from the *Tables 7–11* and absolute risk differences provided from other reports.

#### Alteplase and streptokinase

There have been a number of studies that have compared these two treatments, as outlined in *Tables 7* and *8*. Three major studies influence the comparisons. The first two, GISSI-2/ISG<sup>46,47</sup> and

ISIS-3<sup>48</sup> compared the standard regimen of a slow infusion and showed no clear benefit of alteplase over streptokinase. The third is GUSTO I<sup>18</sup> using a frontloaded or accelerated infusion showing mortality benefit at 30 days.

The GUSTO I study<sup>18</sup> has been the source of much controversy. It had four arms with approximately 10,000 patients in each. The arms were: (a) streptokinase with subcutaneous heparin, (b) streptokinase with intravenous heparin, (c) accelerated alteplase with intravenous heparin, and (d) standard alteplase with streptokinase. It has been argued that the frontloading or accelerated regimen improves the efficacy of alteplase, and achieves earlier artery patency, hence reducing loss of myocardium. This seemed to be supported by the Randomised Angiographic trial of recombinant tissue-type plasminogen Activator (alteplase) in Myocardial Infarction (RAAMI) study<sup>16</sup> which showed that at 60 minutes after initiation of the alteplase infusion, the observed angiographic patency rates were 76% in the accelerated regimen group and 63% in the control group ( $p = 0.03$ ). At 90 minutes these rates were 81% and 77% respectively ( $p = 0.21$ ). On this basis, it might be expected that accelerated regimens might produce better mortality results than standard alteplase, although this has not been tested adequately.

GUSTO I<sup>18</sup> showed an absolute decrease in mortality of 1% (95% CI: 0.37% to 1.6%) at 30 days, favouring accelerated alteplase given with intravenous heparin over streptokinase (two arms merged, one with subcutaneous heparin and one with intravenous heparin). However, there have been numerous criticisms of this study. These can be briefly summarised as follows:

- the benefit of alteplase over streptokinase was largely seen in those patients in GUSTO I treated in North America (i.e. the bulk of the patients in the trial). Results indicated a 1.2% absolute reduction in mortality in US patients versus 0.7% reduction in mortality in non-US patients.<sup>69</sup> This may reflect American familiarity with alteplase-based regimens and relative unfamiliarity with streptokinase, particularly since the trial was not blinded
- there were substantial numbers of protocol violations in the subcutaneous heparin arm of streptokinase treatment (up to 11% in total but more common in patients treated in the USA)
- there were differences in management of patients between centres, for instance, the larger proportion of alteplase patients who received coronary artery bypass grafting and differences

in post-infarct management in the USA compared to non-US study sites

- differences in long-term outcomes between US and non-US study participants may be due to long-term management of these patients<sup>70</sup>
- the merging of the two streptokinase regimes, while choosing not to merge the two alteplase arms, was not scientifically valid.

The GUSTO investigators<sup>71</sup> responded that although not blinded, allocation to treatment was randomised, there was an ITT analysis reported, and the primary end-point of death was collectable in an unbiased and impartial way. They pointed to an angiographic substudy of GUSTO<sup>72</sup> which also showed a higher patency rate of infarct-related artery at 90 minutes compared to streptokinase treatment: this provided a logical pathophysiological explanation for the effects of alteplase in decreasing mortality. Lee and colleagues<sup>73</sup> further reported that among GUSTO patients who did not have coronary artery bypass surgery during the hospitalisation, 30-day mortality was 6.5% in those treated with alteplase compared to 7.6% in those treated with streptokinase, still a clinically and statistically significant difference.

Another criticism relates less to the GUSTO I study itself and more to how it has been interpreted, i.e. that there has been excessive emphasis on GUSTO I to the exclusion of other trials of streptokinase versus alteplase.

Collins and colleagues<sup>11</sup> argue that any differences between thrombolytic regimens are likely to be small compared to the overall benefits of thrombolysis and that studies need to be compared as a whole, without selective emphasis on one trial or on particular subgroups. This group therefore conducted a meta-analysis of ISIS-3, GISSI-2 and GUSTO I trials<sup>11</sup> (note that in our meta-analysis, we have merged the results of GISSI-2 with ISG).

They argue that the biological effect of alteplase was only to achieve earlier patency but by no more than 30–60 minutes. The evidence they quote for this is the angiographic substudy referred to which showed greater TIMI-3 flow rates at 90 minutes but not at 180 minutes (they express some concern that this is reported as TIMI-3 flow rates, and not as the TIMI-2 or -3 rates originally envisaged in the protocol). Accepting earlier patency by 30–60 minutes, and basing their assertions on the mean time of symptom onset to treatment, and the rate of decreased mortality arising from earlier reperfusion as demonstrated in the Fibrinolytic Therapy Trialists' (FTT) meta-

analysis,<sup>28</sup> they argue that it could be expected that no more than 1 to 2 lives per 1000 would be saved (0.2% absolute decrease in mortality at 30 days) by using alteplase rather than streptokinase. They therefore consider the extent of benefit seen in GUSTO I to be implausible and more likely to be a statistical outlier than an accurate definitive result.

The time course of benefit from thrombolysis is an important topic here and will be discussed in more depth later. Collins and colleagues<sup>11</sup> use the conservative FTT time course and dismiss the alternative time course put forward by Boersma and colleagues<sup>26</sup> as being the result of selective emphasis on certain small trials. Whatever the case, given the mean time to thrombolysis in GUSTO I of 2 hours,<sup>18</sup> the differences in mortality by either graph would be small as is made clear later in this review.

Collins and colleagues<sup>11</sup> merged the two alteplase arms and compared them to the merged streptokinase-only arms, even though only one of the alteplase arms used the accelerated regimen. This was controversial but they justified this by arguing that the accelerated nature of alteplase in one arm was not crucial, since the total dose of alteplase actually received by patients in the first hour of treatment was almost identical in both alteplase arms (82 mg in the accelerated arm versus 78 mg in the alteplase/streptokinase arm).

Accordingly they felt justified in merging GUSTO I with GISSI-2 and ISIS-3 in a meta-analysis. This showed a statistically significant difference of 0.49% (4.9/1000 patients treated) in 30-day non-stroke mortality between alteplase and streptokinase, with no evidence of heterogeneity between the trials. This is substantially less than the 1% benefit claimed for most analyses of GUSTO I which compare the two streptokinase-only arms to the alteplase-only arm alone.

The balance between risk and benefit is also uncertain and while there may be benefits in coronary patency and mortality with earlier treatment, the risks in particular of intracranial haemorrhage will be similar across all time bands. In their meta-analysis, Collins and colleagues<sup>11</sup> estimated a statistically significant excess risk of total stroke from alteplase over streptokinase of 3.3/1000 patients treated, and of intracranial haemorrhage of 2.9/1000 patients treated: GUSTO I showed an increased stroke risk in the alteplase group of 3/1000.<sup>18</sup>

Merging these two end-points of 30-day death and stroke in their meta-analysis, Collins and

colleagues<sup>11</sup> concluded that there is no convincing benefit of alteplase over streptokinase (only 1.6 strokes or deaths per 1000 patients treated, and not statistically significant). They concluded that there was no clinically significant difference between the drugs.

Others have argued about this interpretation. A criticism is the assumption that a meta-analysis is superior to the evidence presented in one (very) large trial. Specific points of conflict are whether accelerated alteplase, used in GUSTO I but not in the other studies, is superior (it is in the angiographic RAAMI study,<sup>16</sup> but such angiographic findings may not exist in clinical event reduction e.g. see the RAPID studies (Retepase Angiographic Phase II International Dose-Finding trial and Reteplase versus Alteplase Patency Investigation during Myocardial Infarction trial)<sup>17,56</sup> which suggested a benefit of reteplase over alteplase, not borne out in the GUSTO III study<sup>19</sup>), and that it was inappropriate to merge the two alteplase arms because of the different regimens and because of the confounding by the presence of streptokinase in one arm. It is therefore argued that it is inappropriate to include GUSTO I in a meta-analysis of studies of comparing alteplase to streptokinase.

We therefore present two tables comparing streptokinase to alteplase, based on all the studies identified which compared these drugs, one without and one with GUSTO I. *Table 8*, excluding GUSTO I, indicates no clear benefit for alteplase over streptokinase (difference 0.02% in favour of alteplase, 95% CI: -0.47 to 0.5). *Table 7*, including GUSTO I, shows similar results (difference 0.06% in favour of alteplase, 95% CI: -0.3 to 0.44).

### **Alteplase and reteplase**

Two trials are considered in this comparison, GUSTO III<sup>19</sup> and RAPID 2.<sup>17</sup> Both trials used a regimen of accelerated alteplase.

RAPID 2 was a relatively small angiographic study which showed better coronary arterial patency (TIMI-2/3 flow rates of 82% on reteplase versus 66% on accelerated alteplase at 60 minutes).<sup>17</sup> This led to a postulation of a 20% clinical benefit in 30-day mortality for reteplase over alteplase, based on an expectation of better outcomes with earlier and more complete reperfusion.<sup>74</sup> This was tested in the large GUSTO III study<sup>19</sup> which was planned and powered as a superiority trial, to detect a putative clinical superiority of reteplase over alteplase.

In fact, GUSTO III failed to show the superiority of reteplase with an absolute difference in mortality between the two treatments of 0.23% in favour of alteplase with 95% CIs of -1.1% to 0.66% (i.e. that reteplase could be up 1.1% worse or 0.66% better than alteplase). A later report of 1-year follow-up from GUSTO III shows a difference in mortality of 0.14% in favour of alteplase (with 95% CI: -1.21% to 0.93%).<sup>75</sup>

The failure to show a benefit in mortality despite benefits in reperfusion may mean that the reperfusion results arose by chance and were not typical of what might be expected, or that the correlation between TIMI flow rates and clinical outcomes are not as secure as previously believed (with implications for the interpretation of streptokinase and alteplase in RAAMI<sup>16</sup> and GUSTO I<sup>18</sup>). We should therefore be cautious in accepting surrogate data such as patency rates in relation to thrombolysis but seek trials with true clinical outcomes such as 30-day mortality.

The results of the analysis indicate that there is no statistically significant difference in 30-day mortality. However, if limits of equivalence are set at 1% absolute difference, then the results of this trial cannot be used to say that reteplase is as effective as alteplase. This is a view supported by the ACCP.<sup>13</sup>

However another recent review<sup>64</sup> interprets the GUSTO III study as showing the equivalence of reteplase and alteplase. It does this by merging the outcomes of mortality and disabling stroke, so that the combined event rate is (alteplase) 7.91% versus (reteplase) 7.89% (difference -0.02% 95% CI: -0.9% to +0.8%), and not the 7.24% versus 7.47%. This, the authors comment, is within the preset 1% definition, but this is strictly incorrect since the definition refers to mortality only and not to the combined endpoint of mortality and disabling stroke.

### **Reteplase and streptokinase**

The INJECT study<sup>52</sup> showed a 0.5% absolute difference in 35-day mortality in favour of reteplase (not statistically significant). However, the 95% CIs of -1.98% (reteplase better) to +0.96% (reteplase worse) require interpretation. These CIs imply that reteplase may be marginally better (0.5%) than streptokinase but is unlikely to be better than a 1.98% improvement in mortality over streptokinase and unlikely to be worse by more than 0.96% compared to streptokinase.

At the lower extreme therefore, this fits within the defined 1% CIs of equivalence and therefore it may be said that reteplase is not worse than streptokinase (non-inferior) and could be superior.

The ‘per protocol’ analysis of this study confirms this result (absolute difference in mortality of 0.53% versus ITT analysis of 0.51%). The similarity between the two analyses is of course not surprising, since 98.8% of patients actually received randomised treatment.

### **Alteplase and tenecteplase**

ASSENT-2<sup>20</sup> was designed as an equivalence trial comparing tenecteplase to alteplase in relation to 30-day mortality. The results indicate equivalence in that the clinical efficacy is within the bounds of 1% equivalence. There was however a statistically significant difference in the rate of major bleed (5.94% on alteplase versus 4.66% on tenecteplase), but there are no guidelines on what constitutes equivalence or inequivalence for this end-point. There is a suggestion in a company submission to NICE that this trial underestimated the effectiveness of tenecteplase because of the double dummy approach used, but this seems to us to be unlikely.

### **Indirect comparisons**

The lack of evidence from head-to-head trials between some thrombolytic drugs necessitates some indirect comparisons. Conclusions drawn from such indirect comparisons are more tenuous. This is particularly so when one tries to quantify any degree of superiority. Nevertheless when we turn to an attempt to evaluate the economics of using different drugs in chapter 5, we are forced into making some estimate of the extent of any such differences.

### **Streptokinase versus tenecteplase**

Here we must extrapolate from trials such as ASSENT-2<sup>20</sup> showing equivalence of tenecteplase with alteplase (although with less heart failure and more major bleeds in the alteplase group) and GUSTO I<sup>18</sup> possibly showing superiority of alteplase over streptokinase or equivalence, depending on the interpretation of the alteplase/streptokinase comparison discussed above. Therefore, tenecteplase is either superior to streptokinase (by the same degree as alteplase in GUSTO I), or equally effective and possibly more hazardous. Crudely adding together rates of difference in heart failure between alteplase and streptokinase in GUSTO I (2%) and between alteplase and tenecteplase in ASSENT-2 (0.9%) to produce a reduction in heart failure rates of 2.9%, as in one company submission to NICE, is particularly tenuous.

### **Reteplase versus tenecteplase**

As there have been no direct clinical trial comparisons between tenecteplase and reteplase, we are therefore forced to draw conclusions based on the GUSTO III study<sup>19</sup> and ASSENT-2.<sup>20</sup> This is perhaps the issue where company interests are most divided. If reteplase is equivalent to accelerated alteplase, then it would be considered the equivalent of tenecteplase. If the strict interpretation of the CIs in GUSTO III is adopted however, then reteplase cannot be considered equivalent to alteplase or tenecteplase. This is perhaps a matter for appraisal rather than strict evidence, as outlined below.

### **Adverse events**

The major adverse events differ between the drugs. Allergy or even anaphylaxis occurs with streptokinase but is rare with the other drugs. Although there were substantial differences in the definitions of bleeding and hence the rates of bleeding in different studies, the risk of major bleed was slightly higher on streptokinase than on the other drugs directly compared to it. This may be because streptokinase is less fibrin-specific and can cause a more generalised coagulopathy than the other drugs. Some argue this effect is possibly more marked than the clinical trial data alone show, since the other drugs are usually given with intravenous heparin. However, the analysis by Collins and colleagues<sup>11</sup> casts doubt on this as a significant source of difference.

There was a significant increase in the risk of stroke for alteplase compared to streptokinase. This was largely accounted for by an increase in the incidence of haemorrhage stroke. The meta-analysis shows an absolute risk increase of 2 per 1000 and a relative increase of 83%. GUSTO I<sup>18</sup> alone showed an increase of 42% but the absolute effect was similar. This is an extremely important adverse event that seems clearly related to the drug chosen. It offsets some of the difference in mortality between drugs since patients with intracranial haemorrhages are more likely to suffer severely disabling strokes. This will have an effect on the long-term costs of thrombolysis.

Reteplase treatment was also related to an increased tendency to stroke and a significant increase in haemorrhage stroke compared to streptokinase treatment. In contrast there was no difference between alteplase and reteplase in GUSTO III<sup>19</sup> or between alteplase and tenecteplase in ASSENT-2.<sup>20</sup>

There was no significant difference in reinfarction rates between any of the drugs.

No equivalence definitions have been produced to compare adverse effects nor does the existing definition include provision for difference in adverse effects, except those demonstrated in 30-day mortality.

### **Risk of intracranial haemorrhage with bolus therapy**

It is clear that the newer drugs are associated with an increased risk of intracranial haemorrhage compared to streptokinase. A meta-analysis by Mehta and colleagues<sup>76</sup> suggests that the rate of intracranial haemorrhage in patients receiving bolus thrombolytics such as reteplase, anistreplase, or tenecteplase may be unduly high without any gain in efficacy (OR 1.25, 95% CI: 1.08 to 1.45,  $p = 0.003$ ). We have considered this and agree with the rebuttals by Armstrong and colleagues<sup>77</sup> and Collen and Sobel.<sup>78</sup> The pooling of results from disparate drugs, which have different rates of adverse effects and possibly of primary efficacy, simply on the basis of routes of administration, may be inappropriate. The meta-analysis includes one agent, lanoteplase, which has been withdrawn specifically because of a high rate of intracranial haemorrhage. Our meta-analysis shown earlier demonstrates no increased risk of total stroke rates with reteplase or tenecteplase compared with alteplase. We have therefore not taken this into account in the economic evaluation, other than where differences in point estimates of the event can be derived from the trials.

### **Subgroup analysis**

No trial has been set up to specifically examine subgroups and therefore all conclusions drawn must be treated with great caution. Differences between subgroups may have arisen entirely by chance. The best-known example of this is an analysis from ISIS-2,<sup>\*</sup> showing marked differences in outcome depending on patients' astrological sign. Collins and colleagues warn of the risks of excessive subgroup analysis of studies that compare streptokinase and alteplase also.<sup>11</sup>

There were no consistent differences in response to drug by age, by time to thrombolysis or by site of infarct. Where differences occurred in trials, e.g. in GUSTO III<sup>19</sup> between reteplase and

alteplase, or in ASSENT-2<sup>20</sup> between tenecteplase and alteplase, they seem likely to have arisen as a result of subgroup analysis. Further evidence of any differential benefits in subgroups is required

There is no convincing evidence of relative difference in benefit of different drugs by site of infarct – the absolute benefit of alteplase was greater in treating anterior infarcts in GUSTO I<sup>18</sup> but this only reflects their greater mortality.

There was an increase in reinfarction rate for streptokinase compared to alteplase treatment in ISIS-3,<sup>48</sup> but in no other study. This influences the results in the analysis without GUSTO I, but its clinical significance, if real, is small.

There is therefore no evidence in the subgroup analysis to assist in differentiation between drugs.

### **Heparin**

A study of co-therapies used with thrombolytic drugs, such as the heparins and their route of administration, is outside the scope of this review but the question of heparin use in particular requires some comment, since it affects the feasibility of the use of the drugs outside hospital.

Collins and colleagues<sup>11</sup> considered the use of co-therapies with thrombolysis. It is widely accepted that all patients should receive aspirin, based on the ISIS 2<sup>10</sup> study. GUSTO I<sup>18</sup> used intravenous heparin in the alteplase arm, but subcutaneous (unfractionated) heparin in one streptokinase arm and intravenous heparin in the other. Collins and colleagues,<sup>11</sup> again as part of their meta-analysis of interventions after myocardial infarction, examined the question of whether a high dose subcutaneous heparin regime would be comparable to intravenous regimes. They concluded that in GUSTO I the rate of death in patients on intravenous heparin was 7.4% compared to 7.3% in those on subcutaneous heparin (consistent with a conclusion of equivalence based on ACCP<sup>13</sup> definitions) with similar lack of difference in other end-points including stroke or haemorrhagic stroke. They therefore concluded that high dose subcutaneous heparin is as effective as intravenous heparin. In common practice, streptokinase is not given with intravenous heparin, whereas an alteplase (based on GUSTO I) regime is.

\* Reference 1 (ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,817 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988;2:349–60.) in paper by Collins and co-workers<sup>11</sup>

The ASSENT-3 study<sup>79</sup> is also strictly outside the terms of this review since it does not consider comparisons between thrombolytic drugs. However it does allow a comparison between patients treated with tenecteplase and either intravenous unfractionated heparin or the subcutaneous low molecular weight heparin enoxaparin.

This study used a composite end-point of 30-day mortality, in hospital refractory ischaemia or in hospital reinfarction and found a rate of 11.4% on enoxaparin and 15.4% on unfractionated heparin. There was no statistically significant difference in mortality at 30 days (5.4% on enoxaparin versus 6.0% on unfractionated heparin, difference 0.64%, 95% CI: -0.8% to 2.1%) Applying ACCP<sup>13</sup> criteria, this suggests that enoxaparin is not inferior to unfractionated heparin and may be superior.

While treatment of AMI is not yet a licensed indication for enoxaparin, this trial combined with the review by Collins and co-workers,<sup>11</sup> would seem to indicate that the use of subcutaneous heparin, and in particular a low molecular weight subcutaneous heparin may be as effective as intravenous heparin in AMI. It would seem from the evidence presented by Collins and colleagues that this result was not surprising and could be anticipated to apply to all other thrombolytic drugs in the same way, despite the absence of firm trial evidence for the combination with thrombolytics other than tenecteplase. This would simplify the administration and facilitate the use of thrombolytic agents. One company submission to NICE comments that the Global Registry of Acute Coronary Events (GRACE registry)<sup>80</sup> indicates that 41% of patients with acute MI already receive a low molecular weight heparin with thrombolytics other than tenecteplase. This figure is likely to increase in the light of the results of ASSENT-3,<sup>79</sup> especially (but not exclusively) in conjunction with tenecteplase.

This might be of particular value in pre-hospital thrombolysis as discussed in chapter 4.

The role of other possible co-therapies in AMI (e.g. glycoprotein IIb/IIIa inhibitors) is under extensive study but is not considered further here.

## Conclusions

- differences in the benefit in 30–35-day mortality between drugs are less than the benefit of thrombolysis as a whole

- the scientific evidence comparing the comparative effects of drugs on 30–35-day mortality is open to interpretation, depending on the definitions of equivalence chosen.

Direct comparisons lead to the following firm conclusions:

- streptokinase is as effective as non-accelerated alteplase
- tenecteplase is as effective as accelerated alteplase
- reteplase is at least as effective as streptokinase.

Depending on interpretation of equivalence and of some major trials, the following conclusions are also possible:

- concerning streptokinase and alteplase: streptokinase is as effective as all alteplase, including accelerated alteplase **or** streptokinase is inferior to accelerated alteplase
- concerning reteplase and alteplase: reteplase is as effective as accelerated alteplase **or** reteplase is not (shown to be) as effective as accelerated alteplase.

The following indirect comparisons may also be drawn, and depend on the answers to (d) and (e) (obviously any conclusions drawn here are tentative):

- concerning streptokinase and tenecteplase: depending on the interpretation of point (d), tenecteplase is as effective as streptokinase **or** tenecteplase is superior to streptokinase
- concerning reteplase and tenecteplase: depending on the interpretation of point (e), reteplase is as effective as tenecteplase **or** reteplase is not as effective as tenecteplase.

In the absence of further evidence, the resolution of these is a matter for appraisal rather than for strict scientific interpretation. That the scientific evidence leaves this open to debate is an illustration of the uncertainty of such small differences.

The benefits of thrombolysis have to be set against the potential hazards: in particular stroke is more common on treatment with the newer drugs than with streptokinase, but the newer drugs have a negligible incidence of allergy.

The effects of any clinical differences between the drugs on their cost-effectiveness are considered later (see chapter 5).

## Chapter 4

# Results: clinical effectiveness – pre-hospital

### Included studies

The literature search failed to identify any studies conducted in the pre-hospital setting that compared the effectiveness of different drugs. That is, there were no drug versus drug comparison studies conducted in the pre-hospital setting. Rather, studies conducted in the pre-hospital setting have focused on the feasibility and safety of the delivery of thrombolysis in this setting. In these studies, patients were randomised to receive treatment either in the pre-hospital or hospital setting and all patients received the same drug. Primary outcome measures were time saved and mortality, with additional outcomes of adverse events.

We identified nine such RCTs in our search<sup>81–89</sup> that examined the efficacy and safety of pre-hospital thrombolysis. Six of these were also included in a recent systematic review and meta-analysis that examined the effectiveness on mortality of pre-hospital thrombolysis compared to hospital thrombolysis.<sup>90</sup>

We also consider a number of other non-randomised or audit-type reports that may provide further information on the likely issues regarding the implementation of pre-hospital thrombolysis within the NHS. These are included in the discussion portion of this section (see page 35) and in the chapter dealing with implementation (see chapter 6).

### Characteristics of pre-hospital studies

The characteristics of the nine RCTs are presented in *Table 13*. The studies were carried out in Europe, Canada, Israel, Northern Ireland and the UK. The trial sizes were small except for one large multi-centred study<sup>83</sup> that randomised more than 5000 patients. Diagnosis and decision-to-treat in the studies were by ECG and clinical signs in all of the studies but the one carried out in the UK,<sup>84</sup> where although ECGs were recorded they were not used in the decision-to-treat. Thrombolysis was given by a physician in all the studies except the USA one<sup>89</sup> where it was

provided by paramedics after consultation with a physician.

Morrison and colleagues<sup>90</sup> used six of these studies in their meta-analysis.<sup>82–84,87–89</sup> They excluded three<sup>81,85,86</sup> that did not meet their outcome inclusion criteria of mortality data available at discharge. Since the most common end-point in effectiveness studies is 30–35-day mortality we have included all nine trials in the characteristics table (see *Table 13*).

The trials included in the meta-analysis used a variety of drugs (anistreplase in three, alteplase in two and urokinase in one). Morrison and co-workers<sup>90</sup> considered that it was reasonable to group these disparate drugs together on the grounds of their broad clinical similarities. This ignores any possible differences in effectiveness between drugs as discussed in the previous chapter. In that section, we did not discuss comparisons with anistreplase since it is no longer available, but at least one small (hospital-based) study suggested that anistreplase, the drug most widely used in existing pre-hospital studies, was less effective than accelerated alteplase.<sup>92</sup>

The merging of trials is based on the argument that benefits arising from differences between drugs (maximum 10 lives saved at 1 month/1000 patients treated) may be less important than benefits from differences in time to thrombolysis.<sup>93</sup>

The administrators of the thrombolytic drug and the criteria under which it was administered varied considerably between trials. In most cases ( $n = 7$ ) assessment and treatment were provided by a physician. In the only UK study,<sup>84</sup> this was carried out by a general practitioner (GP). The only study in which treatment was provided by a paramedic was in the USA, the Myocardial Infarction Triage and Intervention trial (MITI),<sup>89</sup> where paramedics assessed the patient, communicated that information to a physician in the hospital and provided treatment as directed by the physician.

Individually these trials failed to show a statistically significant difference between all-cause in-hospital mortality, although the point estimates all favoured

**TABLE 13** Characteristics of trials: pre-hospital

Study	Design	Drug	Number of participants	Location	Diagnosis/decision	Administration
Barbash <i>et al.</i> <sup>81</sup>	RCT	Alteplase	Pre = 43 In = 44	Israel	History ECG	Physician
Castaigne <i>et al.</i> <sup>82</sup>	RCT	APSAC	Pre = 57 In = 43	France MCCU	ECG	Physician
EMIP <sup>83</sup>	RCT stratified by ECG and centre	Anistreplase	Pre = 2570 In = 2719	Europe – 15 countries Canada – 1 centre, 163 centres in all	ECG	Physician
GREAT <sup>84</sup>	RCT	Anistreplase	Pre = 163 In = 148	Scotland 29 GP practices	GP observation ECG done – not used for diagnosis	GP
McAleer <i>et al.</i> <sup>85</sup>	RCT open	Streptokinase	Pre = 43 In = 102	Northern Ireland MCCU	ECG	Physician
McNeill <i>et al.</i> <sup>86</sup>	RCT	Alteplase	Mix of Pre (49) and A&E (8) versus CCU total = 57	Northern Ireland MCCU	ECG	Physician
MITI <sup>89,91</sup>	RCT	Alteplase	Pre = 175 In = 185	USA 19 hospitals	ECG transmitted to physician by paramedic	Paramedic
Roth <i>et al.</i> <sup>87</sup>	RCT	Alteplase	Pre = 74 In = 44 last 29 patients not randomly allocated	Israel MICU	ECG – ST elevation	Physician
Schofer <i>et al.</i> <sup>88</sup>	RCT double-blind	Urokinase	Pre = 40 In = 38	Germany MICU	ECG – ST elevation	Physician

*Pre, pre-hospital data; In, in-hospital data; MCCU, mobile coronary care unit; MICU, mobile intensive care unit*

pre-hospital thrombolysis. Time to administration of pre-hospital thrombolysis ranged from 85–130 minutes from onset of pain. Pre-hospital thrombolysis was initiated approximately 58 minutes sooner than hospital thrombolysis, and this ranged from a 33-minute reduction in the MITI study<sup>89</sup> to a reduction of 130 minutes in the GREAT (Grampian Region Early Anistreplase Trial) study.<sup>84</sup>

The review by Morrison and co-workers<sup>90</sup> shows a pooled benefit in mortality of a relative reduction of 17% with pre-hospital thrombolysis compared to hospital thrombolysis (95% CI: 2% to 30%,  $p = 0.03$ ). In these studies, this translates into an

absolute risk reduction of 1.6% (95% CI: 0.2% to 3% – the paper quotes 2% as the risk reduction but based on the actual figures, the correct reduction is 1.6%), i.e. 16 more patients alive at hospital discharge per thousand patients treated pre-hospital compared with in-hospital.

The authors of the Morrison paper<sup>90</sup> were unable to comment on complication rates or the need for other medical or surgical therapy. They concluded that the benefits of pre-hospital thrombolysis are convincing and argued that the choice of drug is far less important than making a correct diagnosis and providing rapid and safe administration of thrombolysis.



## Discussion

The effectiveness of pre-hospital thrombolysis in improving outcomes would seem to have been resolved by the meta-analysis by Morrison and co-workers.<sup>90</sup> However, none of the methods of treatment administration of the studies included in the meta-analysis correspond exactly to how pre-hospital thrombolysis might be used in the NHS and therefore there are difficulties in interpreting these diverse studies and their applicability to the wider NHS.

None of the identified studies of pre-hospital care met the inclusion criteria of our review. We have broadly described the existing studies which compare pre-hospital thrombolysis with hospital thrombolysis, but which do not provide direct comparisons between drugs. The underlying assumption therefore is that the relative benefits (or lack of benefits) of one drug over another are proportionately maintained in the different settings, and at different times of administration.

The drugs used in the studies were anistreplase, urokinase and alteplase. Two of these drugs (urokinase and anistreplase) are no longer available in the UK. The third (alteplase) has been considered as unsuitable by individual ambulance services for use in the pre-hospital setting (see discussion in chapter 6, page 72). Cohort studies have shown the feasibility of using reteplase, but have not provided any outcome data comparing it to other agents in well-designed trials. To date, we have no data related to the use of tenecteplase in the pre-hospital setting.

Since none of the studies met the inclusion criteria of the review, a formal assessment of their quality has not been carried out. However, these studies do provide important information regarding the implementation of pre-hospital thrombolysis and highlight aspects of relevance to the NHS.

These issues are discussed here in relation to each of the major trials.

### European Myocardial Infarction Project

The European Myocardial Infarction Project (EMIP)<sup>83</sup> was the largest trial to date with over 5000 patients. It was multinational, and compared pre-hospital versus hospital anistreplase. Patients with or without typical ECG changes and typical history were randomised within 6 hours of onset of chest pain. Patients were stratified by their degree of ECG change, and investigators were also allowed to exclude patients at their discretion.

The time saving was 55 minutes and the reduction in 30-day mortality was 13% (mortality 9.7% versus 11.1%, benefit 1.4%, 95% CI: -0.1% to 3.1%,  $p = 0.08$ ). All participating ambulances ('mobile coronary care units') were staffed by a doctor. A total of 32.7% of all patients screened were actually entered into the study, the majority (87.2%) with ST elevation in the ECG. Complications were more common out of hospital and included (early) ventricular fibrillation (1% of cases), and shock including severe allergy (1%).

An important point here is how participation in the trial decreased the hospital door-to-needle time. In this study this time was 15 minutes. This was more rapid than anticipated and may have reduced the anticipated added benefits of pre-hospital administration used in the power calculation, resulting in a non-significant result.

### Myocardial Infarction Triage and Intervention trial

MITI<sup>89</sup> was a smaller trial ( $n = 360$ ) conducted in Seattle, USA, an urban area with a long history of excellence in emergency cardiac care. Patients had typical pain and ECG changes. The drugs used were alteplase (over 3 hours) and aspirin, delivered by random allocation in either the pre-hospital or hospital setting. In the pre-hospital setting, paramedics provided the drug following transmission of ECG results and clinical assessment to a doctor. This may have allowed discretionary application of exclusion criteria and have introduced a selection bias that may limit the generalisability of this study.

The patients included were only 4% of all patients with chest pain screened and 21% of all AMIs. There was a non-significant decrease in 30-day mortality (5.7% versus 8.1%, 2.7% difference, 95% CI: -3% to 7.8%), in favour of pre-hospital treatment. There was no difference in 2-year survival (89% for pre-hospital, and 91% for hospital-treated patients).<sup>91</sup>

Patients contacted emergency services relatively quickly compared with British standards – typically only 27 minutes after the onset of symptoms. The median time to pre-hospital treatment was 77 minutes, and to hospital treatment was 110 minutes, a saving of 33 minutes. Delivering an alteplase infusion in the field delayed transfer time to hospital by 15 minutes. The time saved was modest by comparison with most studies, reflecting the urban nature of the service provided. However, the study also showed a remarkable improvement in hospital door-to-needle time of 40 minutes for patients in the trial. Door-

to-needle time for randomised patients was 20 minutes for MITI patients, as opposed to 60 minutes for concurrent patients seen in the emergency departments of the participating hospitals. This illustrates the potential time savings that can be achieved with active management of the service in the hospital setting.

### Grampian Region Early Anistreplase Trial

The GREAT study<sup>84</sup> is perhaps the most important study from an NHS perspective since it was performed in the UK. In this trial, 311 patients were randomised either to receive anistreplase or placebo from their (specially trained) GP or the alternative drug/placebo on arrival at hospital. GPs selected patients on the basis of a history of chest pain of 20 minutes to 4 hours duration, and treatable within 6 hours of onset of pain. Although ECGs were recorded, they were not used in the decision to administer thrombolysis.

Seventy-eight per cent of patients entered did in fact have a subsequently proven AMI. However, only 51% of patients assessed had ECG changes (ST elevation) that would have meant that they met inclusion criteria for standard trials assessing the effectiveness of thrombolytic therapy. The relative rarity of AMI was illustrated by the fact that each GP recruited a patient on average every 11 months.

Time savings were impressive. The median time to treatment from onset of pain was 101 minutes pre-hospital compared to 240 minutes in the hospital group. There were substantial delays in administering thrombolysis in hospitals – hospital door-to-needle time was not specifically measured but was estimated at around 87 minutes.

The all-cause mortality outcomes are shown in *Table 14* (data are not available to fill all cells).

These benefits from the GREAT study are very impressive but there are grounds for caution in

interpreting them. The GREAT study differs from all other trials of thrombolysis in several respects. Firstly, it was a feasibility study – it was never designed or powered to show a mortality benefit. The fact that it has must be regarded as hypothesis generation rather than hypothesis testing. The benefits seen in the GREAT study were substantially greater than those seen in other studies of pre-hospital thrombolysis or indeed in hospital treatment. The pattern of increasing divergence of mortality up to 2 years (14% absolute difference in mortality) followed by a (predictable) convergence from 5 years onwards is unusual in thrombolytic trials and has not been seen in other trials with long-term follow-up such as ISIS-2<sup>10</sup> or GUSTO I.<sup>18</sup>

The GREAT study may therefore represent a statistical outlier, with extreme results such as are commonly seen in very small trials. As elsewhere, we should examine the whole of the available evidence and not be unduly swayed by one small study.

A contrary view is that few other studies have demonstrated such large time savings between pre-hospital and hospital treatments, and that the greater benefit may be explained by this.<sup>96</sup> In subsequent subgroup analysis and follow-up to 10 years, Rawles (Rawles J, lead investigator GREAT study/consultant cardiologist (retired), Aberdeen: personal communication, 2002) claims that the benefit of pre-hospital thrombolysis was confined to patients with ST elevation or bundle branch block, and in these patients the average survival was 7.4 years (pre-hospital) versus 5.9 years (in-hospital), difference 1.6 years, 95% CI: 0.5 to 2.6 years.

In the absence of other studies supporting the extent of the benefit seen in the GREAT study, it is therefore unclear how to synthesise the findings with other research. Even if correct, there are difficulties in applying such data to other parts of the UK where the transport times and distances are likely to be shorter. The model

**TABLE 14** Mortality at discharge and selected time points in the GREAT study

	Pre-hospital (%)	In-hospital (%)	Relative difference (%)	Absolute difference (%)	p value
Hospital discharge <sup>90</sup>	NA	NA	44 (+23 to 75)	NA	NS
1 month <sup>94</sup>	NA	NA	NA	6 (–0.5 to 12.7)	NS
3 months <sup>84</sup>	8	15.5	49	7.6 (–14.7 to –0.4)	0.04
1 year <sup>94</sup>	10.4	21.6	52 (14 to 89)	11.2	0.007
5 years <sup>95</sup>	25	36		11	< 0.025

of administration of thrombolysis on suspicion alone of AMI is not one generally favoured, and the role of the GP is not as prominent in most models of care currently under consideration. These issues are explored more fully in chapter 6 on implementation.

Two other studies<sup>85,86</sup> have been conducted in the UK, both in Northern Ireland. Both were relatively small and used mobile CCUs with medical staff. McNeil and colleagues<sup>86</sup> assessed the use of alteplase, and McAleer and colleagues<sup>85</sup> evaluated streptokinase.

McAleer and colleagues<sup>85</sup> used an open allocation, the basis for which was not reported. The reported time saving by pre-hospital administration was 34 minutes. The results reported dramatic but not statistically significant reductions in mortality at 14 days in favour of pre-hospital treatment, 2.3% versus 11.7% (difference 9.4%, 95% CI: -1.5% to 17.3%). This difference was still evident at the 1-year follow-up. McNeill and colleagues<sup>86</sup> showed a time saving of 68 minutes, no mortality benefit but an improvement in left ventricular function favouring pre-hospital thrombolysis. The benefit in the McAleer study was extraordinarily large and seems unlikely: the open allocation may explain the results. The model of mobile CCUs is uncommon in the NHS outside Northern Ireland.

### Non-randomised, audit or observational studies

The review team did not carry out a comprehensive search or apply stringent inclusion criteria in the search for non-randomised studies. Those studies presented here have been selected to identify factors to be addressed in relation to the implementation of pre-hospital care.

Pre-hospital thrombolysis has been widely used in the Netherlands for some years. Lamfers and colleagues<sup>97,98</sup> report a small observational study of pre-hospital thrombolysis with anistreplase offered in one Dutch city ( $n = 227$ ), versus retrospective records of hospital patients ( $n = 269$ ) treated with alteplase or streptokinase. Their comparisons reported a time saving of 63 minutes as a result of pre-hospital administration of treatment. GPs or paramedics in the community provided treatment after transmitting ECG and clinical findings to the hospital. They report that a total of 13% of pre-hospital patients were considered to have had their AMI aborted (as evidenced by predefined decreases in ST segment elevation on ECG) compared to 4% of hospital

patients. However there was no reported difference in 12-month mortality rates (pre-hospital 11% versus 10% inpatients receiving hospital treatment).

Handsearching identified one recent abstract authored by Lamfers and colleagues<sup>99</sup> that claims to compare reteplase (120 patients) with anistreplase or streptokinase (130 patients) out of hospital. In fact this was an observational study: patients were sequentially and openly assigned to either drug regimen (anistreplase was the preferred comparator in one trial centre, streptokinase in the other) given pre-hospital. The results were a time saving of 23 minutes for the double bolus reteplase, with no difference in 30-day mortality or other outcome measures. The authors report that reteplase seemed to be as effective as the older drugs but acknowledge the weaknesses of the study design.

An observational study by Herlitz and colleagues<sup>100</sup> from Sweden describes a process of administration using reteplase out of hospital, in ambulances staffed by (for the most part) a nurse in addition to ambulance staff. The number of patients reported was relatively small ( $n = 154$ ) and there was no comparator group. ECG interpretation was by a base hospital and the time to thrombolysis from arrival of the ambulance was approximately 31 minutes. The time to thrombolysis was 91 minutes in densely populated areas, up to 156 minutes in more sparsely populated areas. The latter group is perhaps analogous to the population treated in the GREAT study.<sup>84</sup> There are no outcome measures reported or any comparisons of times saved by pre-hospital thrombolysis.

A further study of reteplase in the pre-hospital setting is available in abstract format in the public domain (a slightly more detailed report is available from in-confidence information data in the Roche company submission to NICE).<sup>101</sup> This is a study which tested the safety and feasibility of pre-hospital administration of reteplase and tried to determine the time saved. It was not directly comparative and only used historical controls. Results to date include 315 patients. The median time from arrival of ambulance to thrombolysis was the same as in the Swedish study,<sup>100</sup> i.e. 31 minutes, compared to 64 minutes in a control – a saving of 33 minutes.

An Italian study<sup>102</sup> reports the use of anistreplase in a rural emergency room ( $n = 102$ ) with no immediate CCU support, perhaps analogous to a community hospital in the UK, compared to

patients transferred directly to a hospital with a CCU ( $n = 178$ ). The method of allocation was not described, and like the McAleer study,<sup>85</sup> doubts are raised about the quality of the results. The decision to thrombolysed was based on an ECG transmitted to a local CCU, and the time saving achieved was 75 minutes. Mortality at 35 days was 7.5% in those treated in the emergency room, compared to 10.7% of those treated in the CCU (3.2% reduction, 95% CI: -4% to 10%, not statistically significant).

Finally, we have received reports from the two ambulance services (East Midlands and Staffordshire)<sup>37,38</sup> currently implementing programmes of pre-hospital thrombolysis in the UK. In these trusts, the USA model of paramedic assessment and transmission of findings to a physician has been adopted. They have confirmed the feasibility of delivering thrombolysis in the pre-hospital setting. However, phasing in of the programme means that the number of patients being treated is small (14 in the first year in one area). This is consistent with reports from one of the few rural centres in Canada that implemented a policy of pre-hospital thrombolysis and did not administer the treatment to any patient in the first year (Shuster M, Director A&E, Banff Mineral Springs Hospital: personal communication, 2002). The impact of a pre-hospital thrombolysis service and the likely volume of patients are discussed in chapter 6.

### **Other pre-hospital thrombolysis studies underway**

The ASSENT-3 Plus study is a RCT comparing tenecteplase with enoxaparin versus tenecteplase with intravenous heparin in pre-hospital thrombolysis and may allow comparison. It does not compare two different thrombolytic drugs and would allow only indirect comparisons with those patients who have received tenecteplase and possibly alteplase in hospital as in ASSENT-3.<sup>79</sup> Recruitment

of 1600 patients is due to be completed in late 2002 and results will be available in early 2003 (Boehringer Ingelheim submission to NICE).

## **Conclusions**

There is no evidence regarding the comparative effectiveness of each drug in the pre-hospital setting. Therefore conclusions regarding choice of drug must be drawn from studies conducted in the hospital setting. Additionally, the choice of drug in this situation will also be influenced by convenience and ease of administration, and possibly cost.

We conclude that pre-hospital thrombolysis is feasible and reduces the time to thrombolysis, though the estimate varies from 30 minutes to 2 hours, the best estimate we believe being the pooled figure of 58 minutes in the analysis by Morrison and co-workers.<sup>90</sup> Given that this saving was achieved in the context of clinical trials, real-world savings are not known. The NSF has laid down guidelines for the provision of thrombolysis and the need to consider pre-hospital thrombolysis when time delays are expected (either due to transport time or distance).<sup>30</sup> The meta-analysis of existing studies shows a mortality benefit, although this is not shown in any individual trial.

It is tempting to extrapolate the results of the GREAT study as providing the best evidence in the NHS but there are several reasons why this should not be done.

The absolute benefit to be expected from the earlier administration of pre-hospital thrombolysis will also depend on the time to administration and on whether one follows the Boersma,<sup>26</sup> Newby<sup>27</sup> or FTT<sup>28</sup> or other plots which are discussed in detail later in the next chapter.

# Chapter 5

## Results: economic analysis

### Introduction

The aim of this chapter is to assess the relative cost-effectiveness of thrombolytic agents currently available in the UK for treatment of AMI in either a hospital or pre-hospital setting. The chapter begins with a review of published literature on the economics of different thrombolytic drugs in hospital, focusing on eight studies. These are limited to the comparison between streptokinase and alteplase and date from either before GUSTO I<sup>18</sup> or after. Their conclusions depend on whether it is accepted that alteplase is superior to streptokinase, i.e. the studies are appropriately driven by the clinical evidence.

A detailed critique is provided of the economic evaluation of the GUSTO I study<sup>18</sup> which compared accelerated alteplase and streptokinase, and also of the GREAT study<sup>84</sup> for the general principles which can be drawn in relation to considering pre-hospital thrombolysis.

A detailed critique and reanalysis was also undertaken of the economic models submitted as part of the industry submissions to NICE. To address potential bias, a more independent set of assumptions was incorporated into the models to assess their impact on the results gained. A key issue is the importance of time to initiation of thrombolysis and this is explored in depth.

### Review of economic literature

The aim of this section is to summarise those published cost-effectiveness analyses of thrombolysis that are based primarily on the results of drug versus drug RCTs. Two reviewers (ABol and AH) searched the economic literature and applied inclusion and exclusion criteria to identify relevant cost-effectiveness evidence. Two reviewers (ABol and RM) then independently assessed the studies that were included in the review. The generalisability of such results to the specific circumstances of clinical practice in the NHS is discussed in a later section (see page 52). The methods used for this review are described in chapter 2, page 8.

### Identification of studies

One reviewer (ABol) examined the titles and abstracts of the 798 articles identified by electronic search, and 98 were considered relevant. In addition, the reviewer looked through all of the articles identified by the clinical effectiveness search strategies and selected a further five papers. Finally, by searching the references of all of the papers obtained, a further four articles were identified for possible inclusion in this review. These 107 articles were then assessed for inclusion in the review using the criteria previously described (see page 8). Eight met the criteria and are considered further here.<sup>103–110</sup>

### Quantity and quality of research available

Of these eight studies, three papers<sup>103,107,108</sup> are linked as the economic evaluations described are primarily based on the same cost-effectiveness model. However, for the purposes of data extraction, these studies have been summarised as individual studies as they address different questions. One paper<sup>105</sup> is based on a previously published clinical model.<sup>111</sup> All of the studies were considered comparisons of different drugs in hospital-based thrombolysis – none addressed the cost-effectiveness of different drugs in pre-hospital thrombolysis. The results of the quality assessment exercise are presented in *Table 15*. Details of the quality checklist items are provided in appendix 8.

Overall the studies were of good quality, except in three areas. First, most of the studies did not measure costs and benefits from the same study population i.e. cost data were often estimated whereas benefit information was taken from a previously published trial. Second, the reader often had to refer to the original efficacy study in order to be sure of the comparator, as the descriptions of alternative interventions were often not sufficiently detailed. Finally the derivation of utility values was not fully explained in any of the studies containing cost–utility ratios.

### Study design

All of the studies were incremental cost-effectiveness analyses (see *Table 16*). A range of cost-effectiveness measures was described but cost

TABLE 15 Quality assessment of published economic evaluations

Checklist items:	Well-defined question	Comprehensive description of alternatives	Effectiveness established	Costs and consequences						Issues of concern to users included
				Identified accurately	Measured credibly	Valued	Adjusted for differential timing	Incremental analysis	Sensitivity analysis (SA)	
	1	2	3	4	5	6	7	8	9	10
Goel and Naylor, 1992; <sup>103</sup> Naylor et al., 1993; <sup>108</sup> Massel, 1999 <sup>107</sup>	✓ perspective explicitly stated	✓/X	✓	✓/X differences in side-effects not specifically modelled, long-term costs not incorporated into analysis	✓	✓	✓ where appropriate	✓	✓	✓/X no subgroup analyses were conducted around age, infarct location or time from onset of symptoms to treatment. Naylor et al. <sup>108</sup> and Massel <sup>107</sup> do not address long-term costs or benefits and so a full discussion of key issues is lacking
Kalish et al., 1995 <sup>104</sup>	✓	✓	✓	✓	✓	✓/X derivation of utility values is unclear	✓	✓	✓ extensive SA under-taken	✓
Kellet, 1996 <sup>105</sup>	✓ perspective explicitly stated	✓	✓/X 20% relative rate of reduction in mortality for alteplase over streptokinase is assumed rather than the conventional 14%	✓	✓	✓/X derivation of utility values is unclear	✓ results presented with and without discounting	✓	✓	✓
Lorenzoni et al., 1998 <sup>110</sup>	✓	✓	✓	✓/X authors explicitly only consider the crude cost of thrombolytic therapy and number of lives saved at 30 days	✓	✓	NA	✓	✓/X discussion of SA results in text was poor	✓/X the authors achieve their stated objectives but in doing so leave key issues undiscussed

continued

TABLE 15 contd Quality assessment of published economic evaluations

Checklist items:	Costs and consequences									
	Well-defined question	Comprehensive description of alternatives	Effectiveness established	Identified	Measured accurately	Valued credibly	Adjusted for differential timing	Incremental analysis	Sensitivity analysis (SA)	Issues of concern to users included
	1	2	3	4	5	6	7	8	9	10
Mark et al., 1995 <sup>106</sup>	✓/X inaccurate perspective stated	✓ medical costs after 1 year are excluded but introduced in SA	✓	✓	✓	✓/X derivation of utility values is unclear	✓ results presented with and without discounting	✓	✓ extensive SA undertaken	✓/X the trial data collected comes from 15 different countries, yet the discussion of results is distinctly US-focused
Pelc et al., 1997 <sup>109</sup>	✓	✓	✓	✓/X only medical costs up to 1 year are considered	✓	✓	NA	✓	✓/X discussion of SA results was more qualitative than quantitative	✓/X the authors achieve their stated objectives but in doing so leave key issues undiscussed
✓, dimension appropriately addressed; ✓/X, dimension partially/maybe addressed										

TABLE 16 Characteristics of economic studies

Study	Type of evaluation and synthesis	Interventions	Study population	Time period of study
Goel and Naylor, 1992 <sup>103</sup>	C-E analysis; cost per life-year gained	Streptokinase, i.v. alteplase	Hypothetical cohort of non-elderly patients with uncomplicated myocardial infarctions. SA allowed extrapolation to higher risk subgroups	Trial data – 4 weeks after AMI; extrapolated data – 5 years
Kalish <i>et al.</i> , 1995 <sup>104</sup>	C-E analysis and cost-utility analysis; cost per QALY gained	i.v. streptokinase, accelerated alteplase	Hypothetical patients with acute MI who were candidates for thrombolytic therapy and who presented within 6 h of symptom onset	Trial data – 1 year; extrapolated data – over remaining lifetime
Kellett <i>et al.</i> , 1996 <sup>105</sup>	C-E analysis and cost-utility analysis; cost per QALY gained	Accelerated alteplase, streptokinase	Hypothetical 65-year-old man with a definite acute MI presenting < 4 h after the onset of symptoms	Trial data – 30 days after AMI; extrapolated data – over remaining lifetime
Lorenzoni <i>et al.</i> , 1998 <sup>110</sup>	C-E analysis; cost per extra life saved	Alteplase, streptokinase	Hypothetical population of 1000 patients with AMI with the clinical characteristics of the patients enrolled in the GUSTO trial <sup>18</sup>	Trial data – 30 days after AMI; extrapolated data based on GUSTO I results
Mark <i>et al.</i> , 1995 <sup>106</sup>	C-E analysis and cost-utility analysis; cost per life-year gained, cost per QALY gained	Accelerated alteplase, streptokinase	Patients enrolled in the GUSTO trial <sup>18</sup>	Trial data – 1 year after MI; extrapolated data – over remaining lifetime
Massel, 1999 <sup>107</sup>	C-E analysis; cost per additional short-run survivor	Streptokinase + aspirin, accelerated alteplase + aspirin	Hypothetical cohort of non-elderly patients with uncomplicated MI who have resistance to streptokinase	Trial data – 5 to 6 weeks after MI
Naylor <i>et al.</i> , 1993 <sup>108</sup>	C-E analysis; cost per additional short-run survivor	Alteplase, recombinant t-PA, i.v. streptokinase	Hypothetical cohort of non-elderly patients with uncomplicated MI. SA allowed extrapolation to higher risk subgroups	Trial data – 5 to 6 weeks after MI
Pelc <i>et al.</i> , 1997 <sup>109</sup>	C-E analysis; cost per life-year saved	Accelerated alteplase versus streptokinase	602 patients who survived initial MI in Feb 1993 and 102 patients who did not survive initial MI during this period	Trial data – 1 year after AMI; extrapolated data based on GUSTO I results

per life-year saved was the most common. Three papers also included incremental cost-utility analyses and used quality-adjusted life-years (QALYs) as a measure of utility. All of the studies considered only one comparison between thrombolytics – that between alteplase and streptokinase – standard alteplase in the pre-GUSTO I studies, and accelerated alteplase in studies published after GUSTO I.

The time period of analysis varied across studies. The time period chosen was primarily determined by the source of efficacy data. Where the studies used modelling techniques to estimate survival, the time horizon of the model was much longer than the time period of the study for which real data were available. Some studies only calculated costs until the end of the first year post-MI whilst others

calculated costs over the entire remaining life expectancy of the patient. Although incremental costs were calculated by all of the studies, few of the studies provided enough cost information to replicate the calculations to check the robustness and reliability of their calculated incremental cost-effectiveness ratios (ICERs).

### Costs

Cost data and their source are presented in Table 17. Some authors used both primary and secondary cost data sources and both national and local sources of cost data were used in the studies. Individual patient costing was not used and none of the studies adopted a societal perspective.

The key categories of costs were similar across all of the studies and can be divided into hospital



TABLE 17 Cost data and cost data sources

Study	Cost items	Cost data sources	Country, currency and year
Goel and Naylor, 1992 <sup>103</sup>	Thrombolytic drugs, cardiac procedures and other treatment of AMI episode. Long-term model did not include differences in costs of medical care in added years of life	Procedural costs based on a comprehensive costing study carried out in four Canadian teaching hospitals from 1986–88. Professional costs from Ontario Health Insurance Plan fee schedule which includes visit and fee charges. Drugs costs from manufacturers	Canada; Canadian dollars (Can\$); 1986–88 (all costs were adjusted to represent constant 1988 dollars using the Canadian Consumer Price Index)
Kalish et al., 1995 <sup>104</sup>	Thrombolytic therapy, haemorrhage, anaphylaxis and procedures. Long-term costs of managing CHD and disabling stroke were calculated	Thrombolytic therapy – medication costs (Brigham and Woman's hospital); hospitalisation – DRG reimbursement rates including professional fees (Brigham and Woman's hospital); miscellaneous – national and published figures, patient-driven data	USA; US dollars (US\$); 1992
Kellett et al., 1996 <sup>105</sup>	Thrombolytic therapy, anaphylaxis, major bleed, major stroke, AMI and heart failure. Long-term costs of nursing home care for major stroke and medical care for CHF were calculated	Irish hospital costs based on DRGs (1988). Drugs costs – list price. Stroke costs – telephone survey. Medical care for CHF – personal communication and estimates	Ireland; Irish pounds (IR£); 1996 (1988 costs were inflated to 1996 prices using a 5% per annum inflation rate). Costs are also presented in pounds sterling (1996)
Lorenzoni et al., 1998 <sup>110</sup>	Only changes in thrombolytic therapy costs were discussed	Drug costs from national formularies: <i>Rote Liste</i> (Germany), <i>L'informatore Farmaceutico</i> (Italy), <i>British National Formulary</i> (UK), <i>Red Book</i> (USA)	Germany; marks; 1995; Italy; lire; 1996; UK; pounds sterling; 1996; and USA; US\$; 1996. Relevant costs were estimated in ECUs and in US\$. Exchange rates as 1 December 1997
Mark et al., 1995 <sup>106</sup>	Thrombolysis therapy, cardiac procedures, length of stay in intensive care unit, rehospitalisation, follow-up hospital days and outpatient visits. No cost differences in treatment groups were calculated after 1 year	Initial hospitalisation – Duke Transition One cost – accounting system and Medicare fee schedule (North Carolina); drugs – list price and average cost of 16 randomly selected GUSTO hospitals; follow-up – Medicare DRG reimbursement rates (North Carolina); physician's fees – Medicare fee schedule	USA; US(\$); 1993
Massel, 1999 <sup>107</sup>	Thrombolytic drugs, cardiac procedures and other treatments of AMI	Procedural costs based on a costing study in four Canadian teaching hospitals from 1986–88. Professional costs were obtained from Ontario Health Insurance Plan fee schedule which includes visit and fee charges. Drugs costs from manufacturers	Canada; Can\$. All costs were inflated to 1997 Can\$ with the Health and Personal Care component of the Canadian Consumer Price Index
Naylor et al., 1993 <sup>108</sup>	Thrombolytic drugs, cardiac procedures and other treatments of AMI	Procedural costs based on a comprehensive costing study carried out in four Canadian teaching hospitals from 1986–88. Professional costs were obtained from Ontario Health Insurance Plan fee schedule which includes visit and fee charges. Drugs costs from manufacturers	Canada; Can\$; 1986–88; all costs were adjusted to represent constant 1991 dollars using the Canadian Consumer Price Index
Pelc et al., 1997 <sup>109</sup>	Days in CCU, thrombolysis, cardiac procedures, drug treatments, rehospitalisation. Costs were only estimated up until 1 year after treatment	Treatment – Treatment Strategy in Myocardial Infarction register which included data from 327 active general hospitals and 1828 patients (Feb 1993) + 1 year extension of this register which involved more than 700 of these patients. Hospital and patient surveys	France; french francs (FF); 1994

DRG, diagnosis-related group

costs and post-discharge continuing care costs. Hospital costs included the thrombolytic drug therapy costs as well as cardiac procedures, length of stay and professional charges. Post-discharge costs included follow-up clinics and the treatment of adverse events. There was significant variation in the estimation of costs related to adverse events with some studies including the continuing cost of strokes and heart failure while others did not.

### Outcomes

All of the studies analysed used a reduction in mortality as their primary outcome measure. The timescale over which mortality improvements were measured and the metric used (number of lives saved, life-years gained, QALY improvements) varied between the studies. The efficacy data sources described vary depending on the publication date of the study (see *Table 18*). Two pre-GUSTO I studies<sup>107,108</sup> used efficacy data from a range of five randomised controlled clinical trials that directly compared streptokinase and alteplase. Both of these papers used sensitivity analysis to address the uncertain efficacy of alteplase over streptokinase. One study<sup>105</sup> used a reduced mortality rate of 20% from the GUSTO I study instead of the conventional 14% reduction. A range of outcomes was stated in the studies. Several papers quoted similar efficacy data from the GUSTO I study including 30-day mortality, 1-year mortality, number of life-years and QALYs gained. Adverse event outcomes of interest included stroke, reinfarction, major bleed, anaphylaxis, and CHF.

Where cost–utility analysis was undertaken, the source of the utility values was usually derived from previously published papers.<sup>104,105</sup> Only one study attempted to calculate utility values directly from real subjects.<sup>106</sup> However, little detail was provided regarding the elicitation of values, making their accuracy and appropriateness uncertain.

### Cost-effectiveness ratios

Most studies were undertaken outside the UK, thus using different cost data and assumptions that were not directly relevant to the NHS.

Five of the studies explicitly conducted subgroup analyses (see *Table 19*), usually based on age, location of infarct and time to treatment. Some studies explored these subgroups in isolation,<sup>104,110</sup> others in combination. Where subgroup analyses were performed, the results demonstrated that more favourable cost-effectiveness ratios were achieved by treating older people, patients with anterior infarcts and those patients who presented early for treatment.

All of the studies conducted sensitivity analysis to some extent. One-way, two-way and three-way approaches to sensitivity analysis were described. The three linked papers<sup>103,107,108</sup> described in this review used sensitivity analysis to investigate the impact of differences in efficacy between alteplase and streptokinase on their results.

One study was supported by a research grant from a pharmaceutical company.<sup>104</sup> Only two studies did not acknowledge funding sources.<sup>109,110</sup> The authors of the six remaining papers acknowledged some form of support from manufacturers of thrombolytic drugs.

### Overall assessment of published economic evidence from RCTs

Incremental cost-effectiveness analysis was the appropriate approach to adopt in all of the studies as it is the change in costs and the corresponding change in benefits which is of interest to the decision maker. All of the studies justified their choice of comparator. Given the publication dates of the included studies, all of the studies included comparators that were relevant alternatives for the treatment of AMI at that time. The majority of studies used efficacy data from the GUSTO I study.<sup>18</sup> This was an international trial but the estimated use of medical resources was derived only from US patients, and is unlikely to translate into other health services. Authors in Europe applied the results of the GUSTO I study to their own settings in an attempt to compare the cost-effectiveness of alteplase versus streptokinase. Consequently, cost-effectiveness ratios were expressed in several currencies, a reflection of the international interest in the choice between alteplase and streptokinase. Clearly the range of costs identified, estimated and valued in an economic evaluation influences the calculation of the cost-effectiveness ratio. Unfortunately some studies did not sufficiently explore the true cost of complications over the lifetime of the patient, nor was this addressed fully by sensitivity analysis.

As it is uncommon for quality of life data to be routinely included as part of a RCT, it is perhaps not surprising that only three studies considered issues that can be addressed by cost–utility analyses. Given that both alteplase and streptokinase have been demonstrated to improve both patient quality and quantity of life, the use of cost–utility analysis in this context would have been informative.

Subgroup analysis was appropriately performed in many of the studies with age, location of infarct

**TABLE 18** Outcome data and data sources

Study	Range of outcomes	Efficacy data sources	Utility values and data sources	Modelling method and data sources	Probabilities and assumptions of model
Goel and Naylor, 1992 <sup>103</sup>	Mortality, life-years gained	5 RCTs that compared directly streptokinase and alteplase (1985–90)	NA	SA was used to project differences in outcome. Short-term mortality based on data from five RCTs. Long-term survival was modelled using data from the ISAM trial* (48 months)	Baseline case assumes short-term mortality with streptokinase is 8% and the annual hazard rate post-streptokinase is 4% allowing combinations of varying short-term and long-term advantages for alteplase to be considered. Short-term re-infarction rate of 6% for streptokinase was also used. Non-fatal events were not considered in the long-term model
Kalish et al., 1995 <sup>104</sup>	Death within 30 days; death within 1 year; survival with stroke; survival with reinfarction; survival with stroke and reinfarction	GUSTO I study <sup>18</sup> (1993)	Published trial (GISSI-2 <sup>46,47</sup> ) where the time-trade off method was used. Paper published in 1994	Life expectancy after MI and after stroke was calculated using the Declining Exponential Approximation of Life Expectancy (DEALE) method. <sup>†</sup> Other life expectancy estimates were based on a consensus of the authors. Baseline probabilities used from published trials	Extrapolation via assumption of constant mortality rate. Baseline case: 9% alteplase mortality, streptokinase 10.1%; cost of alteplase US\$2216, streptokinase US\$313; life expectancy after MI: 14.6 years, stroke rate with alteplase 0.9%, 0.8% with streptokinase; reinfarction rate 4% with alteplase, 3.7% with streptokinase
Kellett, 1996 <sup>105</sup>	Death from MI; life-years gained; QALYs; stroke; major bleed; anaphylaxis; CHF	GUSTO I study; <sup>18</sup> risk of stroke for patients was taken from a review of 13 major trials of thrombolytic therapy (1993)	Previously published studies (1985, 1991, 1995); perfect health (1), alive with major disabling stroke (0.5), alive with CHF (0.9)	Life expectancy estimated using a Markov process. Probability of death from AMI, reduction in mortality from MI due to thrombolytic therapy – published literature. Risk of stroke after thrombolysis taken from a review of 13 major trials of thrombolytic therapy	Reduction in probability of dying from MI if accelerated alteplase given < 4 h = 20%; additional risk of major disabling stroke with alteplase 0.3%–0.4%; reduction in risk of developing CHF with alteplase = 10%
Lorenzoni et al., 1998 <sup>110</sup>	Number of lives saved after 30 days	GUSTO I study <sup>18</sup> (1993)	NA	Data sources based on GUSTO I <sup>18</sup>	Data sources based on GUSTO I <sup>18</sup>
Mark et al., 1995 <sup>106</sup>	Mortality at 30 days; mortality at 1 year; life-years gained; quality of life; disabling non-fatal stroke	GUSTO I study <sup>18</sup> (1993)	Prospective random sample of GUSTO patients (n = 2600). Based on telephone interviews 12 months after treatment. Mean utility weights were same for both groups (0.9)	A Cox proportional hazards model was constructed and included a Gompertz parametric survival function. Survival model was based on the experience of 4379 patients in the Duke Cardiovascular Disease database <sup>112</sup>	Hazard of death after 1 year did not depend on the thrombolytic agent received; patients' pattern of long-term survival was typical of the chronic, stable phase of CHD. Streptokinase survival at 30 days = 92.7%, alteplase = 93.7%; streptokinase survival at 1 year = 89.9%, alteplase = 91% from GUSTO I study <sup>18</sup>

continued

TABLE 18 contd Outcome data and data sources

Study	Range of outcomes	Efficacy data sources	Utility values and data sources	Modelling method and data sources	Probabilities and assumptions of model
Massel, 1999 <sup>107</sup>	Short-term (5–6 weeks) survival	5 RCTs that compared directly streptokinase and alteplase; GUSTO I study <sup>18</sup> (1985–93)	NA	Potential benefits from treatment were estimated only with respect to short-term survival	NA
Naylor et al., 1993 <sup>108</sup>	Short-term (5–6 weeks) survival	5 RCTs that compared directly streptokinase and alteplase. Preliminary results from GUSTO I <sup>18</sup> (1985–93)	NA	Long-term survival was not incorporated into the analysis	NA
Pelc et al., 1997 <sup>109</sup>	Mortality at 1 year; life-years gained	GUSTO I <sup>18</sup> (1993)		Data sources based on GUSTO I <sup>18</sup>	Data sources based on GUSTO I <sup>18</sup>

ISAM, Intravenous Streptokinase in Acute Myocardial Infarction

\* ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. *New England Journal of Medicine* 1986;**314**:71

† Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (The DEALE). I. Validation of the method, and II. use in medical decision-making. *American Journal of Medicine* 1982;**73**:883–97

and time from onset of symptoms to treatment being the three most important groups. However, it should be noted that subgroup analysis by age based on the results of the GUSTO I study<sup>18</sup> should be handled with care as only 30-day efficacy data were available at the time when study results were published. The results of the sensitivity analyses revealed that the mortality differential between streptokinase and alteplase was the factor that consistently influenced the cost-effectiveness ratio. The cost differential between drugs was also important.

### Conclusions

Pre-GUSTO I studies that compared alteplase with streptokinase were in agreement that until any mortality advantage could be identified for alteplase, streptokinase would continue to be the preferred choice of thrombolytic drug. However, with the publication of the GUSTO I study results<sup>18</sup> and the demonstrated mortality benefit of alteplase over streptokinase, subsequent economic studies have shown that alteplase appears to be more cost-effective than streptokinase. The outcome of this review of the economic studies is therefore dependent on whether one accepts the results of the GUSTO I study as illustrating a credible clinical advantage over streptokinase, a matter for appraisal (see chapter 3).

## Detailed analysis of major sources of economic evidence

### Economic analysis of the GUSTO I trial Cost-effectiveness analysis

The GUSTO I clinical trial<sup>18</sup> incorporated an economic subgroup analysis to determine the comparative cost-effectiveness of alteplase and streptokinase. Effectiveness was expressed as the number of additional years of life saved calculated by taking the number of lives saved, multiplied by an estimate of remaining life expectancy. Complex modelling was required to estimate the impact of the short-term benefit on long-term outcome as long-term patient survival was unknown. To translate the survival data (11 extra survivors at 1 year per 1000 patients treated on alteplase) into additional years of survival, the Duke Cardiovascular Disease database<sup>112</sup> was combined with statistical techniques to estimate lifetime survival. From these calculations, it was estimated that each alteplase patient would gain an average of 0.14 life-years from alteplase relative to streptokinase.

The treatment groups had the same rate of bypass surgery (13%) and angioplasty (31%) during the

initial hospitalisation. Overall, the first year health costs excluding the difference in the cost of the thrombolytic agent were US\$24,990 per patient treated with alteplase and US\$24,575 per patient treated with streptokinase. The estimated cumulative increase in medical costs (hospital cost plus physician fees) at 1 year therefore averaged US\$415 for alteplase patients in comparison to streptokinase. When the relative costs of the two thrombolytic agents were added in, the resulting incremental cost for the alteplase arm rose to US\$2845. Because the non-drug cost-differential at 1 year was not significant, the primary analysis assumed that there would be no incremental cost for alteplase after the first year. Thus, US\$2845 was also held to represent the incremental lifetime costs of a patient treated on alteplase, rather than streptokinase.

Using this estimate and a discount rate of 5%, the GUSTO I trial investigators concluded that the cost-effectiveness ratio of using alteplase instead of streptokinase was US\$32,678 per year of life saved. As part of the sensitivity analysis, the costs typically paid by hospitals for thrombolytic agents were substituted for their list price. This alteration reduced the cost per life-year saved to US\$27,115. Although it was stated that a societal perspective had been employed, indirect and non-medical costs were not included in the analysis.

There was consideration of the utility of patients who have had an AMI in the GUSTO I study: patients in the study were generally willing to trade 10 years of life in their post-AMI state of health for 9 years of excellent health. Applying this weighting factor to both alteplase and streptokinase recipients rescaled the cost-effectiveness ratio in the baseline case to US\$36,402 per QALY.

### Subgroup analysis in GUSTO I

Assessment of the comparative costs and benefits arising for selected subgroups (by age and location of infarct) of patients was performed in GUSTO I. This analysis might enable thrombolytic therapy to be targeted upon patients in whom it is most effective or cost-effective. However, as the authors stress, the results of the subgroup analyses should be interpreted cautiously.

In general, cost-effectiveness was greater in patients at higher risk of absolute mortality, i.e. the older patients and those with anterior infarcts. For example, the additional cost per life-year gained of alteplase over streptokinase was estimated to be US\$13,410 for patients older

TABLE 19 Results presented in included studies

Study	C-E ratio	Subgroup analysis and results	SA and results	Authors' conclusions
Goel and Naylor, 1992 <sup>103</sup>	If alteplase is superior to streptokinase, cost per life-year gained would be Can\$58,600; if no immediate survival advantages but greater left ventricular preservation, cost per life-year gained would be Can\$37,400	ns	One-way and two-way SAs were undertaken. Results were relatively insensitive to changes in any factors apart from short- and longer-term mortality rates with alteplase, cost of alteplase and the relative procedure volume ratio	Streptokinase is a more cost-effective choice than alteplase without proven short-term mortality advantages
Kalish et al., 1995 <sup>104</sup>	US\$30,300 per additional QALY gained for use of alteplase versus streptokinase (based on 30-day mortality from GUSTO I <sup>18</sup> ); US\$27,400 per additional QALY using 1 year mortality data	C-E ratios were more favourable in older patients (< US\$50,000/QALY for a projected life expectancy of $\geq 5$ years), in patients treated < 6 h (US\$34,000/QALY) and in AMIs (US\$16,300/QALY)	One-way SA was conducted using 1-year GUSTO mortality data. ICER was sensitive to the difference in mortality seen between streptokinase and alteplase (however, even if relative mortality advantage of alteplase is only half that shown by GUSTO, cost per QALY remains < US\$60,000), cost of thrombolytic therapy and life expectancy after MI	Despite its higher cost compared to streptokinase, alteplase is a cost-effective therapy for myocardial infarction under a wide range of assumptions regarding clinical outcomes and costs
Kelleff, 1996 <sup>105</sup>	ICER of accelerated alteplase over streptokinase was IR£6290.29 per life-year or IR£6176.72 per QALY	Older patients and those with anterior infarctions had improved C-E ratios. Higher risk of stroke worsens C-E ratio (inversion point > 1.9%) and higher probability of dying from MI (no treatment) (inversion point < 6.4%) improves the C-E ratio	Threshold analysis using the IR£10,000 per QALY critical value; results were sensitive to incremental cost of alteplase over streptokinase, discount rate used for survival benefits, time of treatment after onset of symptoms, patient age, probability of dying from MI, probability of stroke	Accelerated alteplase, if given early after symptom onset in specific patient groups, could be a highly efficient use of scarce healthcare resources
Lorenzoni et al., 1998 <sup>10</sup>	Incremental cost (ECUs) per extra life saved: 132,199 (Germany); 146,652 (Italy), 100,757 (UK), 198,254 (US)	C-E ratios were more favourable in older patients and in anterior MIs. Best C-E ratios found in the UK	Based on GUSTO I study <sup>18</sup> 95% CIs of risk reduction. SA results are poorly explained. At the lower extreme of the CI, alteplase can result in higher costs and lower efficacy than streptokinase	C-E of alteplase versus streptokinase varies greatly among countries due to differences in drug costs. Selective use of thrombolytics for some sites of infarction is more cost-effective than the exclusive use of alteplase
Mark et al., 1995 <sup>106</sup>	ICER for the use of alteplase instead of streptokinase was US\$32,678 per life-year gained, incremental cost per QALY was US\$36,402; undiscounted cost per life-year gained = US\$20,468	C-E ratios were more favourable in older patients and in anterior MIs. For anterior, > US\$50,000/QALY for patients 40 years of age or under. For inferior MIs, > US\$50,000/QALY for patients up to 60 years	One-way SA (including threshold analysis). Results were most sensitive to a lowering of the long-term survival benefits of alteplase (cost/life-year gained > US\$50,000 if life-years saved < 7 undiscounted years per 100 patients) and to increases in the projected medical costs for alteplase patients after the first year (if alteplase group had extra costs of US\$1,100 per year past the second year of follow-up, cost per life-year gained > US\$50,000)	C-E of treatment with accelerated alteplase rather than streptokinase compares favourably with that of other worthwhile therapies

continued

TABLE 19 contd Results presented in included studies

Study	C-E ratio	Subgroup analysis and results	SA and results	Authors' conclusions
Massel, 1999 <sup>107</sup>	Alteplase is a cost-effective alternative to streptokinase when resistance is high (Can\$54,158 per short-run survivor with 50% resistance) assuming a 1% absolute risk reduction in mortality. As the level of resistance decreases, alteplase becomes a less cost-effective choice	ns	Two-way SA varying percentage of patients with resistance to streptokinase, and additional absolute reduction in mortality from alteplase use instead of streptokinase. Alteplase was cost-effective when rates of streptokinase resistance were high, even with modest absolute risk reductions in mortality	Using alteplase in patients previously treated with streptokinase is a cost-effective strategy but becomes less cost-effective as resistance increases
Naylor et al., 1993 <sup>108</sup>	Alteplase is cost-effective as a substitute for streptokinase if clinically superior. For a 1% mortality advantage, the cost per additional short-term survivor is Can\$277,860	ns	One-way SA shows that by varying the absolute risk reduction in mortality from 4% to 0.5%, incremental cost per additional short-run survivor varies from Can\$69,465 to Can\$55,721	The final verdict on the C-E of alteplase versus streptokinase must wait for empirical data from the GUSTO trial
Pelc et al., 1997 <sup>109</sup>	Incremental C-E of alteplase (versus streptokinase) was FF70,128 per life-year saved	C-E ratios were less favourable in younger patients and those with inferior infarctions	One-way SA. Costs were substituted with exact (highest possible) unit cost data from a single specialised cardiology centre (FF107,450/life-year gained)	Clinical and C-E data demonstrate that alteplase is a cost-effective first line option for the management of AMI in French general hospitals

than 75 years with anterior MI, and \$16,246 for patients older than 75 years with inferior MI. In contrast, in a low-risk patient such as a patient younger than 40 with an inferior infarction, the cost-effectiveness ratio was US\$203,071 per year of life saved.

In summary, the economic analysis performed alongside GUSTO I demonstrated that alteplase expanded survival at an acceptable cost within the context of a clinical trial undertaken in the USA healthcare system.

### **Critique of the economic analysis of the GUSTO I trial**

The GUSTO I study<sup>18</sup> has been criticised from many viewpoints. Other investigators have commented on the small size of the difference in outcome, differences in the results obtained within and outside of the USA, the open nature of the trial, the high cost differential between the drugs studied, the increased stroke rate with alteplase and other factors that are held to prevent acceptance of the conclusions.<sup>93</sup> All of these factors must be taken into consideration when interpreting the cost-effectiveness ratios of the economic analysis presented by the authors, as their implications might affect the magnitude of the clinical effect and/or limit the relevance of study findings to specific settings.

### **Cost differences in the first year**

The authors only reported cost differences between the groups during the first year post-infarct as they estimated that the cost differences in the second 6 months of the first year were not significantly different. In addition, cost data after the first 12 months were not available. By far, the two most expensive cost items during the initial hospitalisation period were coronary angioplasty and coronary bypass surgery which were performed with equal frequency in both groups. However, given the acknowledged higher rate of aggressive and invasive interventions in the USA compared to other countries,<sup>113</sup> it would have been useful to explore the impact of changing the procedural rates to reflect those of non-USA countries on the estimated cost-effectiveness ratios.

### **Cost differences after 1 year**

If the non-significant cost differential identified between the two groups between 6 and 12 months (US\$508) was annualised and maintained for the entire period of increased survival, then an unacceptable cost-effectiveness ratio of US\$147,333 would have been estimated.<sup>114</sup>

Even if this cost differential were maintained for a period of only 3 years, the incremental cost per life-year gained would be US\$55,300. Clearly inclusion or exclusion of this cost differential has significant implications for the cost-effectiveness of alteplase versus streptokinase.

### **Increased risk of stroke**

Alteplase resulted in significantly more non-fatal disabling strokes than streptokinase, but the additional cost of care for patients who experienced stroke was only incorporated into the economic analysis for the first year post-infarct, after which costs were assumed to be equivalent for both groups. This approach to costing is subject to criticism as it is likely that health services incur costs for a much longer period for this group of patients. The authors, to some extent, addressed this issue using sensitivity analysis. In the sensitivity analysis, a patient with a disabling stroke was assumed to have the same life expectancy as a non-stroke patient but was assumed to require lifetime (15 years) institutionalised care. This assumption reduced the comparative cost-effectiveness of alteplase to US\$42,400 per life-year saved.

### **Quality of life issues**

The methods used to elicit utility values to explore patient quality of life issues were not clearly described by the authors. The elicitation of utility values from patients does not lend itself to telephone interviews given the complex nature of the questions and concepts under discussion. In addition, comparative quality of life data in subgroups of patients receiving alteplase or streptokinase was not analysed. This is an important omission in view of the difference in the rate of strokes between the two groups.

### **Implications for the UK**

The generalisability of the GUSTO I results has been intensively scrutinised. With regard to the economic study, the only concession to differences between non-USA countries and the USA was the use of typical European prices for the drugs in a sensitivity analysis; substitution of European prices leads to a substantially improved cost-effectiveness ratio (US\$13,943 per year of life saved). Unfortunately in the economic analysis, there was no similar reflection of the different patterns of care between non-USA countries and the USA. Evaluation of the GUSTO I data has at least shown that alteplase is more cost-effective than streptokinase in the USA, whether or not these results have less relevance for non-USA countries is the subject of much debate.



### **Economic analysis of the GREAT study**

The cost-effectiveness of pre-hospital versus in-hospital thrombolysis is not the subject of this review. Nevertheless, it is important to review one trial which addressed this issue, the GREAT study,<sup>84</sup> as it considered several important areas within the context of the NHS. The clinical details of this trial have already been discussed in chapter 4; this current section considers the economic evaluation associated with that study.<sup>115,116</sup>

The authors compared the costs and benefits of anistreplase (see chapter 1 – this drug is no longer available in the UK for commercial reasons), administered by GPs before the patient was admitted to hospital, versus hospital thrombolysis in a RCT. This paper was excluded from the detailed review of economic evidence outlined above because the trial was not a direct drug versus drug comparison (anistreplase may be considered a more convenient bolus-administered equivalent of streptokinase) but rather a setting-to-setting comparison.

Relative to hospital thrombolysis, analysis of the GREAT trial has shown that pre-hospital community thrombolysis versus hospital thrombolysis leads to a significantly enhanced probability of survival at 4 years of 11%, at a very modest additional cost (£425 per patient). This gives a marginal cost per life saved of £3890. The cost per life-year saved by pre-hospital thrombolysis is modest compared with, for example, the cost of switching from streptokinase to alteplase in the hospital setting.<sup>115,116</sup>

It was estimated that if all eligible patients had received early thrombolysis, then the total additional cost to the health service would have been £77,000.<sup>115</sup> Therefore it would appear that the benefits of early thrombolysis could be obtained for a comparatively insignificant increase in cost. However, there would be additional costs to the health service as a whole because such early thrombolysis would cause an estimated 1.5% increase in the number of patients surviving AMI until admission to hospital.<sup>115,116</sup>

#### **Critique of the economic analysis of the GREAT study**

A criticism of the economic analysis of the GREAT study is that the economic evaluation was not carried out at the same time as the RCT. The economic analysis<sup>116</sup> was conducted 4 years later and relied on very limited follow-up data.

The economic evaluation would have benefited from some consideration of quality of life issues. Although no study viewpoint was explicitly stated, it can be assumed that the evaluation adopted a NHS perspective that included costs incurred in both hospital and pre-hospital settings.

From the published economic evaluation, it was difficult to determine the exact nature of the two interventions being compared. In particular, a detailed description of hospital thrombolysis was lacking.

Costs included in the economic evaluation were appropriately described in terms of the range of costs included in the analysis. However, physical quantities of costs and unit costs in monetary terms were not presented. It would be impossible for the analysis to be replicated using different parameter values more suited to the reader's setting.

The authors conducted sensitivity analysis to a limited extent. In their cost analysis of pre-hospital thrombolysis, the authors used low and high estimates regarding the additional length of GP visits and capital equipment. No parameters were varied in the analysis of hospital costs. The probability of survival after pre-hospital thrombolysis compared to hospital thrombolysis was based on the latest data from the GREAT trial, and at 4 years the additional probability of survival was 0.11 (95% CI: 0.01 to 0.21). As the GREAT study was not designed with a cost-effectiveness question in mind, the CIs around the cost per life saved were very wide. Low estimates revealed a range of £1990 to £42,820 whereas high estimates revealed a range of £4100 to £88,100.

In summary, the cost per life saved by community thrombolysis headlined in the paper by the authors was modest and ranged between £3890 and £8000 (figures from low-estimate calculations). It would have been appropriate for the authors to present the results of their economic analysis in terms of cost per life-year saved in keeping with other economic studies.

Although impressive, the results of the GREAT study need to be tempered by comparison with other trials that have shown a lesser benefit, as discussed in chapter 4. The applicability of the GREAT study to the NHS as a whole is therefore uncertain, as are the results of its cost-effectiveness analysis.

## Discussion of key issues highlighted by reviews of economic evidence

### Perspective

The perspective from which economic analyses of AMI are undertaken is crucial as the viewpoint adopted influences the range of costs to be identified, measured and valued. No studies have addressed the indirect costs to patients or their families of an AMI or of a disabling stroke following thrombolysis. There is debate about the most appropriate way of measuring such indirect costs and whether and how such measurements should include loss of productivity. Most studies therefore adopt a simple health service or payer perspective.

### Treatment costs

The treatment cost of an uncomplicated AMI in the NHS is estimated at £903<sup>117</sup> and this figure is based on an average of 5 inpatient days. The figures provided in the industry submissions to NICE are higher (around £1900 for an uncomplicated MI, excluding costs of thrombolysis) and seem more plausible to us. In either event, the costs of thrombolysis other than with streptokinase are a very significant element of the costs of AMI.

Most previously published economic evaluations considered the cost of drug treatments for AMI small by comparison with the associated costs of inpatient stay. This may be correct if subsequent follow-up care is included, especially when expensive diagnostic and treatment techniques are utilised or if the patient suffers serious adverse events. Several studies in North America and Europe have suggested that the contribution of the thrombolytic drug to the total cost of care ranges from approximately 0.5% (streptokinase) to 5% (alteplase).<sup>93</sup>

The biggest costs are perhaps those of rehabilitation and support following disabling stroke. Attributing a single cost to stroke is complicated by the many different levels of care associated with different severities of stroke. The impact of variations in the incidence of stroke on the comparative cost-effectiveness of different thrombolytics will depend on the comparative incidence and lifetime support costs associated with this adverse outcome. In general, this aspect of long-term costs has not been well managed in economic studies published to date.

### Generalisability of economic evaluations conducted alongside clinical trials

Economic evaluations are likely to be strengthened by being linked to clinical trials as this provides scientifically credible data on which to base economic analysis. However, real-world clinical practice is not as controlled as in the clinical trial framework, and the issues around generalisability of trials to real-world clinical practice has been discussed above. Major problems occur in comparing the results due to differences in methodology, clinical setting, assumptions made and study perspective. Jonsson and Weinstein<sup>118</sup> discussed methods of addressing the problems that arise in economic evaluations linked to international trials of AMI. Clinical trials generally enrol patients who have a lower mortality than expected in a general population and therefore the benefits of a therapy in high-risk patients such as the elderly may be underestimated. Conversely, a clinical trial may not enrol patients with co-morbidity and thus may underestimate the adverse effects of a therapy if it were given routinely in a community hospital. In addition, cost structures vary in different environments and patterns of care, including indications, threshold for interventions, duration of hospital stay and readmission rates will vary widely. Some costs may occur because of protocol-driven costs that are outside the normal clinical care of the patient. It is important therefore that these be distinguished from standard care.

In economic evaluations based on multicentre studies e.g. thrombolytic trials, some of these difficulties are compounded by the fact that many patients will be cared for in health services where the care received and its cost are substantially different from those in the NHS. For instance, in the economic evaluation of the GUSTO I study<sup>18</sup> the one concession made to translating the American cost to a European setting was a sensitivity analysis around the cost of the drug. This ignored different patterns of medical care and different costs for procedures or staff in Europe and makes the results unreliable for this reason. Such studies, although they lack generalisability, may provide the data that allow translation to other settings.<sup>118</sup>

### Summary from review of economic evidence

Any estimate of the relative cost-effectiveness of accelerated alteplase compared with streptokinase depends critically on the weighting of evidence

between GUSTO I<sup>18</sup> and previous trials. However, the data on thrombolysis in AMI is evolving and more clinical and economic data are required to demonstrate benefits both in the pre-hospital and hospital settings. A range of factors on both the cost and effectiveness side will considerably influence cost-effectiveness in the future. The price of thrombolytic drugs may decrease, practice patterns may change and there may be further improvements in pharmacological therapy. For thrombolysis, as in other situations, effectiveness data in routine clinical practice will be crucial with such factors as bleeding complications, stroke rates, and timing of intervention likely to vary from those identified in the efficacy data identified in clinical trials.

The comparative cost-effectiveness of the different drug regimes appears to be uncertain from current available evidence, especially regarding the use of reteplase and tenecteplase. In addition, comparative drug costs must be placed in the context of the total cost imposed on the health service by each of the therapeutic options.

## Critique and re-analysis of industry-submitted economic models

### Introduction

Review of the economic evidence on early thrombolysis for the treatment of AMI reveals that very little up-to-date evidence of cost-effectiveness exists in the published literature. Upon further investigation, it is clear that those studies that do exist are limited in their relevance to the UK NHS. No economic evaluations of reteplase or tenecteplase were identified by the literature search. However, in the industry submissions to NICE both these drugs together with streptokinase and alteplase were the focus of detailed cost-effectiveness analyses. We felt that it was appropriate to appraise the economic models as presented in the industry submissions and offer our own conclusions on the relative cost-effectiveness of thrombolytics based on exploration of a range of potential scenarios reflecting uncertainty in the underlying model assumptions and parameter values.

### Industry submissions

Submissions to NICE were received from the following manufacturers/sponsors:

- Aventis Behring Ltd
- Boehringer Ingelheim Ltd
- Roche Products Ltd.

Two of the three industry submissions include detailed cost-effectiveness models in support of the clinical evidence presented (Boehringer Ingelheim and Roche). All three companies include a cost-impact analysis for the extended use of their product. This critique focuses on the submissions offered by Boehringer Ingelheim and Roche as they comprehensively address the cost-effectiveness of thrombolysis in both hospital and pre-hospital settings. In doing so, they assess the relative costs and benefits of streptokinase, alteplase, reteplase and tenecteplase. In contrast, the Aventis Behring submission is a brief cost-minimisation study, and does not present detailed analysis of costs or benefits of any of the drugs. Valid comparisons of cost-effectiveness can only therefore be made based on the Boehringer Ingelheim and Roche submissions.

### Industry models

*Table 20* offers a brief overview of the models submitted by Roche and Boehringer Ingelheim which highlights the main differences between them.

In both of these submissions, results are presented for both pre-hospital and hospital thrombolysis comparisons. Each model has been carefully appraised both in terms of the appropriateness of its structure and the specific assumptions concerning parameter values made when generating cost-effectiveness results. In the following sections, key aspects are discussed in relation to evidence available. Also the relative impact of alternative assumptions on the results presented has been assessed.

The basis of each company's claim to cost-effectiveness can be summarised as follows:

#### **Hospital thrombolysis**

The submission from Roche considers all four products to be equally efficacious in reducing 30–35-day mortality, but claims that earlier administration of reteplase and tenecteplase yields some additional benefit in reducing mortality further compared to non-bolus products (streptokinase and alteplase). By combining differences in list price, drug use and adverse event costs, the Roche submission claims an overall cost slightly less than that for alteplase and tenecteplase. Thus a cost-minimisation argument is used by Roche to suggest that reteplase should be considered the preferred treatment for hospital thrombolysis.

The Boehringer Ingelheim submission claims a slightly better efficacy (30-day mortality) for

**TABLE 20** Main features of submitted cost-effectiveness models

Feature	Roche model	Boehringer Ingelheim model
Type of model	Basic accounting tables of costs and outcomes at 30 days, with simple projection of mortality gains beyond 30 days	Decision-analytic model with time points at 30 days, 1 year and 10 years
Short-term survival	All survival benefit accrued by 30 days	Most survival benefit accrued by 30 days; some additional benefit results from reduction in CHF among 30-day survivors
Long-term survival	General assumption of mean survival of 10 years for all 30-day survivors	Survival projected separately for patients with/without CHF from 30 days to 1 year and 10 years
Thrombolysis administration time	Assumed pre-hospital administration time is 60 minutes earlier than in-hospital time; also bolus products assumed to be given 20 minutes earlier than infused products	Assumed pre-hospital administration time is 60 minutes earlier than in-hospital time; also bolus products assumed to be given 15 minutes earlier than infused products
Time-dependent mortality	Assumption of 2 life-years gained per hour of reduced delay to thrombolysis; no functional model of time delay–efficacy assumed	Boersma non-linear model <sup>26</sup> of time delay–efficacy assumed, this is combined with distribution of delay times to estimate mortality changes; delay times are represented in the model in time bands
Costing	Costs only calculated for 30 days; costs not discounted; list prices of drugs used; all adverse events attributed the same average cost; additional drug wastage cost included to reflect 'saved doses' for some patients with adverse events	Detailed costing model for 10 years; costs discounted at 6%; list prices of drugs used; adverse events costed separately in detail; long-term costs and events differentiated for patients with/without CHF; restricted to cardiac events and care; long-term stroke care costs also included
Life-years and utility	Single utility value used for all survivors at all times; discounting applied at 1.5% to long-term survival	Different utilities for reinfarcts and strokes (with and without disability); life-years discounted at 1.5%
Efficacy of thrombolysis	All four drugs assumed to be equivalent in efficacy	Alteplase and tenecteplase assumed to be superior to reteplase, which is better than streptokinase

tenecteplase than the other thrombolytics, and also a reduced incidence of post-infarct heart failure. By projecting these effects over 10 years, they claim slightly reduced discounted costs compared to alteplase and reteplase. Thus, they claim that tenecteplase dominates other treatments in both costs and effectiveness.

#### **Pre-hospital thrombolysis**

Only the two bolus-administered products are considered suitable for pre-hospital use in the industry submissions, and so streptokinase and alteplase are not assessed here for use outside the hospital environment.

The submission by Roche uses similar arguments to those for hospital thrombolysis to claim reduced costs compared to tenecteplase (assuming equivalent clinical efficacy). The submission from Boehringer Ingelheim again relies on a supposed mortality benefit (deduced from indirect comparison) together with reduced incidence of heart failure leading to lower long-term costs, as the basis for claiming superiority for tenecteplase over reteplase.

#### **Mortality, survival and the impact of thrombolysis**

Both submitted models refer to survival experience at 30 days, 1 year and 10 years but not in a consistent manner. However long-term follow-up studies of thrombolytic use show a consistent pattern of effect. Cohorts receiving thrombolysis suffer fewer early deaths in the days immediately following their acute infarction, and the difference is sustained at a constant level thereafter for up to 10 years. The maximum divergence between survival curves in trials occurs at times ranging from 1 month (GISSI-1<sup>9</sup>) to 6 months (ISIS-2<sup>10</sup>), the majority of benefit occurring within the first 2 weeks. Thus the two most appropriate measures of survival benefit are the case-fatality rates at 1 month and 12 months, representing immediate and maximum survival benefit. There is no convincing evidence that thrombolysis affects survival after this period, despite the unusual results of the GREAT study.<sup>84</sup>

#### **Effect of time to thrombolysis on mortality**


A study to deliberately randomise patients to treatment at different times would be unethical,

and therefore in assessing time to benefit we are forced to conduct retrospective analyses of existing trials set up for other purposes. Since the general effect of thrombolytic therapy is to prevent fatal damage in the early hours and days post-infarct, it is reasonable to expect that quicker administration of thrombolysis should lead to larger numbers of patients receiving benefit. However, this effect may be confounded by an increasing chance that patients thrombolysed very soon after the onset of symptoms will include some whose prognosis is very poor. Thus the relationship between mortality reduction and time of administration may not be simple, or even monotonic in form.


This ambiguity is evident in three published studies:

- The FTT Collaborative Group<sup>28</sup> presented a meta-analysis of 45,000 patients from large trials (greater than 1000 patients) of hospital-administered thrombolysis, analysed by time from onset of symptoms to randomisation. Collins and colleagues<sup>11</sup> on behalf of the FTT group concluded that “the slope of absolute gradient plotted against increasing delay is fairly gradual and is not significantly steeper in the first few hours”. As a consequence they fitted a linear function of time by regression.
- Newby<sup>27</sup> described a time-based analysis of GUSTO I results, and derived an observational trend line which exhibits three phases: a gradual near-linear increase in mortality with increasing delay from 4 hours upwards, a steeper near-linear increase in the 2–4-hour delay period, and a reverse trend (reducing mortality with increasing delay) for delays of less than 2 hours.
- Boersma and colleagues<sup>26</sup> carried out a further meta-analysis adding in additional smaller trials of over 100 patients. This included many of the trials in the Morrison pre-hospital thrombolysis meta-analysis,<sup>90</sup> most notably the EMIP study.<sup>83</sup> They reported evidence of a non-linear relationship with time delay, and fitted a curve involving a hyperbolic component (though without offering any justification for this choice).

These differences in 30-day mortality are compared in *Figure 1*, and the corresponding reductions in mortality suggested by an improvement in time to thrombolysis of 1 hour are shown in *Figure 2*.



**FIGURE 1** Alternative models of mortality as a function of delay of treatment (—, FTT; ---, Boersma, et al.; - · - · -, GUSTO I; ·····, EMIP)



**FIGURE 2** Impact of 1 hour reduction in treatment delay on 30-day mortality (—, FTT; - - -, Boersma, et al.; - · - · -, EMIP; ·····, GUSTO I)

The different models provide similar results in the mid-ranges of their estimates, but significantly different results (particularly in the case of the two non-linear models) at the extremes of both very short and very long delays.

There is no definitive basis for selecting between these models, based as they are on different data sets and with different assumptions. However, we may offer some observations. The FTT line has the strength of simplicity, and is based on good quality large-scale trials. However, it has small numbers of patients at the extremes of the time delay distribution, and is therefore not sensitive to any deviations from linearity. The FTT result suggests that no mortality benefit should arise from thrombolysis when the time delay from onset of symptoms exceeds 21 hours. This may or may not be clinically reasonable, but there is no strong evidence to support this inference.

Newby<sup>27</sup> did not attempt to fit a pre-defined functional form to her data, but presented a stylised representation of a non-linear fit to observational data. The result is intuitively appealing, suggesting that there is a sizeable subpopulation whose prognosis is so poor that thrombolysis is irrelevant to the fatal outcome, but that within the 12-hour time horizon of the

trial data, benefit continues to accrue slowly even among those groups treated very late. In particular, Newby's<sup>27</sup> results suggest that the primary operational aim should be to thrombolysed within 2.5 hours of onset of symptoms, with a secondary aim to treat within 4 hours. The greatest incremental advantage arises from speeding patients to treatment, who are currently thrombolysed between 2.5 and 4 hours of onset of symptoms.

The choice of non-linear function by Boersma and colleagues<sup>26</sup> was arbitrary, but implies an extreme relationship with time delay that probably cannot be supported by either evidence or clinical experience. Projecting backwards toward zero delay in thrombolytic administration, the fitted function implies that immediate treatment would completely eliminate AMI mortality. This seems to be unduly optimistic, as clinical experience suggests that many patients die within minutes of symptoms beginning, well before any thrombolysis could take effect. In addition, the Boersma function implies that no mortality benefit should accrue when the time delay exceeds 34 hours (compared with 21 hours for FTT.<sup>28</sup> Boersma and colleagues<sup>26</sup> also used eight pre-hospital studies to conclude that the benefit from earlier thrombolysis in these studies was of the order of 21/1000 treated per hour saved, based only on two time points and

dominated by the evidence from the largest trial, EMIP.<sup>83</sup> Since these results and the Morrison<sup>90</sup> meta-analysis have most studies in common it is unsurprising that they reached similar conclusions.

Both the meta-analysis undertaken by Morrison and co-workers<sup>90</sup> and that reported by Boersma and co-workers<sup>26</sup> of pre-hospital studies were heavily dependent on a single trial (EMIP<sup>83</sup>) which contributed 85% and 83% respectively of the aggregate patient populations. To assess the confidence that may be placed in these meta-analyses it is therefore important to look in detail at the results of the EMIP<sup>83</sup> trial. Although EMIP reports an important (non-significant) reduction in absolute mortality risk at 30 days of 1.4%, it is less helpful in determining the nature of the influence of time to treatment on outcome. Of the figures shown in Table 4 of the EMIP paper,<sup>83</sup> only those for time to first injection for the pre-hospital group provide reliable evidence of a direct temporal effect (all other results involve multiple time intervals without any indication of inter-period temporal correlations). Plotting these data against time suggests a simple linear relationship (at least up to 6 hours from onset of symptoms), with a gradient equivalent to an absolute risk reduction of 0.62% per hour saved in reaching treatment. The difference between this result and that of Boersma and colleagues,<sup>26</sup> 2.1%, is attributable to the inclusion of some small studies with relatively extreme results in the latter analysis, as well as the apparent compounding of inter-arm differences with underlying temporal trends. In the absence of better evidence we offer a fourth option for estimating mortality risk due to earlier treatment based on the more reliable component of the EMIP<sup>83</sup> results: this is exhibited on a common basis to the other options in *Figures 1* and *2*.

We must consider why the overall benefit of 1.4% associated with a difference in time of 55 minutes from EMIP<sup>83</sup> is greater than the time-effect derived from Table 4 of the EMIP report. This is not clear: however, it seems likely that the overall effect of 1.4% is due not only to time but also to additional confounding factors which differ systematically between the pre-hospital and hospital settings. To take only two estimates of difference (e.g. 1.4% in the EMIP results,<sup>83</sup> or 1.6% in the meta-analysis from Morrison and co-workers<sup>90</sup> or 2.1% in the pre-hospital meta-analysis of Boersma and colleagues,<sup>26</sup> both of which draw heavily on EMIP<sup>83</sup>) and to attribute all of the difference to time alone is clearly a questionable assumption.

Rawles<sup>94</sup> examined time to thrombolysis and outcome in the GREAT<sup>84</sup> study and reported a saving of 21 (2.1%) lives at 30 days per thousand (95% CI: 1 to 94) treated per hour, and 69 lives (95% CI: 16 to 141) at 30 months per 1000 treated. Although this calculation agrees with that from Boersma and colleagues,<sup>26</sup> this is probably only because they both utilise the same approach of attributing all differences to time alone, which has already been questioned above. With regard to the Rawles<sup>94</sup> results, it is also important to acknowledge that the results of the GREAT study<sup>84</sup> themselves appear to be exceptional, as outlined in chapter 4: it has shown a mortality benefit, though never intended or powered to test the hypothesis of reduced mortality; the benefit is greater than for most other studies of thrombolysis; and the mortality benefit continues to diverge up to 2 years in contrast to the fixed benefits after 30 days in all larger studies. The reasons for such exceptional results are likely to relate to the small size of the study and the atypical trial environment in which the data was collected.

Rawles questioned why the benefits observed in the pre-hospital settings are greater than those in Newby's<sup>27</sup> data or in either the FTT<sup>28</sup> model or in the main Boersma model.<sup>26</sup> He argued that existing models are flawed,<sup>96</sup> confounded by the fact that sicker patients will seek help and be thrombolysed sooner; such patients will always have a higher mortality. Newby<sup>27</sup> in particular seems to illustrate this from the GUSTO I study<sup>18</sup> (see *Figure 1*) – i.e. that patients treated very early had a worse prognosis than those treated later and this was also seen to some extent in the GREAT study<sup>84</sup> where presentation at 1 hour was associated with twice the mortality of those presenting at 4 hours.<sup>96</sup> This, Rawles<sup>96</sup> argues, would confound the *post hoc* analysis of mortality related to time in all studies. Rawles<sup>96</sup> argues that pre-hospital versus hospital trials would come closest to the design of a study set up to examine time differences alone. Despite these arguments, the EMIP<sup>83</sup> data clearly suggest that there are other differences between settings, apart from the time to thrombolysis.

We have therefore questioned the often quoted figure of 2% extra benefit per hour saved in time to thrombolysis in the following calculations and have attempted to isolate a more accurate relationship between these two crucial elements of the economic evaluation.

This issue is important when considering whether or not to undertake pre-hospital thrombolysis (which is

not the subject of this appraisal). In comparing the efficacy of two products equally suitable for pre-hospital thrombolysis, and which are both administered at the same time, the specific timing has no impact in differentiating by efficacy between the candidate drugs. In the context of in-hospital thrombolysis, timing of administration is only important if we have evidence that one drug can be administered more quickly than another in a real-life environment. Then the four relationships described above can each be used to estimate mortality differences attributable to differences in time of administration.

Both the Roche and Boehringer Ingelheim submissions make similar assumptions about the timing of bolus delivered drugs compared to infused drugs (15–20 minutes quicker) on the basis of published audit studies. Consultations with specialist staff suggest that this difference may now be overstated in the UK, where differences of only 5–6 minutes have been reported (see chapter 6). Applying these figures to the four proposed relationships with a 20 minute time advantage, FTT<sup>28</sup> yields 0.5 fewer deaths per 1000 and EMIP<sup>83</sup> 2.1 per 1000 regardless of timing, Boersma and co-workers<sup>26</sup> project 0.3 fewer deaths per thousand at a delay of 12 hours, increasing to 0.9 per thousand at 4 hours, 3.1 per thousand at 2 hours and 11 per thousand at 40 minutes. Newby<sup>27</sup> suggests a benefit of 0.6 per thousand fewer deaths for longer time delays (over 6 hours), and a maximal benefit from the 20 minute advantage of 4–5 per thousand in the 2–4 hour delay time window. If instead we prefer the 5–6 minute estimate of timing advantage for bolus-administered drugs, then the quoted incremental improvements in mortality should be divided by four. On this basis we conclude that the proposed gains in health outcomes from faster administration of bolus drugs in the in-hospital context are generally very small, regardless of the chosen relationship between mortality reduction and time delay from onset of symptoms.

A further related issue may be whether the speed of onset of thrombolysis for a bolus product may be faster than for an infusion, and manifest by higher coronary artery patency rates. This is not considered separately here since any such benefit should be present implicitly in clinical efficacy in comparative clinical trials, and any additional allowance would amount to double counting.

#### **Comparative efficacy of thrombolytic drugs**

As described in the chapter on clinical evidence, it is difficult to rank the four drugs in terms of their

relative effects on mortality and morbidity. In particular there are no direct head-to-head trials involving reteplase and tenecteplase. Attempts to estimate differences between these two drugs rely on inference from trials where each is compared to alteplase, and inferences on such a basis may not be reliable. As mentioned above, the Roche submission claims that there is no basis to assume any meaningful difference between the four products on mortality, whereas the Boehringer Ingelheim submission holds that tenecteplase and alteplase yield similar benefits, but that reteplase is significantly less efficacious. In the absence of any basis in evidence to choose between these positions we are obliged to evaluate the consequences of each on overall cost-effectiveness to assess the impact of this uncertainty on the relative ranking of the drugs.

#### **Short-term adverse events and long-term sequelae of AMI**

A range of adverse events may occur in the hours and days immediately following an AMI. Most of these are quite rare and lead either to early death or to recovery following additional emergency intervention. The impact of these on mortality is largely accounted for through 30–35-day mortality rates, but the additional costs incurred must be explicitly calculated where drugs differ in their adverse events profile. *Table 21* summarises the short-term adverse events included in either model, and the rates assumed for each product.

The Roche and Boehringer Ingelheim submissions to NICE cite GUSTO I<sup>18</sup> and III<sup>19</sup> and ASSENT-2<sup>20</sup> as sources for their figures. Despite this apparent commonality, both definitions and parameter values derived do not generally correspond. Only the Boehringer Ingelheim report provides any details of the manner of derivation of their figures: those for alteplase and streptokinase are obtained directly from GUSTO I,<sup>18</sup> tenecteplase figures for haemorrhagic strokes (directly) and serious bleeding and reinfarctions (indirectly) are obtained from ASSENT-2,<sup>20</sup> with all other figures assumed equal to GUSTO I<sup>18</sup> rates for alteplase. Some figures in the Roche submission can be traced directly to GUSTO III,<sup>19</sup> but others are not readily verified. The most significant discrepancies evident in *Table 21* relate to episodes of bleeding, and to incidence of CHF. Both submissions therefore appear to be selective in their choice of adverse drug effects and corresponding parameter values.

#### **Long-term effects of thrombolysis**

Two conditions (disabling stroke and CHF) have enduring consequences which persist and tend to worsen throughout the remaining lifetime of



**TABLE 21** Incidence rates (%) of adverse events assumed in submitted models

	Streptokinase		Alteplase		Retepase		Tenecteplase	
	Roche	Boehringer Ingelheim	Roche	Boehringer Ingelheim	Roche	Boehringer Ingelheim	Roche	Boehringer Ingelheim
<b>Short-term adverse event</b>								
Bleeding requiring transfusions	8.43	12.90	6.20	11.10	5.90	11.10	4.86*	8.66*
Reinfarction	–	3.71*	–	4.00	–	4.00	–	4.32
Hypotension	22.25	–	19.50	–	20.60	–	19.26*	–
Cardiogenic shock	5.87	–	4.40	–	4.60	–	4.29*	–
Tamponade or cardiac rupture	0.90	–	0.90	–	0.80	–	0.77*	–
Asystole	4.20	–	4.20	–	4.20	–	4.20	–
Anaphylaxis	0.09	–	0.06	–	0.05	–	0.03*	–
Pulmonary embolism	0.13	–	0.10*	–	0.10*	–	0.23	–
<b>Events with possible long-term sequelae</b>								
CHF	19.17	15.39	17.50	13.50	17.20*	13.50	17.20*	11.75*
Intracranial haemorrhage	–	0.58*	–	0.80	–	0.80	–	0.80
Ischaemic stroke	–	0.71*	–	0.75	–	0.75	–	0.75
All strokes	1.33*	1.29*	1.80	1.55	1.60	1.55	1.93	1.55
* Best performing product for each model/event								

sufferers, and which adversely affect future risk of further cardiac events, the costs of health and social care, and the patient's quality of life. Potentially, small differences in incidence of these conditions among survivors of AMI could lead to substantial differences in both costs and outcomes, and it is therefore important to assess carefully how these conditions are treated in the two submitted models.

### Stroke

In the Roche model, stroke is treated in an identical manner to all other adverse events. The probability of a patient suffering a stroke is related only to an additional treatment cost, and has no impact on outcomes in the long-term. No attempt is made to assess the proportion of stroke patients left with significant disability, or to consider whether this alters their life expectancy or quality (utility) of life. This is a surprising omission in view of the claimed superiority of reteplase over both alteplase and tenecteplase concerning stroke incidence. Since disabling stroke is known to be associated with a generally poor prognosis and reduced longevity, the Roche approach to modelling stroke is clearly unsatisfactory.

The Boehringer Ingelheim model estimates the numbers of patients surviving with disabling

haemorrhagic and ischaemic strokes, which are used to apply appropriate utility values to survival for these patients. Long-term mortality does not appear to be adjusted for such patients.

### Congestive heart failure

As in the case of stroke, the Roche model includes CHF only in a very basic manner, as another short-term adverse event. No adjustments are made to future mortality risks, nor are costs augmented to reflect additional therapies or hospital admissions consequent on the presence of CHF.

By contrast, the Boehringer Ingelheim model includes a facility to reflect differential mortality risks between those with and without CHF, projected out to 10 years. In the submission, three options are presented based on assuming different impacts of CHF on survival. Costs of long-term treatment are also included, separately for patients with and without CHF.

### Utility values

The application of health-related utility values to differences in life expectancy enables calculation of incremental differences in QALYs and ICERs as a common currency of comparison between different uses of scarce health service resources. The utility values used in the models

differ, reflecting the underlying assumptions of the modellers.

The Roche model includes utility only as a common post-analysis adjustment factor (multiplied by 0.7) applied without discrimination to all changes in life expectancy, regardless of the health state of the patient, based on a single reference from 1988.<sup>119</sup> As a result, utility in the Roche model has no effect on ICERs beyond a general rescaling. This approach is consistent with the view that surviving AMI does not lead to any long-term sequelae which in any way impact on quality of life, long-term prognosis, or health or social care costs. In view of the recognised risks of stroke and heart failure associated with thrombolysis, and their well-attested consequences for patient experience and resource use, this seems to be an unduly optimistic assumption.

In the Boehringer Ingelheim model, some differentiation is attempted between the various outcome states following recovery from AMI:

- after full recovery without any enduring sequelae, utility is assumed to be 1.0 (i.e. full health)
- a severe bleeding episode is considered (arbitrarily) to reduce utility by 5% in the index year, but to have no impact thereafter
- a reinfarction is assumed to reduce the utility of all subsequent life-years by 20%
- life after suffering a stroke is also presumed to cause a continuing loss of utility of 45% for haemorrhagic strokes and 39% for ischaemic strokes.

Only the assumptions about stroke utilities are supported by a reference.<sup>120</sup> In addition, the modellers have introduced a user-modifiable utility variable for use with patients suffering CHF after AMI. In one reported analysis this was used to test a possible utility reduction of 5% due to CHF.

Both models assume that patients who survive AMI without long-term sequelae are in 'perfect health'. In view of the predominance of middle-aged and elderly people among those suffering AMI, this seems to be an unduly optimistic assumption. As people advance in age, there is a rise in chronic health problems of all sorts, and a general diminution in physical activity and capability, so that the utility accorded to a year of life for the typical 70 year old would normally be somewhat diminished compared to that of the typical 25 year old. This assumption has no effect on the ranking of cost-effectiveness between

different thrombolytic drugs, but may distort comparisons with ICERs calculated for other treatments in different population subgroups.

The Boehringer Ingelheim approach to utility calculations is to be preferred to that of Roche in that it reflects the well attested negative impact on both physical, mental and social functioning of a disabling stroke. The values assumed for other conditions are less secure.

When attempting to run identical options within the two scenarios of the Boehringer Ingelheim model, we found that the QALY calculations did not yield identical results. Having traced the sources of this anomaly, we have corrected some errors in the model logic – as a result in some cases the results obtained differ slightly from those included in the Boehringer Ingelheim submission to NICE.

## Costing issues

### **Drug and administration costs**

A central issue to determining comparative cost-effectiveness between the different products is the ascertainment of accurate estimates on the cost of the drugs and their administration. At first sight this should be a straightforward calculation, but in practice an examination of the two models and supporting text reveals subtle differences which result in important variations in the cost differences (the important parameter).

The Roche submission to NICE begins with standard *Monthly Index of Medical Specialities* list prices, assuming the two available dosages of tenecteplase are used in equal proportions (50:50). To these are added the cost of an infusion pump. Infusion pumps are required for the administration of streptokinase and alteplase and for the heparin infusions associated with alteplase, reteplase and tenecteplase. In addition a 'wasted dose' cost is added, which aims to reflect that a proportion of patients suffering an early adverse event will have thrombolysis aborted, thus 'wasting' the whole dose, whereas some of these will only receive the first dose of reteplase, the cost of the second dose being 'saved'. Although this argument may have merit, the costing method employed is fallacious: the correct approach is to reduce the average cost of administering reteplase, leaving the cost of other products unchanged. In practice, correcting this error has a minor impact on the result. A further element of the Roche calculations concerns the costs of additional infusions required for patients treated with

alteplase. An excess cost of £96 is included for this derived from a paper by Seyedroudbari and colleagues<sup>121</sup> from a USA costing study. From the results in the original paper, it appears that the findings in Table 5 of that paper have been misinterpreted – we estimate that a cost differential of just £16 is justifiable for extra consumables for this effect.

The Boehringer Ingelheim submission also begins with the published list prices, though assuming that 60% of doses will be of the lower dose. To this is added a nursing cost for administration of the drug. This is varied according to the supposed nursing time required, which varies from 6 minutes for tenecteplase, 10 minutes for

reteplase, 15 minutes for alteplase, to a maximum of 20 minutes in the case of streptokinase. We are of the opinion that these differences in nursing time, even if real (see chapter 6), are not realisable in cash terms, since they represent small redeployments of resources which are already committed costs to the hospital, and in operational terms the appropriate opportunity cost is negligible.

Table 22 summarises the calculations using both methods, and shows the extent to which pairwise cost differences are affected by apparently small assumptions. We show both the original model calculations as well as amended versions based on the corrections/alterations identified. Finally we

**TABLE 22** Calculation of thrombolysis and administration costs (£)

Component	Streptokinase	Alteplase	Reteplase	Tenecteplase	
<b>Roche method – as submitted</b>					
Drug list price	81.18	600.00	716.25	735.00	
Infusion pumps	98.00	196.00	98.00	98.00	
Wasted dose	24.00	153.00	96.00	185.00	
<b>Total</b>	<b>203.18</b>	<b>949.00</b>	<b>910.25</b>	<b>1018.00</b>	
<b>Roche method – amended for dose-saving and source figures</b>					
Drug list price	81.00	600.00	716.00	735.00	
Infusion consumables	23.03	39.04	23.03	23.03	
Saved doses	0.00	0.00	-95.62	0.00	
<b>Total</b>	<b>104.03</b>	<b>639.04</b>	<b>643.41</b>	<b>758.03</b>	
<b>Boehringer Ingelheim method – as submitted</b>					
Drug list price	81.00	600.00	716.00	728.00	
Nurse time	12.54	9.50	6.35	3.80	
<b>Total</b>	<b>93.54</b>	<b>609.50</b>	<b>722.35</b>	<b>731.80</b>	
<b>Preferred method</b>					
Drug list price	81.00	600.00	716.00	728.00	
Infusion consumables	23.03	39.04	23.03	23.03	
Saved doses	0.00	0.00	-95.62	0.00	
<b>Total</b>	<b>104.03</b>	<b>639.04</b>	<b>643.41</b>	<b>751.03</b>	
<b>Cost differences</b>					
Comparison drugs	Roche method		Boehringer Ingelheim method		Preferred method
	Original	Amended	Original	Amended	
Alteplase–streptokinase	745.82	535.01	515.96	519.00	535.01
Reteplase–streptokinase	707.07	539.38	628.81	635.00	539.38
Tenecteplase–streptokinase	814.82	654.00	638.26	647.00	647.00
Reteplase–alteplase	-38.75	4.37	112.85	116.00	4.37
Tenecteplase–alteplase	69.00	118.99	122.30	128.00	111.99
Tenecteplase–reteplase	107.75	114.62	9.45	12.00	107.62

have prepared our own estimates based on our preferred method which combines the best elements of both. On this basis it appears that for the cost of thrombolytic drugs and their administration, tenecteplase is about £100 more expensive than both alteplase and reteplase, while streptokinase is very much less expensive than all other products.

### Adverse event costs

In the Roche model a very simple method is adopted to costing adverse events. A list of adverse events is presented with an estimated incidence rate for each (see *Table 21*). The incidence rates are summed and the expected number of events is estimated from this total and costed at a single average cost of £2,000 per adverse event. Not only does this approach obscure differences between the adverse event profiles of the various thrombolytics, it also confuses events with short- and long-term consequences. In particular, patients who suffer a disabling stroke or develop CHF are accorded only a single additional health cost, ignoring altogether the heavy and continuing long-term health and social care costs of these serious conditions. For these reasons we consider the Roche model seriously deficient in this aspect of costing care.

The Boehringer Ingelheim model is much more detailed in dealing with adverse events. The costing model for the immediate AMI event can be expressed as shown in *Box 1*.

BOX 1 Cost of AMI hospital treatment	
Cost of AMI hospital treatment (excluding thrombolysis) per patient	= £1940.60
if patient dies	-£102.10
if suffering intra-cranial haemorrhage	+£6720.45
if suffering ischaemic stroke	+£4423.98
if suffering reinfarction	+£3833.76
if suffering from major bleeding	+£1184.36

Other adverse events occurring within the index hospital episode are implicitly costed by inclusion within the basic cost.

Long-term care for surviving patients is costed as the sum of two components:

- patients who have suffered a stroke, and not fully recovered incur health costs of £824

per annum if not disabled, and £10,632 per annum if disabled

- patients who do not have CHF cost £2356.56 per annum in their first year, and £1144.50 per annum thereafter
- patients who do have CHF cost £4134.70 per annum in their first year, and £2337.42 per annum thereafter.

Although some elements of this costing structure may be disputable, the overall impression is of credible costs reasonably well reflecting the main short- and long-term drivers of healthcare cost.

## Defining a preferred baseline

On the basis of the foregoing findings and review of available evidence, a preferred set of assumptions and parameter values was assembled, to establish a consistent baseline from which to assess relative cost-effectiveness, as set out below.

### Thrombolytic drugs and administration

The net costs of thrombolytics and their administration are as set out in the 'preferred method' of *Table 22*.

### Long-term life expectancy

A basic mean life expectancy of AMI survivors of 8.0 years is assumed (consistent with the default assumption in the Boehringer Ingelheim model, based on analysis of Capewell and colleagues' results.<sup>122</sup>

### Adverse events and 30-day mortality

*Table 23* summarises the assumed outcome values, based on combining the results of GUSTO I<sup>18</sup> and III<sup>19</sup> and ASSENT-2<sup>20</sup> to preserve relativities between agents for each outcome variable. The one area of contention concerns the estimation of episodes of 'major bleeding'. There is no consistency between the various trials in defining a 'major bleed', so that values are reported varying from under 1% of patients to more than 12%. Clearly, these are not comparable figures, and so we have arbitrarily adopted a rate of 12.25% for streptokinase and adjusted all other rates pro-rata to this, to preserve relativities.

To check the impact of this assumption with regard to bleeding rate, the analysis was rerun utilising a rate of 1% for streptokinase and that for the other drugs altered pro rata (data not shown). Although using such a rate slightly increased the apparent cost-effectiveness of thrombolytic therapy as a whole, it had an

**TABLE 23** Outcome values (%) for preferred baseline

	30-day mortality	Strokes (all kinds)	Major bleed	Reinfarction	CHF
Streptokinase	7.65	1.37	1.11	3.78	18.00
Alteplase	6.60	1.63	0.90	4.07	16.00
Retepase	6.82	1.49	0.71	4.06	15.73
Tenecteplase	6.64	1.75	0.71	4.39	13.94

insignificant impact on the comparative cost-effectiveness of each individual drug.

Details of the derivation of outcome estimates used in the preferred method are shown in appendix 10.

## Cost-effectiveness comparisons

To evaluate the relative cost-effectiveness of the different drugs, we conducted economic modelling. Rather than develop a wholly new model, we chose to introduce the above key values into the two submitted models (after correction of any logic errors detected). We also introduced variants of the most contentious parameters as proposed in the company submissions to NICE, in order to test the sensitivity of the cost-effectiveness results to the interpretations of evidence most favourable to the various products (see *Table 24*). By this means we have incorporated the alternative positions regarding the equivalence/non-equivalence of efficacy for reteplase, alteplase and tenecteplase as described earlier in this report. The findings are summarised in *Table 25* in terms of incremental changes in total costs and in QALYs, relative to streptokinase as the current service

comparator. Where appropriate, ICERs have been calculated.

The relationship between incremental costs and incremental QALYs is shown graphically in *Figure 3* (using the Boehringer model) and *Figure 4* (using the Roche model). In both cases, streptokinase is used as the comparator drug with the additional costs and QALYs associated with treatment with alteplase (A), reteplase (R) and tenecteplase (T) being plotted on the graph. The results are provided for each of the three sets of assumptions (our 'preferred' assumptions, the assumptions used in the Roche model and the assumptions used in the Boehringer model) used in our modelling process. For illustrative purposes, the slope of the relationship between the incremental cost-effectiveness of alteplase and the different set of assumptions employed is emphasised on each figure.


These figures emphasise two main factors. First, the differences in benefits in QALYs between any of the new drugs and streptokinase are small (less than 0.1 QALY over 10 years), while the difference in cost between streptokinase and the newer drugs is substantial. This means that the variability in incremental cost-effectiveness

**TABLE 24** Outcome values (%) for variant analyses


	30-day mortality	Strokes (all kinds)	Major bleed	Reinfarction	CHF
<b>Roche assumptions</b>					
Streptokinase	7.37*	1.33	8.43	3.75*	19.17
Alteplase	6.76*	1.80	6.20	4.04*	17.50
Retepase	6.98*	1.60	5.90	4.04*	17.20
Tenecteplase	6.80*	1.93	4.86	4.36*	17.20
<b>Boehringer Ingelheim assumptions</b>					
Streptokinase	7.29	1.29	12.90	3.71	17.87
Alteplase	6.10	1.55	11.10	4.00	15.67
Retepase	6.28	1.55	11.10	4.00	15.67
Tenecteplase	6.10	1.55	8.66	4.32	13.64
* Unchanged from preferred baseline					

TABLE 25 Cost-effectiveness results using submitted models

	Scenario	Streptokinase	Alteplase	Tenecteplase	Reteplase
<b>Using Boehringer Ingelheim model</b>					
Total discounted cost (£)	Original model	11,208.65	11,672.23	11,646.47	11,772.97
	Preferred	11,105.88	11,621.98	11,597.63	11,569.35
	Roche variant	11,272.02	11,806.89	11,895.68	11,745.38
	Boehringer Ingelheim variant	11,178.67	11,685.57	11,637.93	11,670.74
Total discounted QALYs	Original model	7.44	7.50	7.51	7.50
	Preferred	7.37	7.44	7.43	7.43
	Roche variant	7.37	7.44	7.42	7.43
	Boehringer Ingelheim variant	7.40	7.48	7.48	7.47
Incremental cost versus streptokinase (£)	Original model	–	463.58	437.82	564.32
	Preferred	–	516.10	491.75	463.47
	Roche variant	–	534.87	623.66	473.36
	Boehringer Ingelheim variant	–	506.90	459.26	492.07
Incremental QALYs versus streptokinase	Original model	–	0.06	0.07	0.06
	Preferred	–	0.07	0.06	0.06
	Roche variant	–	0.07	0.05	0.05
	Boehringer Ingelheim variant	–	0.08	0.08	0.07
ICER versus streptokinase (£)	Original model	–	7,294.00	5,892.00	9,215.00
	Preferred	–	7,219.00	8,321.00	7,893.00
	Roche variant	–	8,176.00	11,702.00	8,646.00
	Boehringer Ingelheim variant	–	6,095.00	5,793.00	7,172.00
<b>Using Roche model</b>					
Total discounted cost (£)	Original model	1,308.85	1,801.20	1,802.57	1,727.63
	Preferred	1,064.89	1,504.84	1,575.71	1,517.26
	Roche variant	1,233.82	1,644.24	1,727.59	1,652.66
	Boehringer Ingelheim variant	1,296.49	1,700.64	1,724.71	1,725.06
Total discounted QALYs	Original model	4.93	4.93	4.93	4.93
	Preferred	4.93	4.99	4.98	4.97
	Roche variant	4.93	4.99	4.98	4.97
	Boehringer Ingelheim variant	4.93	4.99	4.99	4.98
Incremental cost versus streptokinase (£)	Original model	–	492.35	493.72	418.78
	Preferred	–	439.95	510.82	452.37
	Roche variant	–	410.42	493.78	418.84
	Boehringer Ingelheim variant	–	404.15	428.22	428.57
Incremental QALYs versus streptokinase	Original model	–	0.000	0.437	0.437
	Preferred	–	0.056	0.054	0.044
	Roche variant	–	0.056	0.054	0.044
	Boehringer Ingelheim variant	–	0.063	0.063	0.054
ICER versus streptokinase (£)	Original model	–	NA	1,130.00	959.00
	Preferred	–	7,878.00	9,509.00	10,247.00
	Roche variant	–	7,349.00	9,192.00	9,488.00
	Boehringer Ingelheim variant	–	6,385.00	6,766.00	7,978.00
N.B. 'Original model' uses models corrected for logic and factual errors					



**FIGURE 3** Incremental costs and QALYs (compared to streptokinase) using the Boehringer Ingelheim model. Referent scenario (at origin) is streptokinase. Alternatives represented as A: accelerated alteplase, R: reteplase, T: tenecteplase. —, ■: preferred Boehringer Ingelheim model settings; - · - ·, ▲: Roche-favouring variant; ·····, ●: Boehringer Ingelheim-favouring variant



**FIGURE 4** Incremental costs and QALYs (compared to streptokinase) using the Roche model. Referent scenario (at origin) is streptokinase. Alternatives represented as A: accelerated alteplase, R: reteplase, T: tenecteplase. —, ■: preferred Boehringer Ingelheim model settings; - · - ·, ▲: Roche-favouring variant; ·····, ●: Boehringer Ingelheim-favouring variant

estimates is related to variations in cost far more than to variations in outcome. Secondly, the comparative positions of the newer drugs show no consistency: as the assumptions behind each model change, so too does the apparent comparative cost-effectiveness of each drug. Again, this emphasises the comparatively small and inconsistent variation in outcome derived from each drug depending on the assumptions, but the primacy of cost in determining comparative cost-effectiveness.

Although the majority of previous analyses have focused on cost per life-year gained as an outcome measure, the industry submissions comply with NICE requirements by estimating incremental cost per QALY. As this incorporates estimates of the impact of treatment on both the quality and quantity of life experienced by patients, our reanalysis of the models concentrates entirely on this outcome measure. The utility adjustments underlying the QALY calculation were entirely derived from the Boehringer Ingelheim and Roche submissions. Both models assume that all patients are in perfect health before AMI (quality adjustment of 1.0). Given the age and co-morbidities associated with many such patients, this is probably an overestimate. This may overstate the number of QALYs gained through thrombolytic therapy and understate the true incremental cost per QALY. While this implies that the analysis may overstate the true cost-effectiveness of thrombolysis, it will not significantly alter the comparative cost-effectiveness exhibited by each individual drug.

In all cases we see that a consistent picture emerges: differences in discounted QALYs for the four drugs used in a hospital setting are very small (less than 0.1 compared to streptokinase, equivalent to less than 1.2% of baseline expected QALYs in the Boehringer Ingelheim model). Variations in discounted costs are also small with a maximum difference from streptokinase of £580. In general, it is evident that these model-generated cost differences are of the same order of magnitude as the pairwise differences in the costs of thrombolysis and its administration. This has implications for the robustness of rankings of cost-effectiveness for the four thrombolytic agents, in that the most important determining parameters are the relative prices of the drugs – small changes in these differences can easily alter model rankings of alteplase and the two bolus products. The most reliable result is that streptokinase is much cheaper than all other drugs, and is only a little less effective (as

measured by discounted QALYs). In practice, streptokinase is currently only used as part of a protocol including alteplase as an alternative where streptokinase is contra-indicated.

These examples of economic models do not take account of claimed benefits from faster administration of the bolus agents over infused agents. However, we can readily estimate the impact of the assumed 15–20-minute reduction in time to treatment: assuming an overall life expectancy for survivors of about 8 years, and a mean baseline delay to treatment of 3 hours, we calculate that the bolus agents should show additional discounted QALYs of between 0.003 and 0.014 depending on our choice of delay model (FTT,<sup>28</sup> EMIP,<sup>83</sup> Boersma and co-workers<sup>26</sup> or Newby<sup>27</sup>). In most scenarios this has the effect of narrowing the gap in outcomes between the bolus agents and alteplase, further confirming these conclusions.

Of course, differences in time to angiographic reperfusion after drug administration are already included in measures of effect of differing drugs, and must not be double-counted.

The results shown in *Table 25* for the Boehringer Ingelheim model are based on the option with no assumption of differential relative risk of mortality for patients with heart failure. As the use of such differentials has the effect of narrowing differences in ICERs, this assumption is conservative.

It is evident that the claimed differences in efficacy and adverse event profiles for reteplase and tenecteplase do not translate into any consistent and reliable difference in cost-effectiveness. The largest and most influential source of these variations appears to be the relative prices of the competing agents. We therefore conclude that any choice between the two is largely governed by their relative local prices at the time of acquisition.

The final cost/QALY for the newer drugs compared to streptokinase ranges from £11,000 to £17,000 using our preferred assumptions. For broad comparison only, a headline figure for the cost-effectiveness of streptokinase compared to no thrombolysis would be of the order of £800–£1000/QALY.

### Pre-hospital thrombolysis

Since only the two bolus-administered drugs are considered suitable for use in a community setting, and since we may assume that the choice of which drugs are used has no effect on other aspects of care or outcome prior to or following hospital



admission, then the previous analysis in the hospital context applies equally to pre-hospital thrombolysis. The only basis for moving away from this position would be if the time to administer the drug was significantly different between reteplase and tenecteplase in the community, but we have no basis for such a presumption. We are therefore obliged to conclude that it is not possible to distinguish between the two bolus-administered products on grounds of cost-effectiveness when used for pre-hospital thrombolysis.

If the infusion products were to be used in pre-hospital thrombolysis, their cost-effectiveness would be similarly enhanced, but the relative ranking of the drugs would be unchanged.

### Comparison with the literature

Perhaps the most reliable conclusion in the literature review around the cost-effectiveness of streptokinase compared to alteplase was that of Mark and colleagues,<sup>106</sup> which quotes an incremental cost of US\$36,000/QALY. We have criticised this study not least for its failure to consider settings other than the USA. However the study of Lorenzoni and colleagues<sup>110</sup> compares cost-effectiveness in the UK and the USA, and finds that cost per QALY in the UK is approximately half that in the USA. If this is correct, it would imply a UK cost per QALY in 1993 of US\$18,000 or approximately £13,000 using 2002 exchange rates. If a rate of inflation of 3% is allowed, this becomes £16,500.

It is not possible to draw direct comparisons between these figures from the model of Mark and colleagues<sup>106</sup> extrapolated with several assumptions to the UK in 2002, and our figure of £11,000 to £17,000 per QALY, which we have derived in different models, using different assumptions and costings. Nevertheless, the broad similarity of these figures tends to validate the methodologies used in both studies.

### Conclusions

Given the general comparability of the drugs, any attempt to identify a comparative advantage economically for any individual drug would require large scale and robust clinical and economic analyses to be undertaken within the specific context of the NHS. With a few notable exceptions, the general quality of existing

economic analyses undertaken in this area has been disappointing and largely focused on evaluating cost-effectiveness in healthcare environments outside the NHS. Without such evidence to differentiate the cost-effectiveness analysis, the variations in outcome are insufficient to provide a conclusive result. The only consistent conclusion is that streptokinase is the most cost-effective drug, judged by virtue of its lower price.

From the economic perspective, the variations in outcome between the individual drugs are so small that the economic modelling finds it difficult to come to any definitive conclusion. The case for a differential between each of the newer drugs compared to streptokinase is therefore uncertain. Supposed advantages presented in the industry submissions to NICE relate to comparatively minor variations in efficacy or minor improvements in aspects of the side-effect profile associated with each individual drug. Given such similarity in outcome, cost-effectiveness becomes largely determined by the comparative level of resources required for each drug. This largely comes down to the cost of the drug since other differences in costs of administration are small.

Considering the scenarios put forward for appraisal at the end of chapter 3:

- **Is streptokinase as effective as alteplase (and hence other drugs)?** This is considered in the Roche model. Put simply, if streptokinase is as effective as other drugs, then its lower costs means that it dominates all other therapies.
- **Is reteplase equal to alteplase (and hence tenecteplase)?** In our preferred model we have assumed that reteplase is largely similar to alteplase, based on the results of GUSTO III.<sup>19</sup> The ICER for reteplase compared to streptokinase then comes out worse than alteplase but better than tenecteplase – largely as a result of its purchase price. However, differences are small.

In these circumstances, drug choice becomes largely determined by clinical or pragmatic preference, and by the purchase price of the individual drugs. This close relationship between acquisition price and cost-effectiveness presents a challenge to both NHS purchasers and the pharmaceutical companies involved in the manufacture of thrombolytic drugs.



# Chapter 6

## Implementation

### Introduction

The context of this review has been to separate and differentiate between the provision of early thrombolysis for AMI by clinical setting (hospital or pre-hospital). Although there are physical reasons (ease of administration, ability to deal with adverse events) that mean that the delivery of treatment may be different in the pre-hospital setting there is no reason to believe that the physiological action of the agents will differ between settings.

It is not within the remit of this review to evaluate the effectiveness of pre-hospital thrombolysis or strategies related to the delivery of early thrombolysis. However, the economic analysis as presented earlier makes an assumption that there currently exist, in both settings, the mechanisms necessary to deliver care. Although these mechanisms are in place in the hospital setting, audit data indicate an inability of hospitals to meet prescribed 'door-to-needle' time. In the pre-hospital setting there are issues related to the appropriate model of care to be adopted to meet these standards, as well as the equipment and further training of individuals to provide the care.

The discussion in the first part of this chapter will focus on key components related to implementation of change: time to thrombolysis and selection of drug to be used. It goes on to propose three models of care that might be considered in relation to change in practice and to meeting the nationally established treatment criteria.

### Time to thrombolysis

There is no debate regarding the fact that to be effective, thrombolytic therapy needs to be provided early. However, as pointed out in the previous chapter, extensive debate exists regarding the steepness of the time/treatment-effectiveness curve. The various aspects of this debate have been outlined earlier and will not be repeated here. It is safe to assume that the debate will continue.

What discussion regarding the time window fails to address is the fact that the majority of people suffering from AMI do not contact medical services within that first 'golden' hour. *Table 26* provides the data extracted from the RCTs of pre-hospital trials and indicates the recorded times from symptom onset to call for help.

As can be easily seen, with the exception of the MITI study<sup>89</sup> conducted in a city that has an active Heart Saver/Community awareness programme and excellent ambulance services including advanced cardiac life support since the early 1980s, the normal call time is close to an hour after the onset of symptoms. Translated into clinical practice this means that, with the exception of patients with sudden and severe symptoms (excruciating chest pain, shortness of breath, or collapse), it will be uncommon to assess patients in the first hour after the onset of their symptoms. It is not the purpose of this review to examine this issue but the general consensus of opinion is that we have not yet identified a public health

**TABLE 26** Time from symptom onset to call for help

Study	Contact	Time (minutes)	
Castaigne <i>et al.</i> , 1989 <sup>82</sup>	Mobile care unit	Mean	65
GREAT, 1992 <sup>84</sup>	GP calls	Median (range)	45 (0–340)
EMIP, 1993 <sup>83</sup>	Ambulance	Median (range)	75 (70–76)
MITI, 1993 <sup>89</sup>	911/ambulance	Median (range)	
		Pre-hospital	27 (30–60)
		Hospital	28 (11–58)
Schofer <i>et al.</i> , 1990 <sup>88</sup>	Ambulance	Mean (SD)	
		Pre-hospital	52 (47)
		Hospital	63 (46)

initiative to change this health-seeking behaviour in any sustainable way.

We therefore concentrate our efforts on areas we believe we can change – the delivery of care once the patient has sought treatment. The effectiveness of early thrombolysis has been known for some time. However, it has been the institutionalisation of the NSF<sup>30</sup> for Coronary Heart Disease and the NHS Plan<sup>31</sup> that have provided the impetus for healthcare professionals and healthcare managers to take action and implement change within healthcare settings to decrease what has been called ‘time to needle’. This is indeed no small task and some have been so bold as to say that the goals as set are not realistic (anonymous – at request of sources – personal communications, 2002).

However, there are a number of things that we do know about ability to impact change in time to delivery of treatment. We have evidence that we can decrease time to treatment with improved outcome in the pre-hospital setting. The meta-analysis by Morrison and colleagues<sup>90</sup> has shown us that time to treatment can be decreased by approximately 58 minutes.

Interestingly, two pre-hospital trials<sup>83,89</sup> also showed that during the trial of pre-hospital thrombolysis, ‘door-to-needle’ time for patients treated in hospital was decreased. The MITI<sup>89</sup> investigators showed that when they compared trial patients treated in hospital to patients who had arrived in the emergency department but were not part of the trial, ‘time to needle’ for trial patients was much shorter (20 minutes versus 60 minutes).

In the UK we have examples of programmes that have been able to successfully decrease ‘door-to-needle’ time within the hospital setting. Initiatives in the early 1990s in Brighton<sup>123</sup> showed this was possible but that maintaining these improved treatment delivery times was difficult. When key individuals involved in the initiative were no longer involved, ‘door-to-needle’ times increased (Chamberlain D, JRCALC, Sussex: personal communication, 2002). Other initiatives, such as those implemented in Scotland<sup>124</sup> have successfully fast-tracked patients to the CCU while others have moved treatment out of the CCU into the A&E department.

In the GREAT study,<sup>84</sup> pre-hospital thrombolysis was administered by GPs in Scotland. After the GREAT study was completed, the rate of use of

pre-hospital thrombolysis declined rapidly among GPs in Grampian. However a sustained effort of education and audit has renewed and maintained interest in this treatment.

Therefore, in terms of all time to treatment we know that providing treatment early leads to improved outcomes. It is unclear (depending on which specific time/effect model you accept) the exact impact that the minutes saved will have on morbidity and mortality. We know that we do not have an effective method for decreasing the time it takes for patients experiencing AMI to contact medical services. However, we do know that we can decrease the time from when they do make contact until they receive treatment.

## Choice of drug

The evidence related to the clinical effectiveness of available drugs was presented in chapter 3 and point estimates of effectiveness have been calculated as a part of the economic analysis in chapter 5. Assuming ‘relatively’ similar effectiveness and adverse events, the choice of drug is then dependent on cost and ease of administration. The information presented here has been gathered from arguments within the literature and from clinical experts familiar with the delivery of thrombolytic treatment in both hospital and pre-hospital settings.

On the basis of cost and cost-effectiveness, streptokinase would be the drug of choice. In addition, this drug can be given by paramedics under the terms of the Medicines Act without any further arrangements of patient group directions and requires no pre-hospital heparin administration. However, given the problem of antigenicity, any protocol for its use would be required to include a second drug choice for patients who had previously received treatment with streptokinase. In terms of cost, all of the other alternatives are similarly priced.

The issues regarding ease of administration are less straightforward. The issues basically revolve around whether a drug is delivered as a bolus or an infusion, whether a standard dose or individually calculated dose is required and the adjunct treatments required (e.g. heparin).

## Infusion versus bolus

Within the hospital setting, mechanisms are already in place for the delivery of infusion

medications. The uncertainty within the pre-hospital setting and the logistics of using additional equipment such as infusion pumps means that these are issues to be addressed. Our clinical experts were reluctant to consider using infusions in patients travelling to hospital. In part this is because of inconvenience, including the storage of infusion bags, costs of infusion pumps, and also because of potential hazards problems (quoting risks of disconnecting infusions, and Medical Devices Agency concerns about difficulties with infusion pumps).

Delays due to setting up an infusion were also mentioned. We have limited evidence to compare the time required in either clinical setting for the preparation of infusions versus bolus administration of drugs. The MITI<sup>89</sup> study reported an extra 15 minutes on-scene to set up an alteplase infusion but has no comparator. Two company submissions to NICE suggest a 15 minute saving with bolus delivery of treatment. In a review of 500 patient records Seydroudbari and colleagues<sup>121</sup> measured a decrease in time to treatment for reteplase over alteplase of 34 versus 51 minutes. However, 21 minutes of this delay in alteplase involved an increased amount of time to make a decision to treat patients who received alteplase, leaving the time for administration almost equal. Consultation with hospital and pre-hospital healthcare providers indicates that provision of new equipment such as infusion pumps means that the difference in 'time to needle' between infusion drugs and bolus drugs is close to negligible.

Our experts also cast doubt on whether bolus delivery would be more than 5 minutes faster than infusion. This makes the suggestions that bolus products will help hospitals meet their NSF targets less likely to be true. Rather it implies that reorganisation of the form seen in the MITI<sup>89</sup> and EMIP<sup>83</sup> trials and in UK NHS practice will be more important in decreasing time to treatment than choice of drug

Trials of pre-hospital thrombolysis have successfully used drugs that were delivered by infusion. However, these trials took place prior to the availability of drugs delivered by bolus. Centres that have previously used infusions in the pre-hospital setting are currently evaluating the use of bolus reteplase.<sup>125</sup> Anecdotal reports also indicate a view among thrombolysis nurses that the inconvenience of providing the infusion is balanced by the ability to stop delivery of the drug should adverse events occur.

## Drug dosage/adjunct treatment

Dosages for infusion drugs are somewhat complicated but well established. Dosages for the two bolus drugs each have their own complications. In addition, each calls for the pre-administration of an intravenous bolus of heparin.

Reteplase is given as 'a slow infusion' over 2 minutes. Its practicality as a drug for pre-hospital thrombolysis is demonstrated by the successes of its use by East Midlands and Staffordshire Ambulance Services NHS Trusts and also by the ER-TIMI 19<sup>101</sup> study and Swedish<sup>100</sup> and Dutch<sup>125,126</sup> studies. Reteplase is given as two doses separated by 30 minutes. In practice, we have no data to indicate how frequently the second dose would need to be administered by the ambulance service. There has also been discussion surrounding delay in administration of the second dose if the patient is re-assessed upon arrival in hospital.

Reteplase is also administered with heparin. A bolus of heparin is administered at the time of the first bolus and an infusion started after the second. This means that the infusion is administered in hospital rather than in the ambulance and avoids the need for infusion in the pre-hospital setting.

It has been argued in a company submission to NICE that reteplase is more difficult to administer than tenecteplase because of its incompatibility with heparin. This would seem to require two intravenous lines (one for each drug), which might be difficult to secure in very ill patients. In practice where this is not readily possible, the ambulance services use one line, flushing the line carefully between administration of the two drugs. This is standard clinical practice and is consistent with recommendations in the drug company literature. This therefore does not seem to be a significant objection to the use of reteplase. Communication from the authors of the TIMI 19 trial indicates that the heparin bolus was given in some cases. They also encouraged the insertion of two intravenous lines, but when that was not possible one line was used and flushed between drugs (Morrow D, TIMI study chairman: personal communication, 2002). The Dutch study of reteplase did not administer heparin in their pre-hospital evaluation (Lamfers E, consultant cardiologist, Nijmegen, The Netherlands: personal communication, 2002).

Administration of tenecteplase is by bolus injection over 10 seconds and this would seem to make it eminently suitable for pre-hospital administration.

However, it is followed by a heparin infusion, which makes it less suitable for pre-hospital use. A number of contacted experts felt this would mitigate against the acceptance of its use in the pre-hospital setting. However, the results of the ASSENT-3 study<sup>79</sup> suggested that subcutaneous enoxaparin (which could be easily given in the pre-hospital setting) was as effective as an intravenous infusion of unfractionated heparin, although this is not yet a licensed regimen. The regimen of tenecteplase and enoxaparin in pre-hospital thrombolysis is being examined in the ASSENT-3 Plus study. If this regimen were licensed, it would facilitate the use of tenecteplase with enoxaparin as a pre-hospital therapy. Given this option, our experts were divided – some would opt for tenecteplase, some to stay with reteplase with which they are familiar. One ambulance service has expressed a preference for tenecteplase, but does not make clear how it would deal with the issue of a heparin infusion. There is as yet little experience of tenecteplase in this setting but the ASSENT-3 Plus study should provide this.

The second issue of individualising dose is related to tenecteplase. It requires a weight adjustment of dose, based on evidence of increased bleeding with 50 mg doses in TIMI 10B.<sup>56</sup> It has been suggested that this might lead to errors in dosing in the pre-hospital setting, but to counter this, evidence has been put forward that health professionals are good at assessing a patient's weight. The opinions of our experts were mixed, some indicating that weight estimation is easy, others indicating that estimation of weight by paramedics could lead to medication errors. We are inclined to accept that any minor errors that may occur are unlikely to be detrimental to patients.

The question of whether it is more appropriate to give thrombolysis based on patient weight or as 'a single dose fits all' is unresolved. The former approach has appeal and there exists some evidence to support it, but it requires further definitive trial evidence. This whole issue is not considered further here as it is beyond the remit of this review.

## Models of care

Based on the results of the literature reviews, both clinical and economic, and discussions with experts in the field of thrombolysis, there appear to be three main models of care for the delivery of early thrombolysis. These models of care can be categorised as follows:

- hospital thrombolysis
- collaborative care delivered jointly in the pre-hospital and hospital settings
- pre-hospital thrombolysis by an autonomous operator.

Within each of these models there are a number of implementation options. For instance the JRCALC<sup>127</sup> has outlined five different options of care within these. Our initial analysis identified ten distinct options. In this section we do not attempt to be exhaustive in our description but to outline key aspects that have been or need to be addressed by healthcare decision-makers (clinicians or managers) who are attempting to implement changes in practice to decrease current time to treatment of patients with AMI.

Prior to discussing the models of care it is worth examining a small part of the history and evolution of the care of patients suffering from AMI in relation to who provides their care. A part of the current debate regarding early thrombolysis is the question of who should assess the patient, make the diagnosis and then provide the treatment. The shift of provision of care to patients experiencing AMI both in the hospital and in the community setting is not new. There is historical precedent and lessons that can be learned from the implementation of basic and then advanced cardiac life support first in hospital settings by physicians and then by hospital nurses and finally in the community by paramedics.

Similarly, there has been a parallel shift in the provision of thrombolytic therapy by hospital physicians to thrombolysis nurses in hospital and to paramedics and GPs in the community. The debate that evolved in the 1980s is being repeated and the focus revolves around what happens to the role of the hospital doctor, or even GP when these roles are changed. This review does not enter into this debate. However, the position taken in the following discussion is that treatment should be delivered by healthcare professionals who are adequately trained and equipped to assess, diagnose, provide treatment and deal with any adverse events of that treatment. This may be a physician (GP), a paramedic or a nurse working in isolation or in collaboration with others.

The following section provides an overview of the models, discussing issues that have been identified to decrease 'call-to-treatment' time of patients with AMI. As might be expected, there are areas of overlap between the models and all focus on establishing an environment in which healthcare

professionals are enabled to deliver the best quality care in the shortest period of time. *Table 27* outlines strategies that have been identified to decrease 'call-to-treatment' time within each of the models.

### Hospital thrombolysis

In this model, all assessment and care is provided within the hospital setting. These could be patients who self-refer to the A&E department or are referred by their GP. Calls to the ambulance service, in this model, result in standard care and transport of the patient to hospital. On arrival, patient assessment may vary and handover in the A&E department would include basic information as designated by the Ambulance Trust for patients with symptoms of AMI. This model then would focus on the ability to decrease the time from when the patient arrives in the A&E department until the patient receives treatment.

As discussed earlier, reports exist that document the ability to decrease 'door-to-treatment' time. More recently teams of thrombolysis nurses have been established to work within A&E departments as a strategy to decrease 'door-to-needle' time.

Initially a number of these initiatives were funded by pharmaceutical companies (Rees K, charge nurse, CCU, Countess of Chester Hospital: personal communication, 2002). Later the roles were integrated within the hospital staffing. Thrombolysis nurses are typically CCU nurses who took on extended roles in the A&E department. Their roles and responsibilities vary, with the norm being that they carry out initial assessment, communicate with medical staff and provide treatment and aftercare until patients are transferred to the CCU. No official training programme for these nurses was identified during this review.

### Collaborative care delivered jointly in the pre-hospital and hospital setting

There are at least two options within this model. In the first instance, the responding GP or paramedic could assess the patient, perform an ECG and transmit the findings to the receiving hospital thus alerting hospital staff to the fact that they will be arriving with a patient who requires thrombolysis. The theory is that by alerting the hospital in advance they will be prepared to receive and treat the patient as soon as possible after arrival and

**TABLE 27** Implementation considerations

Time interval	Hospital model	Combined care	Pre-hospital model
Call to response	Appropriate triage in A&E Mechanism to fast track AMI patients to dedicated thrombolysis teams Rapid transfer of patients from A&E to CCU if appropriate	Ambulance availability Community rapid response teams GP call systems Improved organisation between ambulance services, GPs and community hospitals Improved communication between ambulance teams and receiving hospital	Ambulance availability Community rapid response teams GP call systems Improved organisation between ambulance services and GPs
Initial assessment	Suitably trained thrombolysis team Availability of appropriate equipment and skill	Suitably trained GPs and paramedics Availability of appropriate equipment (e.g. 12 lead ECG, telecommunication) and skills Access to remote ECG interpretation	Suitably trained GPs and paramedics Availability of appropriate equipment (e.g. 12 lead ECG) and skills
Assessment to decision	Professional on hand to make treatment decision quickly	Autonomous GP or paramedic able to transmit data or make treatment decision Professional on hand to make treatment decision quickly in hospital	Autonomous GP or paramedic able to make treatment decision
Decision to treatment	Appropriately trained individual to provide treatment, monitor results and deal with adverse events Availability of appropriate drugs and equipment	Appropriately trained individual to provide treatment, monitor results and deal with adverse events Availability of appropriate drugs and equipment	Appropriately trained individual to provide treatment, monitor results and deal with adverse events Availability of appropriate drugs and equipment

therefore 'door-to-needle' time will be decreased. In France transmission of ECGs in advance of patient arrival was found to reduce the 'door-to-needle' time from 84 to 36 minutes.<sup>128</sup>

In the second option of collaborative care, the patient receives thrombolysis on-site. The GP or paramedic would first of all carry out an assessment of the patient. If the assessor is a GP then they could, if they chose, make a decision to thrombolysise the patient before transfer to hospital. If the assessor is a paramedic or a GP who is not equipped or comfortable with emergency diagnosis and treatment, they could perform an ECG, transmit the clinical findings and ECG readings to a receiving centre (normally the hospital to which the patient will be transferred) and receive direction regarding treatment. The patient would receive thrombolysis on-site and be transferred to hospital.

Each of these options requires additional training of GPs and paramedics in assessment, conducting of ECGs, transmission of ECGs, delivery of treatment and dealing with any adverse events. Hooghoudt and colleagues<sup>98</sup> in The Netherlands have identified several barriers to collaborative pre-hospital thrombolysis including medical, legal and organisational difficulties. They found that the training of GPs and paramedics was time-consuming, and that many purchasers question the value of pre-hospital thrombolysis given the lack of clear evidence of benefits (written before Morrison meta-analysis<sup>90</sup>). Delays in Holland at the time included hospital 'door-to-needle' times of around 84 minutes.

Research in Wales has shown that paramedics can acquire the appropriate diagnostic skills to identify patients with AMI and that they already have the skills related to conducting patient assessments and delivering intravenous therapy.<sup>129</sup> A specialist training programme for paramedics and GPs to deliver thrombolysis has been jointly designed by JRCALC and Boehringer Ingleheim (Chamberlain D, JRCALC, Sussex: personal communication, 2002).

Research also conducted in Wales shows that the transtelephonic transmission of ECGs is problematic and is associated with a 25% failure rate.<sup>129</sup> Similar anecdotal experiences have been reported from the current evaluation study in Lancashire (Bastow P, Lancashire Ambulance Services NHS Trust: personal communication, 2002) Given the advances in telecommunications, it would be hoped that these problems can be overcome.

Another problem that has arisen in both the Welsh<sup>129</sup> and Lancashire (Paul Bastow, R&D officer, Lancashire Ambulance Services NHS Trust, 2002) research projects is the issue of who is responsible for receiving the patient data and making treatment decisions (e.g. A&E department, CCU). Neither project has solved these problems.

The second issue regarding paramedic administration of thrombolytic therapy is whether or not paramedics actually feel that the provision of thrombolysis is within their remit and whether or not they will provide the treatment. A comparator is the implementation of the provision of aspirin to patients with symptoms of AMI presenting to the ambulance service. An audit carried out in the Ambulance Services of England and Wales found that the majority of services (26/35) were not collecting the data to assess implementation of this treatment. Of those that did collect data, the survey found that between 15% and 75% of eligible patients were not receiving the drug.

The discussion regarding the use of pre-hospital thrombolysis by GPs has been carried out at great length in terms of the GREAT study.<sup>84</sup> Rawles and colleagues<sup>130</sup> demonstrated that even in urban areas of one city in Scotland, the GP was the first point of medical contact in 68% of cases of suspected AMI (97% in rural areas), and so should not be lightly excluded as a possible medium for thrombolysis even in cities. In this follow-on to the GREAT study, rural GPs administered thrombolysis in 35% of cases at a median time of 45 minutes after onset of pain. Clearly in some areas with sufficient professional interest, additional training in resuscitation and administration of thrombolysis and provision of equipment such as defibrillators, the model of GP-delivered thrombolysis may be worth pursuing.

### **Pre-hospital thrombolysis by an autonomous operator**

In this proposed model the delivery of thrombolysis would be totally under the remit of emergency response personnel. This might be a GP or the ambulance service.

In this model the patient is assessed, diagnosed and treated on-site without a secondary medical opinion. This means that GPs or paramedics would be acting autonomously in the pre-hospital setting. This model raises the same issues regarding training of GPs and paramedics as the second model, with the added fact that they require additional diagnostic skills. There have also been



questions regarding legal responsibility for this care delivered in the community.

In relation to the UK it is worth noting the differences in healthcare providers. The majority of pre-hospital studies used either medical or nursing staff in the ambulance, or a mobile CCU, neither of which is common in the NHS. American studies have used paramedics who participate in a significantly more extensive training and preparation programme than is provided in the UK. As noted earlier, a training programme has been developed. This added training may allow paramedics to administer the thrombolytic drugs with greater confidence.

This is a model favoured in Wales where telecommunication of patient information has been problematic.

## Conclusions

There are a number of points within the 'call-to-treatment' time continuum where changes can be initiated to decrease 'call-to-treatment' time. The decision regarding the appropriate model of care to be adopted by individual trusts to meet the NSF standards will depend on the organisation of current care patterns, time/distance factors for transporting patients and the ability to decrease 'door-to-needle' time in the hospital setting. The synthesis of these data will allow current healthcare providers and decision-makers to design appropriate implementation strategies to improve 'call-to-treatment' time and ensure the provision of optimal and safe care for the patient.

## Costs associated with the implementation of early thrombolysis models of care

### Introduction

This section estimates the impact of different scenarios of the use of thrombolytic therapy on drug costs to the NHS. Significant international variations are evident in clinical preference for individual drugs. In the UK, the majority of patients receive streptokinase whereas in the USA the majority receive alteplase. Such variations are likely to reflect the nature and level of budgetary constraints imposed on health services, combined with the perceived relevance of the clinical evidence generated in support of each individual drug. In the UK, streptokinase remains the drug of choice with newer drugs being

largely reserved for patients who have previously received treatment, are allergic to streptokinase or who, on the basis of subgroup analyses, are most likely to benefit from alteplase therapy.

### Budget impact analysis

The aim of a budget impact analysis is to estimate the costs associated with switching patients from one thrombolytic drug to another in both the hospital and pre-hospital setting. In order to carry out a budget impact assessment, accurate information is required concerning the comparative cost of the thrombolytic drugs, the market share for each drug and the total patient population.

### Cost of the drugs

Table 28 presents the list prices for a treatment dose of streptokinase (non-proprietary), alteplase (Actilyse<sup>®</sup>), reteplase (Rapilysin<sup>®</sup>) and tenecteplase (Metalyse<sup>®</sup>) as quoted in the *British National Formulary* (September 2001). The price of tenecteplase is based on the average cost of the 40 mg (£700) and 50 mg (£770) vials.

TABLE 28 List price of drugs

Product	BNF <sup>21</sup> list price (£)
Streptokinase	80
Alteplase	600
Reteplase	716.25
Tenecteplase	735

### Current market share

The current total market shares for each of the four thrombolytic drugs are discussed in the company submissions to NICE and are presented in Table 29. Aventis's market share is based on data from International Medical Statistics DataView (Centre de Recherche Public Centre Universitaire Hospital) only. The Boehringer Ingelheim submission to

TABLE 29 Total market share

Product	Total market share (%) as presented in each of the submissions		
	Aventis	Boehringer Ingelheim	Roche
Streptokinase	64.5	53	55.41
Alteplase	23	31	32.45
Reteplase	12.5	15	11.77
Tenecteplase	Not licensed	1	0.37

NICE does not state the source of their information on market share but it was probably derived from the National Audit of Myocardial Infarction (NAOMI) database, and Roche's data on market share is from company market research 2001. The differences between these data are minor. The baseline budget impact analysis incorporates all of these market shares by calculating costs based on the range (minimum and maximum) of market shares presented.

### Patient population

Estimation of the incidence of AMI is difficult with reported estimates exhibiting large variability. Determining the size of the patient population for thrombolytic therapy is further complicated by variations in its criteria for use. The number of patients presenting with chest pain in whom thrombolytic therapy is used is typically determined by local treatment guidelines.

The company submissions to NICE include very different estimates of the total number of patients treated by thrombolysis as they consider different patient populations. Aventis estimate that approximately 105,000 patients per year are eligible for thrombolysis in the UK and state that only 86,500 patients actually receive thrombolysis. The Boehringer Ingelheim report estimates that approximately 46,000 administrations of thrombolytic agents are administered in England and Wales per annum. The Roche submission to NICE estimates that approximately 54,400 receive thrombolysis in England.

Given these variations in the numbers of patients treated, we have carried out our budget impact analysis based on information derived from two recently published ambulance services documents.<sup>36,129</sup> Our estimates of numbers of patients eligible for thrombolysis and pre-hospital thrombolysis are presented in *Table 30* and are based on the analysis described by Woollard and

colleagues.<sup>129</sup> Validation of the assumptions behind these figures is provided by Birkhead<sup>23</sup> who estimated that of patients with AMI, roughly equivalent numbers of patients (45% in each case) arrive at hospital as a consequence of an emergency call and GP referral, with the remaining 10% of patients self-referring to hospital. Woollard and co-workers,<sup>129</sup> writing from an ambulance service perspective, do not consider these 'self-referrals' and we have omitted them here also.

This figure of 49% of patients potentially receiving pre-hospital thrombolysis broadly agrees with the industry submission from Boehringer Ingelheim which estimates that 55% of patients will be assessed for pre-hospital thrombolysis and approximately 35% will receive it.

This means that approximately 6% of all chest pain patients seen by the ambulance service may be eligible for pre-hospital thrombolysis (53,555/880,000 multiplied by 100 is 6%), or about 23% of all AMIs. The figure of 6% is similar to the percentage reported in the study with the most comparable data, MITI,<sup>89</sup> where 8863 patients with chest pain were assessed but only 360 patients were eligible for pre-hospital thrombolysis (4.1%).

### Results

Using the list prices and the assumptions described above, the current annual cost to the NHS of thrombolytic drugs is estimated to range between £30,817,738 and £42,039,251 for all patients eligible for thrombolysis (see *Table 31*). These are the figures used as a baseline for comparisons.

However, to illustrate the cost of switching eligible patients from one thrombolytic drug to another, annual costs for the following scenarios have been calculated and are presented in *Table 32*. As in all such scenarios it is unrealistic to assume that

**TABLE 30** Assumptions made for numbers of patients who may be suitable for pre-hospital thrombolysis

Assumptions	Numbers of patients
Total number of emergency calls to ambulance services, England 2000–01	4.4 million
10% of emergency calls are to patients with chest pain	440,000
GPs refer the same number of chest pain patients as are seen by 999 calls	440,000
<b>Subtotal</b>	<b>880,000</b>
27% of patients with chest pain will have suffered from an AMI	237,600
49% are eligible for thrombolytic drugs	116,424
46% may be suitable for pre-hospital treatment	53,555

**TABLE 31** Current cost to the NHS of thrombolytic drugs in England

Thrombolytic drug	BNF <sup>21</sup> list price, 2001 (£)	Low estimate of market share	Number of patients treated	High estimate of market share	Number of patients treated	Low cost (£)	High cost (£)
Streptokinase	80	0.53	61,705	0.645	75,093	4,936,378	6,007,478
Alteplase	600	0.23	26,778	0.3245	37,780	16,066,512	22,667,753
Reteplase	716.25	0.1177	13,704	0.15	17,464	9,814,849	12,508,304
Tenecteplase	735	0	0	0.01	1,164	0	855,716
<b>Total</b>						<b>30,817,738</b>	<b>42,039,251</b>

**TABLE 32** Budget impact estimates – hospital patients (100%)

Thrombolytic drug	BNF <sup>21</sup> list price, 2001 (£)	Estimate of market share	Number of patients treated <sup>a</sup>	Total cost (£)	Additional cost based on low estimate (£)	Additional cost based on high estimate (£)
Streptokinase	80	0.7	81,499	6,519,744		
Alteplase	600	0.3	34,927	20,956,320		
			<b>Subtotal</b>	<b>27,476,064</b>	<b>-3,341,674</b>	<b>-4,563,187</b>
Alteplase	600	1	116,424	69,854,400	39,036,662	27,815,149
Reteplase	716.25	1	116,424	83,388,690	52,570,952	41,349,439
Tenecteplase	735	1	116,424	85,571,640	54,753,902	43,532,389

<sup>a</sup> Based on total population of 116,424

all patients can or should be transferred onto a single drug. However, these figures provide an indication of the cost-impact of altering the patterns of thrombolytic drug use in the hospital environment. The cost of switching all eligible patients to streptokinase has not been estimated as it is contraindicated in those patients that have already received streptokinase previously – we have arbitrarily assumed that 30% of patients would get alteplase instead. By setting the number of patients at 116,000, this indicates the probable maximum, but several audits have shown that many eligible patients do not receive thrombolysis – this would decrease costs but we have no data to identify by how much.

As the organisation and delivery of pre-hospital thrombolysis is currently being developed, and is expected to be routinely available throughout England in the near future, the following annual cost estimates to the NHS have also been calculated based on expert opinion of potential market share options. The total cost of thrombolytic drugs includes the costs in both hospital and pre-hospital settings. Table 32 provides the cost implications of switching to each individual drug solely in the

hospital environment. Table 33 also provides the cost implications of using a less expensive infusion drug in hospital and a more expensive bolus out of hospital.

#### **Impact of pre-hospital thrombolysis**

If the majority of the required diagnostic and treatment procedures are common, it is only those that vary between each intervention that require detailed analysis. Pre-hospital thrombolysis requires investment in equipment, and organisation and training to enable the service to be provided. However, a commitment to this has already been made by the UK government. In addition, drug costs may change as patient selection, choice of drug and drug costs are likely to be different between pre-hospital and hospital treatment.

The additional costs associated with the development of pre-hospital thrombolysis in the UK are likely to be comparatively small. The service is using and adapting existing organisational structures and therefore no fundamental new structure of service is required. Provision of the service, therefore, would require additional training and a limited expansion of the service to

**TABLE 33** Budget impact estimates – hospital (54%) and pre-hospital (46%) patients

Product	Market share (hospital population = 62,869)	Total cost (hospital) (£)	Product	Market share (pre-hospital population = 53,555)	Total cost (pre-hospital) (£)	Total cost (hospital + pre-hospital) (£)	Additional cost based on low estimate (£)	Additional cost based on high estimate (£)
Streptokinase + alteplase	70% + 30%	14,837,084	Retepase	100%	38,358,768	53,195,852	22,378,114	11,156,602
Streptokinase + alteplase	70% + 30%	14,837,084	Tenecteplase	100%	39,362,925	54,200,009	23,382,271	12,160,758
Streptokinase + alteplase	70% + 30%	14,837,084	Retepase + tenecteplase	50% + 50%	38,860,846	53,697,930	22,880,192	11,658,680

cope with any additional workload. However, because such factors do not affect comparative drug choice in the pre-hospital environment, no attempt has been made to cost them. The most significant cost is likely to be the additional drug costs resulting from a change in the choice of thrombolytic agent.

Given that the remit of this review is restricted to identifying the comparative cost-effectiveness of different drug therapies the only factor that will vary between the two therapies identified as being suitable for use in the pre-hospital situation will be the drug acquisition costs. The infrastructure and training required for provision of both reteplase and tenecteplase is likely not to be significantly different and therefore the choice collapses to one simply of which drug can be obtained most cheaply for use in the pre-hospital environment. Currently, reteplase appears to have a price advantage and the cost penalty attached to the treatment of pre-hospital thrombolysis patients with reteplase in comparison to the current pattern of hospital provision would conserve scarce NHS resources. The precise costs would depend largely on local managers' ability to negotiate favourable drug prices and the method of pre-hospital thrombolysis utilised.

The list price of thrombolytics is not an accurate guide to the price that can be negotiated by large hospital purchasers. We have used list prices throughout but actual prices may be substantially less than this. In recognition of this fact, the GUSTO I study<sup>18</sup> incorporated an

estimate of actual drug costs (rather than listed drug prices) as part of its sensitivity analysis and this significantly improved the cost-effectiveness of thrombolytic treatment. Although the details of these contracts within the NHS remain confidential, the ability to negotiate a favourable price with any of the competing suppliers represents one of the most important local variables that must be incorporated into the decision-making process.

#### Long-term costs

From a long-term perspective, more extended use of thrombolytic therapy may lead the population as a whole to grow by up to 1%, the number of people with cardiac ischaemia could increase by 20% and the annual rates of AMI could also increase by about 20%. The total drugs bill may also increase by approximately 3% because of the growth in the elderly population.<sup>93</sup>

#### Conclusion

This impact analysis does not aim to provide definitive answers, but indicates factors determining how the NHS can obtain the greatest benefit from the limited healthcare resources available for investment in thrombolysis. It is also important to recognise that the results of this impact analysis are not static and that a range of factors on both the cost and effectiveness side will considerably influence cost-effectiveness over time. The price of thrombolytic drugs may decrease, practice patterns may change and there may be further improvements in drug regimens.

# Chapter 7

## Discussion

The format of this review has included a discussion at the end of each relevant section. The final decision regarding the most appropriate drug rests on the appraisal of clinical issues (whether the evidence of difference between drugs in outcomes is considered clinically relevant), economic issues (whether the ICERs demonstrated are considered worthwhile), and pragmatic issues (whether infusion drugs can be administered out of hospital and whether the time saving and convenience from use of bolus drugs helps meet NSF targets). The latter in particular are matters that may require local decisions within a national framework provided by NICE.

The objective of this review was to assess which is the most appropriate thrombolytic therapy in each of two settings; hospital and pre-hospital. In this it has been limited by the need to make indirect comparisons where no direct comparisons exist, and to assume that the results of hospital comparative studies would also apply in pre-hospital settings. The limitations of the available evidence have been discussed in each chapter.

In the economic evaluation of therapy, the complexity and detail of the models provided by the pharmaceutical industry submissions to NICE were superior to any that we could develop in the time and within the resources available. We therefore chose to use these models with different assumptions to test the cost-effectiveness of different drugs. One drug, streptokinase, is only a fraction of the cost of any of the others, yet has all or almost all of the effectiveness of these drugs. It therefore was clearly going to be the most cost-effective drug and the baseline against which all other drugs would be compared.

The resulting ICERs for the other drugs compared to streptokinase are within the range of interventions that have been funded previously in the UK and in other health services, following assessments of this kind. The extent of the incremental benefits of other therapies, if any, and of their risks, is a matter for appraisal. However, we have an effective and inexpensive

drug, streptokinase, which can be given in hospital and with which we have extensive experience.

The preferred options used in the economic evaluation are open to question. The options for comparability between drugs set out in the clinical section could only be tested to a limited degree, since no two drugs were equal in all their aspects, i.e. mortality, stroke rate, bleeding rates etc. It was necessary therefore to use point estimates which are transparently derived and which can be justified as we have presented. A range of assumptions were tested and the results in ranking order for the drugs and in their scale were robust to these. Further assumptions could be tested if necessary given more time and resources. However the key conclusions, that streptokinase is the most cost-effective drug and that differences in cost-effectiveness between other drugs are minor, are robust to any reasonable set of assumptions.

There are a number of points within the 'call-to-treatment' time continuum where changes could be initiated to decrease 'call-to-treatment' time. The decision regarding the appropriate model of care to be adopted by individual trusts to meet the NSF standards will depend on the organisation of current care patterns, time/distance factors for transporting patients and the ability to decrease 'door-to-needle' time in the hospital setting. The synthesis of these data will allow current healthcare providers and decision-makers to design appropriate implementation strategies to improve 'call-to-treatment' time and ensure the provision of optimal and safe care for the patient.

Given more time, a wider range of consultation could have been undertaken in this area. Instead we depended on the opinions of a selective search of the literature and a limited number of experts in this area. Although we have sought to obtain balanced views at all times, it is possible that their prejudices are reflected in this review. It is clear that this is a rapidly changing area, and NICE's recommendations will be eagerly awaited.



# Chapter 8

## Conclusions

### Clinical effectiveness

Trial data are not available to provide direct comparison between all drugs included in this review. As stated in the results section, the evidence for differences in clinical effectiveness of the drugs is uncertain and dependent upon *a priori* decisions regarding equivalence. The resolution of the controversies is a matter for appraisal and judgement.

Data are available from studies conducted in the hospital setting. No trials were identified that compared drug effectiveness in the pre-hospital setting. There is no reason to believe that the effectiveness of a drug will be altered by administration in the pre-hospital setting.

Definitive conclusions on efficacy (30–35-day mortality) are that streptokinase is as effective as non-accelerated alteplase, that tenecteplase is as effective as accelerated alteplase, and that reteplase is at least as effective as streptokinase.

Some conclusions require interpretation of data, i.e. whether streptokinase is as effective as, or inferior to accelerated alteplase; and whether reteplase is as effective as accelerated alteplase or not.

Depending on these, two further conclusions on indirect comparisons arise, whether tenecteplase is superior to streptokinase or not, and whether reteplase is as effective as tenecteplase or not.

That these questions remain to be resolved illustrates that any differences in mortality between drugs is small.

Streptokinase causes more allergic reactions than other drugs.

There seem to be significant differences between drugs in incidence of stroke, with streptokinase having the lowest rate.

The decision regarding which agent to use is therefore a balance of risks and benefits related to these two factors. No clear conclusion, based on statistical comparison, can be drawn.

It is possible to use all four drugs for pre-hospital treatment but in practice bolus products seem the

most convenient. The required use of heparin with both of the bolus products does not seem to provide any practical barrier to their widespread use.

### Economic evaluation

Existing economic evaluations are of limited value in determining the relative cost-effectiveness of drugs in the NHS. The existing studies are almost all industry-funded and depend on whether one accepts or rejects the superiority of alteplase over streptokinase.

Further economic modelling was therefore required to evaluate the cost-effectiveness of different drugs in the NHS. Company models were used as the basis of this modelling with modification of assumptions that may have favoured one drug over another. The conclusion of these modelling exercises is that differences in QALYs gained between drugs are small, and that the single most important factor in determining the ICER was the acquisition cost of the drug. On this basis, streptokinase was the most cost-effective drug; this conclusion was robust despite several variations in assumptions of benefit or harm.

In contrast, the relative positions of alteplase, tenecteplase or reteplase varied slightly depending on the assumptions made.

Given the existing prices, the cost per QALY of newer drugs compared to streptokinase was between £12,000 and £17,000.

The benefits of earlier thrombolysis have not yet been well quantified. Minor time savings achieved by the bolus drugs over infusion drugs do not significantly affect the ICERs.

### Implementation

There are substantial opportunities for refining hospital thrombolysis procedures to meet NSF targets. Changing drugs is a very minor element in achieving improved 'door-to-needle' time.

Pre-hospital thrombolysis will be necessary in some areas to allow NSF targets to be met. The choice of

drug for pre-hospital thrombolysis is determined by acquisition cost and by convenience. Our experts did not wish to consider the use of infusion products (e.g. alteplase or streptokinase) but preferred bolus administration (reteplase and tenecteplase).

The cost-impact of switching to the more expensive bolus drugs could be as much as £50 million per year, over and above existing costs of approximately £30–40 million for the NHS in England and Wales.





## Acknowledgements

This work was commissioned by the Health Technology Assessment Programme on behalf of NICE.

The authors would like to thank the following panel members who provided comments on review protocol and draft documents:

Mrs P Alexander, Lecturer, Department of Nursing, University of Liverpool, UK.

Professor S Capewell, Professor of Clinical Epidemiology, Department of Public Health, University of Liverpool, UK.

Professor D Chamberlain, Chairman, Joint Royal Colleges Ambulance Liaison Committee, UK.

Professor F Hobbs, Head of Division, Department of General Practice, University of Birmingham, UK.

Dr S Saltissi, Consultant Cardiologist, Royal Liverpool and Broadgreen University Hospital, UK.

Dr E Tunn, Consultant, Royal Liverpool and Broadgreen University Hospital, UK.

Professor R Vincent, Head of School, Postgraduate Medical School, University of Brighton, UK.

Dr N Waugh, Senior Lecturer, Wessex Institute for Health Research and Development, University of Southampton, UK.

Dr K Wilmer, Consultant Cardiologist, West Cumberland Hospital, UK.

We would also like to thank the following experts who provided advice and clinical information in specific areas:

Mr P Bastow, Lancashire Ambulance Services NHS Trust, UK.

Mr E Lamfers, Consultant Cardiologist, Nijmegen, The Netherlands.

Dr D Morrow, Brigham and Women's Hospital, UK.

Ms K Rees, Countess of Chester Hospital, UK.

Mr A Silver, Clinical Governance Officer, East Midland Ambulance Services NHS Trust, UK.

Dr M Shuster, A&E Department Banff, Alberta, Canada.

Mr A van Dellen, Staffordshire Ambulance Services NHS Trust, UK.

Dr P Williamson, Statistics Department, University of Liverpool, UK.

### Contributions of the authors

Angela Boland conducted the review of economic effectiveness, developed the framework of models of care, conducted the budget impact analysis and prepared the results of both for publication; Yenal Dundar conducted the review of clinical effectiveness and prepared the results for publication; Adrian Bagust conducted the review and analysis of economic models; Alan Haycox assessed and data-extracted information from economic studies to inform the economic review and model development; Ruaraidh Hill assisted in the data extraction from clinical studies and checking and production of the final report; Ruben Mujica Mota assisted in the review of economic effectiveness, analysis of company submissions to NICE and testing of the economic model; Tom Walley coordinated the review production as well as the data analysis and interpretation and Rumona Dickson coordinated review activities.

All contributors took part in the final editing and production of the report.

The views expressed in this publication are those of the authors and not necessarily those of the review panel, the HTA Programme, NICE or the Department of Health. Any errors are the responsibility of the authors.





## References

1. British Heart Foundation. British Heart Foundation statistics database 2002. URL: <http://www.dphpc.ox.ac.uk/bhfhprg/stats/2000/2002/index.html>
2. American Heart Association. American College of Cardiology/AHA guidelines for the management of patients with acute myocardial infarction. 1999. URL: <http://216.185.112.5/presenter.jhtml?identifier=2865>
3. European Society of Cardiology and the European Resuscitation Council. The pre-hospital management of acute heart attacks: recommendations of a task force of the European Society of Cardiology and the European Resuscitation Council. *European Heart Journal* 1998;**19**:1140–64.
4. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994;**90**:583–612.
5. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HAW, *et al.* Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. *Heart* 1998;**80**:40–4.
6. Walker M, Shaper A, Lennon L, Whincup P. Twenty year follow-up of a cohort based in general practices in 24 British towns. *Journal of Public Health Medicine* 2000;**22**:479–85.
7. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. *Annals of Internal Medicine* 1995;**122**:96–102.
8. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, *et al.* Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. *European Heart Journal* 1985;**6**:556–85.
9. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). *Lancet* 1986;**1**:397–402.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS2. *Journal of the American College of Cardiology* 1988;**12**:3–13A.
11. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. *New England Journal of Medicine* 1997;**336**:847–60.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *British Medical Journal* 2002;**324**:71–86.
13. Ohman E, Harrington R, Cannon CP, Agnelli G, Cairns J, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. *Chest* 2001;**119** Suppl:253–77S.
14. Weston C, Penny W, Julian D. Guidelines for the early management of patients with myocardial infarction. *British Medical Journal* 1994;**308**:767–71.
15. Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, *et al.* Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). *Journal of the American College of Cardiology* 1992;**19**:885–91.
16. Carney R, Murphy G, Brandt T, for the RAAMI study investigators. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. *Journal of the American College of Cardiology* 1992;**20**:17–23.
17. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, *et al.* Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. *Circulation* 1996;**94**:891–8.
18. GUSTO. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. *New England Journal of Medicine* 1993;**329**:673–82.
19. Topol EJ, Califf R, Ohman E, Skene A, Wilcox R, Grinfeld L, *et al.* A comparison of reteplase with alteplase for acute myocardial infarction. *New England Journal of Medicine* 1997;**337**:1118–23.

20. Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, *et al.* Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999;**354**:716–22.
21. British Medical Association. British National Formulary: British Medical Association. 2001. URL: <http://www.bnf.org/>
22. European Society of Cardiology. Task force on the management of acute myocardial infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in hospital management. *European Heart Journal* 1996;**17**:43–8.
23. Birkhead J. Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. *Heart* 1997;**78**:28–33.
24. Norris R. Fatality outside hospital from acute coronary events in three British health districts, 1994–5 (NKHAS Collaborative Group). *British Medical Journal* 1998;**316**:1065–70.
25. United Kingdom Heart Attack Study (UKHAS) Collaborative Group. Effect of time from onset to coming under care on fatality of patients with acute myocardial infarction: effect of resuscitation and thrombolytic treatment. *Heart* 1998;**80**:114–20.
26. Boersma E, Mass A, Deckers J, Simoons M. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *Lancet* 1996;**348**:771–5.
27. Newby K. Clinical outcomes according to time to treatment. *Clinical Cardiology* 1997;**20** (11 Suppl 3):III11–15.
28. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *Lancet* 1994;**343**:311–22.
29. Weaver WD. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. *Journal of the American College of Cardiology* 1995;**25**(7 Suppl):3–9S.
30. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health; 2000. URL: <http://www.doh.gov.uk/nsf/coronary.htm>
31. Department of Health. The NHS Plan. London: Department of Health; 2000.
32. Royal College of Physicians. Clinical Effectiveness and Evaluation Unit. Myocardial Infarction National Audit Project (MINAP); 2002. URL: [http://www.rcplondon.ac.uk/college/ceeu/ceeu\\_ami\\_home.htm](http://www.rcplondon.ac.uk/college/ceeu/ceeu_ami_home.htm)
33. MINAP. Data quality study report – December 2001. London: Royal College of Physicians, Clinical Effectiveness and Evaluation unit; 2001.
34. MINAP. Trial study report – May–September, 2000. London: Royal College of Physicians, Clinical Effectiveness and Evaluation unit; 2001.
35. Birkhead J, Georgiou A, Knight L, Walker L, Lowe D. A baseline survey of facilities for the management of acute myocardial infarction in England 2000. London: Royal College of Physicians – Clinical Effectiveness and Evaluation Unit; 2001.
36. Department of Health. Ambulance Services, England: 2000–01. London: Department of Health; 2001.
37. Staffordshire Ambulance Service NT. Pre-hospital thrombolysis protocol. Stafford: Staffordshire Ambulance Service; 2001.
38. East Midlands Ambulance Service NHS Trust. Pre-hospital thrombolysis pilot: experience gained from the first 14 months: East Midlands Ambulance Service NHS Trust, Nottingham; 2002.
39. NHS Wales. Clinical indicators for the NHS 2001. Cardiff: National Assembly for Wales; 2001.
40. Bastow P. Results of ongoing trials using 12 lead telemetry. Preston: Lancashire Ambulance Service NHS Trust; 2002.
41. Khan K, Ter Riet G, Glanville J, Sowdon A, Kleijnen J. NHS Centre for reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. CRD Report No. 4 (2nd ed). York: University of York; 2001.
42. Drummond M, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications; 1987.
43. Taylor GJ, Moses HW, Koester D, Colliver JA, Katholi RE, Dove JT, *et al.* A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study). *American Journal of Cardiology* 1993;**72**:1010–14.
44. Cherng WJ, Chiang CW, Kuo CT, Lee CP, Lee YS. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. *American Heart Journal* 1992;**123**:841–6.
45. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, *et al.* Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. *Lancet* 1985;**1**:842–7.

46. Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, *et al.* GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. *Lancet* 1990;**336**:65–71.
47. Van de Werf F, Wilcox RG, Barbash GI, Diaz R, Franzosi MG, Hampton JR, *et al.* In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. *Lancet* 1990;**336**:71–5.
48. Hunt D, Varigos J, Dienstl F, Lechleitner P, Mauel C, Dienstl A, *et al.* ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. *Lancet* 1992;**339**:753–70.
49. Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, *et al.* A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. *Circulation* 1991;**84**:540–9.
50. Magnani B. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. *Journal of the American College of Cardiology* 1989;**13**:19–26.
51. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, *et al.* Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation* 1987;**76**:142–54.
52. Hampton JR, Schroder R, Wilcox RG, Skene AM, Meyer-Sabellek W, Heikkila J, *et al.* Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. *Lancet* 1995;**346**:329–36.
53. Six AJ, Louwerenburg HW, Braams R, Mechelse K, Mosterd WL, Bredero AC, *et al.* A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. *American Journal of Cardiology* 1990;**65**:119–23.
54. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, *et al.* Safety assessment of single-bolus administration of tenecteplase tissue- plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. *American Heart Journal* 1999;**137**:786–91.
55. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, *et al.* Tenecteplase-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. *Circulation* 1998;**98**:2805–14.
56. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, *et al.* More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. *Circulation* 1995;**91**:2725–32.
57. Van de Werf F, Adgey A, Agnelli G, Aylward P, Biabrek A, Col J, *et al.* A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. *New England Journal of Medicine* 1997;**337**:1124–30.
58. Xu C, Lu M, Ding W, Zhang J, Shao G, Cui L, *et al.* A comparative study of intravenous accelerated streptokinase dose regimen with conventional dose regimen for coronary thrombolysis. *Chinese Medical Sciences Journal* 1996;**11**:236–8.
59. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, *et al.* Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. *New England Journal of Medicine* 1989;**320**:817–21.
60. Schultz K, Grimes D. Blinding in randomised trials: hiding who got what. *Lancet* 2002;**359**:696–700.
61. Topol E, Califf R, Lee K. More on the GUSTO trial. *New England Journal of Medicine* 1994;**331**:277–8.
62. Ware J, Antman E. Equivalence trials. *New England Journal of Medicine* 1997;**337**:1159–61.
63. Van de Werf E. Thrombolytic therapy for myocardial infarction [letter]. *New England Journal of Medicine* 1998;**338**:545–8.
64. Llevadot J, Giugliano R, Antman E. Bolus fibrinolytic therapy in acute myocardial infarction. *Journal of the American Medical Association* 2001;**286**:442–9.
65. Brophy JM. Thrombolytic therapy for myocardial infarction [letter]. *New England Journal of Medicine* 1998;**338**:545.
66. Jones B, Jarvis P, Lewis J, Ebbutt A. Trials to assess equivalence: the importance of rigorous methods. *British Medical Journal* 1996;**313**:36–9.
67. Thron C. Thrombolytic therapy for myocardial infarction [letter]. *New England Journal of Medicine* 1998;**338**:546.
68. Ware J, Antman E. Thrombolytic therapy for myocardial infarction [letter]. *New England Journal of Medicine* 1998;**338**:547.

69. Van de Werf E, Topol E, Lee K, Woodlief LH, Granger C, Armstrong P, *et al.* Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. *Journal of the American Medical Association* 1995;**273**:1586–91.
70. Ridker P, O'Donnell C, Marder VJ, Hennekens CH. Large scale trials of thrombolytic therapy for acute myocardial infarction GISSI-2, ISIS-3 and GUSTO-1. *Annals of Internal Medicine* 1993;**119**:530–2.
71. Mark DB. Is the use of t-PA as compared with streptokinase cost effective? [letter]. *New England Journal of Medicine* 1995;**333**:1010.
72. Reiner JS, Lundergan CF, Fung A, Coyne K, Cho S, Israel N, *et al.* Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. *Circulation* 1996;**94**:2441–6.
73. Lee K, Califf R, Simes J, Van de Werf E, Topol E. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *Annals of Internal Medicine* 1994;**120**:876–81.
74. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. *Circulation* 1993;**87**:1829–39.
75. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, *et al.* Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: Results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial. *Circulation* 2000;**102**:1761–65.
76. Mehta S, Eikelboom J, Yusuf S. Intracranial haemorrhage with bolus thrombolytic agents [letter]. *Lancet* 2000;**356**:1848–50.
77. Armstrong P, Granger C, Van de Werf F. Bolus fibrinolysis: risks, benefit and opportunities. *Circulation* 2001;**103**:1171–3.
78. Collen D, Sobel B. Intracranial haemorrhage with bolus thrombolytic agents. *Lancet* 2000;**356**:1848.
79. Van de Werf FJ, Armstrong PW, Granger C, Wallentin L. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet* 2001;**358**:605–13.
80. Fox K, Goodman S, Klein W, Brieger D, Steg P, Dabbous, O, *et al.* Management of acute coronary syndromes. Variations in practice and outcome; finding from the Global Registry of Acute Coronary Events (GRACE). *European Heart Journal* 2002;**23**:1177–89.
81. Barbash GI, Roth A, Hod H, Miller HI, Modan M, Rath S, *et al.* Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. *American Journal of Cardiology* 1990;**66**:261–6.
82. Castaigne AD, Herve C, Duval-Moulin AM, Gaillard M, Dubois-Rande JL, Boesch C, *et al.* Prehospital use of APSAC: results of a placebo-controlled study. *American Journal of Cardiology* 1989;**64**:30–33A; discussion 41–42A.
83. European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. *New England Journal of Medicine* 1993;**329**:383–9.
84. GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. *British Medical Journal* 1992;**305**:548–53.
85. McAleer B, Ruane B, Burke E, Cathcart M, Costello A, Dalton G, *et al.* Prehospital thrombolysis in a rural community: short- and long-term survival. *Cardiovascular Drugs and Therapy* 1992;**6**:369–72.
86. McNeill A, Cunningham S, Flannery D, Dalzell G, Wilson C, Campbell N, *et al.* A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. *British Heart Journal* 1989;**61**:316–21.
87. Roth A, Barbash G, Hod H, Miller H, Rath S, Modan M, *et al.* Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. *American Journal of Cardiology* 1990;**15**:932–6.
88. Schofer J, Butternner J, Geng G, Gutschmidt K, Herden H, Mathey D, *et al.* Prehospital thrombolysis in acute myocardial infarction. *American Journal of Cardiology* 1990;**66**:1429–33.
89. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, *et al.* Prehospital-initiated vs hospital-initiated thrombolytic therapy: the myocardial infarction triage and intervention trial. *Journal of the American Medical Association* 1993;**270**:1211–16.
90. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. *Journal of the American Medical Association* 2000;**283**:2686–92.

91. Brouwer MA, Martin JS, Maynard C, Wirkus M, Litwin PE, Verheugt FW, *et al.* Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). MITI Project Investigators. *American Journal of Cardiology* 1996;**78**:497–502.
92. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene MRPK, Sequeira RF, *et al.* Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. *Journal of the American College of Cardiology* 1994;**24**:1602–10.
93. Barton S, Walley T. Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics. *Pharmacoeconomics* 1996;**10**:441–52.
94. Rawles J. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: New evidence from Grampian region early anistreplase trial (GREAT). *British Medical Journal* 1996;**312**:212–15.
95. Rawles J. Call to needle times after acute myocardial infarction [letters]. *British Medical Journal* 1998;**317**:576–8.
96. Rawles J. What is the likely benefit of earlier thrombolysis? *European Heart Journal* 1996;**17**:991–5.
97. Lamfers E, Hooghoudt T, Uppelschoten A, Stolwijk P, Verheugt F. Effect of prehospital thrombolysis on aborting acute myocardial infarction. *American Journal of Cardiology* 1999;**84**:928–30.
98. Hooghoudt T, Lamfers E, Uppelschoeten A, Verheugt F. Study of time intervals in myocardial ischemic syndromes (STIMIS). *Cardiologie* 1998;**5**:23–30.
99. Lamfers E, Uppelschoeten A, Hooghoudt T, *et al.* Cost effectiveness of pre-hospital thrombolysis: an approach using different models. *European Heart Journal* 2003;in press.
100. Herlitz J, Svensson L, Zedigh C, Ahlstrom P, Nordlander R. Aspects of safety and delay times in pre-hospital thrombolysis in Sweden in relation to population density in the community. *European Heart Journal* 2001;**22** Suppl:25.
101. Morrow D, Antman E, Syah A, Schuhwerk K, Bhargava R, Rosenberg D, *et al.* Pre-hospital administration of reteplase for ST segment elevation MI: preliminary results of ER-TIMI 19 trial. *European Heart Journal* 2001;**22** Suppl:25.
102. Coccolini S, Berti G, Bosi S, Pretolani M, Tumiotto G. Prehospital thrombolysis in rural emergency room and subsequent transport to a coronary care unit: Ravenna myocardial infarction (RaMI) trial. *International Journal of Cardiology* 1995;**49** Suppl:S47–58.
103. Goel V, Naylor CD. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. *Canadian Journal of Cardiology* 1992;**8**:31–8.
104. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. *Journal of General Internal Medicine* 1995;**10**:321–30.
105. Kellett J. Cost-effectiveness of accelerated tissue plasminogen activator for acute myocardial infarction. *British Journal of Medical Economics* 1996;**10**:341–59.
106. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, *et al.* Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *New England Journal of Medicine* 1995;**332**:1418–24.
107. Massel D. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. *Canadian Journal of Cardiology* 1999;**15**:173–9.
108. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. *Canadian Journal of Cardiology* 1993;**9**:553–8.
109. Pelc A, Dardenne J, Frelon JH, Hanania G. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting. *Pharmacoeconomics* 1997;**11**:595–605.
110. Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, *et al.* Pitfalls in the economic evaluation of thrombolysis in myocardial infarction: the impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. *European Heart Journal* 1998;**19**:1518–24.
111. Kellett J, Clarke J. Comparison of 'accelerated' tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. *Medical Decision Making* 1995;**15**:297–310.
112. Pryor B, Harrell FE Jr, Rankin JS, Lee KL, Muhlbaier LH, Hlatky MA, *et al.* Trends in the presentation, management, and survival of patients with coronary artery disease: the Duke database for cardiovascular disease. In: Higgins MW, Luepker RV, editors. Trends in coronary heart disease mortality: the influence of medical care. New York: Oxford University Press, 1988. p.76–87.

113. Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, *et al.* Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. *Lancet* 1997;**349**:75–8.
114. Barradell LB, Goa KL. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. *Pharmacoeconomics* 1995;**8**:428–59.
115. Vale L, Silcock J, Rawles J. An economic evaluation of thrombolysis in a remote rural community [report]. Aberdeen: Health Economics Research Unit, University of Aberdeen; 1996.
116. Vale L, Silcock J, Rawles J. An economic evaluation of thrombolysis in a remote rural community. *British Medical Journal* 1997;**314**:570–2.
117. Department of Health. National schedule of reference costs. London: Department of Health; 2000.
118. Jonsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. *International Journal of Technology Assessment in Health Care* 1997;**13**:49–58.
119. Vermeer F, Simoons ML, de Zwaan C, van ES GA, Vergheut FW, van der Laarse A. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase: twelve month follow-up report of the randomized multicentre trial conducted by the Interuniversity Cardiology Institute of the Netherlands. *British Heart Journal* 1988;**59**:527–34.
120. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. *Pharmacoeconomics* 1999;**16**:577–93.
121. Seyedroudbari A, Kessler ER, Mooss AN, Wundeman RL, Bala M, Hilleman DE. Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA. *Journal of Thrombosis and Thrombolysis* 2000;**9**:303–8.
122. Capewell S, Livingston BM, MacIntyre K, Chalmers JWT, Boyd J, Finlayson A, *et al.* Trends in case-fatality in 117,718 patients admitted with acute myocardial infarction in Scotland. *European Heart Journal* 2000;**21**:1833–40.
123. More R, Moore K, Quinn E, Perez Avila C, Davidson C, Vincent R, *et al.* Delay times in the administration of thrombolytic therapy: the Brighton experience. *International Journal of Cardiology* 1995;**49** Suppl:S39–46.
124. Pell A, Miller H, Robertson C, Fox K. Effect of 'fast track' admission for acute myocardial infarction on delay to thrombolysis. *British Medical Journal* 1992;**304**:83–4.
125. Lamfers E, Schut A, Hooghoudt T, Hertzberger D, Boersma E, Simoons ML, *et al.* Prehospital thrombolysis with reteplase; the Nijmegen/Rotterdam experience. Department of Cardiology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; 2002.
126. Lamfers E, Hooghoudt T, Uppelschoeten A, Boersma E, Simoons ML, Verheugt F. Prehospital thrombolysis for acute myocardial infarction with reteplase: the Nijmegen/Rotterdam experience. *European Heart Journal* 2001;**22** Suppl:25.
127. Joint Royal Colleges Ambulance Liaison Committee (JRCALC). Models of care survey. London: JRCALC; 2001.
128. Gibler WB, Kereiakes DJ, Dean EN, Martin L, Anderson L, Abbottsmith CW, *et al.* Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial. *American Heart Journal* 1991;**121**:1–11.
129. Woollard M, Pitt K, Hayward T, Charters K, Whitfield R, Colquhoun M. Early thrombolysis for the treatment of acute myocardial infarction [Position paper]. Cardiff: Welsh Ambulance Services NHS Trust; 2002.
130. Rawles J, Sinclair C, Jennings K, Ritchie L, Waugh N. Audit of pre-hospital thrombolysis by general practitioners in peripheral practices in Grampian. *Heart* 1998;**80**:231–4.



# Appendix 1

## In-hospital thrombolysis assessment, Countess of Chester Hospital NHS Trust, 2001

### Thrombolytic prescription – sheet one

1. Are criteria for thrombolysis fulfilled?  
(see *Box I*)
2. Are there **definite** contraindications to thrombolysis (if 'yes' indicate in *Box II*)
3. Are there possible/treatable contraindications? (if 'yes' indicate in *Box II*)
4. Is alteplase indicated? (see *Box III*, if 'no' use streptokinase)
5. Has treatment been discussed with the patient?

#### BOX I Criteria for thrombolysis

All of the following:

- myocardial ischaemic pain for 30 minutes or other symptoms compatible with AMI
- ECG at least one of the following
  - 1 mm ST segment elevation in 1 or more limb leads
  - 2 mm ST elevation in 2 or more contiguous precordial leads
- symptoms for up to 12 hours (24 hours if pain recurrent).

#### BOX II Contraindications for thrombolysis

##### Definite contraindications:

- probable aortic dissection
- cerebrovascular accident within 3 months
- pregnancy
- gastrointestinal bleed with 6 months
- active peptic ulcer
- acute pericarditis
- major trauma/surgery within 6 weeks
- **prolonged** cardiopulmonary resuscitation.

##### Possible contraindications:

- known bleeding diathesis
- anti-coagulation (warfarin)
- current menstruation
- other condition which may predispose to bleeding
- other serious or life-threatening disease.

##### Treatable contraindications:

- systolic blood pressure more than 200 mmHg: treat blood pressure
  - if reduced to below 200 mmHg proceed with thrombolytic therapy
  - discuss with cardiac team/physician of the week if unable to reduce below 200 mmHg.

#### BOX III Indications for alteplase treatment

One or more of the following:

- significant persistent hypotension (< 100 mmHg on several readings)
- previous streptokinase or anistreplase (APSAC) treatment **at any time**
- recent proven streptococcal infection
- fulfilling all of the following:
  - presentation within 4 hours of onset of symptoms
  - age  $\leq$  75 years
  - anterior MI
  - likelihood of invasive procedure e.g. temporary pacemaker insertion.

### Conclusions

6. To receive thrombolysis?
  - yes: complete side 2 [sheet two] of this sheet. Give alteplase/streptokinase as appropriate
  - no: review after discussion/further treatment (see point 7 below).
7. Result of review
  - give thrombolysis
  - other.

### Thrombolytic prescription – sheet two

'Door-to-needle' time: (measured in hours/minutes – time infusion started minus time of admission) less than 30 minutes? Yes/No

#### Alteplase (t-PA)

If not already receiving aspirin give 300 mg soluble aspirin then:

- give 5000 units heparin intravenous bolus through venflon in one arm then:
  - follow alteplase regime using IVAC P7000 pump through another venflon in the other arm. Use infusion table (see *Table 34*), set pump according to patient's approximate weight using one of the categories given
  - intravenous heparin infusion to run concurrently and start at 1300 U/h (1.3 ml/h as 40,000 units in 40 ml)

**TABLE 34** Alteplase infusion rate (1 mg/ml solution)

Weight	Bolus	50 mg/50 ml 0.75 mg/kg over 30 minutes	35 mg/35 ml 0.5 mg/kg over 60 minutes	Please tick the regime used
70 kg	15 ml	100 ml/h	35 ml/h	–
60 kg	15 ml	90 ml/h	30 ml/h	–
55 kg	15 ml	83 ml/h	28 ml/h	–
50 kg	15 ml	75 ml/h	25 ml/h	–
45 kg	15 ml	68 ml/h	23 ml/h	–
40 kg	15 ml	60 ml/h	20 ml/h	–

- measure activated partial thromboplastin time (APPT) at 6 hours (aim for APPT 60–80 s (as in GUSTO I<sup>18</sup>)); follow heparin protocol.

Prescriber's signature/date.

N.B. heparin and alteplase must be given through separate venflons.

#### **Streptokinase**

- if not already receiving aspirin give 300 mg soluble aspirin then:
  - 1.5 million units streptokinase intravenous over 1 hour in 100 ml of saline
- start subcutaneous heparin 5000 units twice daily

Prescriber's signature/date.

#### **Thrombolytic infusion details**

- batch number:
- date started:
- time started:
- time stopped:

- time restarted:
- time finished:
- amount infused:
- total amount infused:

Nurse's signature/date.

Please complete the variance analysis sheet (see *Box IV*).

#### **BOX IV Variance analysis sheet**

Please indicate complications of thrombolysis including why treatment was stopped/interrupted:

- mild hypotension
- anaphylaxis
- haemorrhage
- urticaria
- cerebrovascular accident
- arrhythmia
- other:
  - comments.

## Appendix 2

### Pre-hospital thrombolysis assessment, East Midlands Ambulance Service NHS Trust

#### Primary assessment

- Is the patient conscious, coherent, and able to understand that clot-dissolving drugs will be used?
- Has the patient had symptoms characteristic of a coronary heart attack and did the worst pain build up over several minutes, rather than starting totally abruptly over several seconds, with a typical distribution of pain for 30 minutes' duration or more?
- Is the patient aged between 14 and 75 years of age?
- Did the continuous symptoms start less than 3 hours ago? [modified from 6 hours]
- Can you confirm that breathing does not influence the severity of pain?
- Can you confirm that the heart rate is between 40 and 140?
- Can you confirm that the systolic blood pressure is more than 80 mmHg and less than 160 mmHg and that the diastolic pressure is below 95 mmHg?
- Does the electrocardiogram show abnormal ST segment elevation of 2 mm or more (0.08 seconds after the J point) in at least two standard leads or at least two adjacent precordial leads, not including V1? (ST elevation can sometimes be normal for V1 and V2)
- Is the QRS width 0.12 mm or less, and is bundle branch block absent from the tracing?
- Can you confirm that there is **no** atrioventricular block greater than 1st degree? (if necessary after treatment with intravenous atropine).

#### Secondary assessment (contraindications)

- Can you confirm that the patient is not likely to be pregnant, nor has delivered within the last 2 weeks?
- Can you confirm that the patient has not had a peptic ulcer within the last 6 months?
- Can you confirm that the patient has not had a stroke of any sort within the last 12 months and no permanent disability from a previous stroke?
- Can you confirm that the patient has not been treated for any other serious brain condition? (this is intended to exclude patients with cerebral tumours).
- Can you confirm that the patient has no diagnosed bleeding tendency, has had no blood loss within the last 8 weeks (except for normal menstruation), and is not on **any** anticoagulant therapy (i.e. heparin, warfarin) except aspirin?
- Can you confirm that the patient has not had any surgical operation, tooth extractions, significant trauma, or head injury within the last 3 months?
- Can you confirm that the patient has not had chest compression for resuscitation for a period of longer than 5 minutes within the last 10 days?
- Can you confirm that the patient is not being treated for liver failure, renal failure, or any other severe systemic illness?



## Appendix 3

### Search for clinical studies

**TABLE 35** Search for clinical studies: summary

Database	Years	Search strategy	References Identified
MEDLINE	1980–2001	See appendix 4	1387
EMBASE	1980–2001	See appendix 5	1301
Science Citation Index/ Web of Science	1988–2001	<b>(Alteplase or tPA or streptokinase or reteplase or tenecteplase or anistreplase or urokinase) and (thrombolysis or myocardial infarction)</b>	2358
Cochrane Trials Register (Issue 4)	2001	<b>(Alteplase or tPA or streptokinase or reteplase or tenecteplase or anistreplase or urokinase) and (thrombolysis or myocardial infarction)</b>	621
NHS CRD HTA	1992–2001	<b>Alteplase or tPA or streptokinase or reteplase or tenecteplase or anistreplase or urokinase</b>	75
DARE	1982–2001	<b>Alteplase or tPA or streptokinase or reteplase or tenecteplase or anistreplase or urokinase</b>	50
		<b>Total references identified:</b>	<b>5792</b>



## Appendix 4

### Search strategy (MEDLINE 1980–2001)

- |    |  |    |  |
|----|--|----|--|
| 1  | randomized controlled trial.pt.  | 18 | animal.sh.   |
| 2  | randomized controlled trials.sh.   | 19 | human.sh.  |
| 3  | random allocation.sh.  | 20 | 18 not (18 and 19)   |
| 4  | double blind method.sh.  | 21 | 17 not 20  |
| 5  | single blind method.sh.  | 22 | alteplase.ti,ab.   |
| 6  | clinical trial.pt.   | 23 | tPA.ti,ab.   |
| 7  | clinical trials.sh.  | 24 | reteplase.ti,ab.   |
| 8  | controlled clinical trials.sh.   | 25 | streptokinase.ti,ab.   |
| 9  | (clin\$ adj25 trial\$).ti,ab.  | 26 | tenecteplase.ti,ab.  |
| 10 | ((singl\$ or doubl\$ or tripl\$) adj25<br>(blind\$ or mask\$)).ti,ab.                  | 27 | anistreplase.ti,ab.  |
| 11 | random\$.ti,ab.  | 28 | urokinase.ti,ab.   |
| 12 | research design.sh.  | 29 | 22 or 23 or 24 or 25 or 26 or 27 or 28                                     |
| 13 | exp evaluation studies/<br>follow up studies.sh.                                       | 30 | exp Myocardial Infarction/<br>(myocard\$ adj4 (infarct\$ or acute)).ti,ab. |
| 14 | pro prospective studies.sh.  | 31 | 30 or 31   |
| 15 | (control\$ or prospective\$ or volunteer\$).ti,ab.                                     | 32 | 21 and 29 and 32   |
| 16 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10<br>or 11 or 12 or 13 or 14 or 15 or 16 | 33 | limit 33 to yr=1980-2001   |
|    |  | 34 | limit 34 to english language   |
|    |  | 35 |  |





## Appendix 5

### Search strategy (EMBASE 1980–2001)

- |    |  |    |  |
|----|--|----|--|
| 1  | randomized controlled trial/                                   | 15 | alteplase.ti, ab.                      |
| 2  | randomization/   | 16 | tPA.ti, ab.                            |
| 3  | double blind procedure/  | 17 | reteplase.ti, ab.                      |
| 4  | single blind procedure/  | 18 | streptokinase.ti, ab.                  |
| 5  | Clinical trial/  | 19 | tenecteplase.ti, ab.                   |
| 6  | Controlled study/  | 20 | anistreplase.ti, ab.                   |
| 7  | random\$.ti, ab.   | 21 | urokinase.ti, ab.                      |
| 8  | Methodology/   | 22 | 15 or 16 or 17 or 18 or 19 or 20 or 21 |
| 9  | Evaluation/  | 23 | Heart infarction/                      |
| 10 | Follow up/   | 24 | "MYOCARDIAL INFARCTION". mp            |
| 11 | Prospective study/   | 25 | 23 or 24                               |
| 12 | (control\$ or prospective\$ or volunteer\$).ti, ab             | 26 | 14 and 22 and 25                       |
| 13 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10<br>or 11 or 12 | 27 | limit 26 to yr=1980-2001               |
| 14 | limit 13 to human  | 28 | limit 27 to english language           |



## Appendix 6

### Quality assessment checklist for clinical studies

Studies of clinical effectiveness will be assessed using the following criteria, based on CRD Report No. 4, University of York.<sup>41</sup>

- Was the method used to assign participants to the treatment groups really random? (Computer generated random numbers and random number tables will be accepted as adequate, whilst inadequate approaches will include the use of alternation, case record numbers, birth dates or days of the week.)
- Was the allocation of treatment concealed? (Concealment will be deemed adequate where randomisation is centralised or pharmacy-controlled, or where the following are used: serially numbered containers, on-site computer-based systems where assignment is unreadable until after allocation, other methods with robust methods to prevent foreknowledge of the allocation sequence to clinicians and patients. Inadequate approaches will include: the use of alternation, case record numbers, days of the week, open random number lists, and serially numbered envelopes even if opaque.)
- Was the number of participants who were randomised stated?
- Were details of baseline comparability presented in terms of treatment-free interval, disease bulk, number of previous regimens, age, histology and performance status?
- Was baseline comparability achieved for treatment-free interval, disease bulk, number of previous regimens, age, histology and performance status?
- Were the eligibility criteria for study entry specified?
- Were any co-interventions identified that may influence the outcomes for each group?
- Were the outcome assessors blinded to the treatment allocation?
- Were the individuals who were administered the intervention blinded to the treatment allocation?
- Were the participants who received the intervention blinded to the treatment allocation?
- Was the success of the blinding procedure assessed?
- Were at least 80% of the participants originally included in the randomisation process followed up in the final analysis?
- Were the reasons for any withdrawals stated?
- Was an intention-to-treat analysis included?

Items graded as:

- ✓ **yes** (item adequately addressed);
- ✗ **no** (item not adequately addressed),
- ✓/✗ **partially** (item partially addressed);
- unclear** or not enough information;
- na** (not applicable) or **ns** (not stated).



# Appendix 7

## Search for cost-effectiveness studies

**TABLE 36** Search for cost-effectiveness studies: summary

Database	Years	Search strategy	References identified
MEDLINE	1985–2001	(Alteplase or tPA or streptokinase or reteplase or tenecteplase and decision; alteplase or tPA or streptokinase or reteplase or tenecteplase) and cost	88 182
EMBASE	1988–2001	(Alteplase or tPA or streptokinase or reteplase or tenecteplase) and decision; (alteplase or tPA or streptokinase or reteplase or tenecteplase) and cost	126 257
Science Citation Index/ Web of Science	1984–2001	(Alteplase or tPA or streptokinase or reteplase or tenecteplase) and (decision or cost)	211
Cochrane Trials Register (Issue 3)	2001	Thrombolytic therapy and cost	48
NHS EED	1995–2001	Alteplase or tPA or streptokinase or reteplase or tenecteplase	41
NHS CRD HTA	1995–2001	Alteplase or tPA or streptokinase or reteplase or tenecteplase	73
DARE	1995–2001	Alteplase or tPA or streptokinase or reteplase or tenecteplase	47
		Total references identified	1073
		Duplicates	275
		<b>New total</b>	<b>798</b>
<b>Search stages</b>			
		Papers identified via cost-effectiveness search	98
		Papers identified via clinical effectiveness search	5
		Papers identified after handsearching of references	4
		Total number assessed using inclusion/exclusion criteria	107
		Total number included in review	8



## Appendix 8

### Quality assessment checklist for cost-effectiveness studies

- well-defined question
  - comprehensive description of competing alternatives
  - effectiveness established
  - all important and relevant costs and consequences for each alternative identified
  - costs and consequences measured accurately
  - costs and consequences valued credibly
  - costs and consequences adjusted for differential timing
  - incremental analysis costs and consequences
- sensitivity analyses to allow for uncertainty in estimates of costs or consequences
  - study results/discussion include all issues of concern to users.

The scores used for each dimension were as follows:

- ✓ dimension appropriately addressed;
- ✓/✗ dimension partially/maybe addressed;
- na, dimension not applicable.





## Appendix 9

### Current contraindications to thrombolysis

Current contraindications as listed in recommendations from the European Society of Cardiology for treatment<sup>3</sup> are related to risk of bleeding and are divided into absolute and relative:

#### **Absolute contraindications**

- gastrointestinal bleeding in the previous month
- history of cerebrovascular disease especially recent events or with any residual disability
- bleeding disorder or on anticoagulant therapy
- major surgery, trauma or head injury in previous 3 weeks
- prolonged cardiopulmonary resuscitation (> 30 minutes)

- hypertension (> 180 mmHg systolic)
- aortic dissection
- acute pancreatitis
- lung cavitations
- in the case of streptokinase, previous allergic reactions to either streptokinase or anistreplase or administration of either drug in the previous 2 years.

#### **Relative contraindications**

- major hepatic or renal disease
- non-compressible puncture site
- known terminal illness
- recent retinal laser treatment.



## Appendix 10

### Derivation of 'preferred method' efficacy parameters

#### Mortality at 30 days

Results from three trials for 30-day mortality are combined, using alteplase arms as the common referent. A standard mortality rate for alteplase is calculated from GUSTO I<sup>18</sup> and GUSTO III,<sup>19</sup> and then this is used, together with ASSENT-2<sup>20</sup> to estimate equivalent mortality rates for streptokinase, reteplase and tenecteplase. This method preserves the relativities of action within each individual trial while establishing an overall consistent ranking. The calculations are summarised in *Table 37*, with the final parameter values highlighted in bold type.

To assess the robustness of this formulation, the calculations were repeated with the influence of GUSTO I<sup>18</sup> results weighted at only 50% the weight accorded to GUSTO III.<sup>19</sup> Only very small changes in pairwise differences were found (no more than 0.007%), insufficient to have

any serious effect on relative rankings on the agents. A similar recalculation was carried out including the ASSENT-2<sup>20</sup> alteplase figures in the combined rate: although this changed the absolute risks estimated, pairwise differences changed by only a maximum of 0.014% – again insufficient to have any real impact on efficacy rankings.

#### Incidence of any stroke

The same method was used to calculate a set of mutually consistent stroke rates from the same three trials. The results are shown in *Table 38*.

Reducing the influence of GUSTO I<sup>18</sup> led to pairwise changes no greater than 0.008%, and including ASSENT-2<sup>20</sup> in the alteplase combined rate led to changes of no more than 0.006%, so that the stroke estimates are also robust to various assumptions.

**TABLE 37** Calculated values of mortality rates

Trial	GUSTO I <sup>18</sup>	GUSTO III <sup>19</sup>	ASSENT-2 <sup>20</sup>
	<b>Alteplase</b>	<b>Alteplase</b>	<b>Alteplase</b>
Reported mortality rates (%)	6.303	7.234	6.150
<b>Combined rate (%)</b>	<b>6.603</b>		–
Adjustment factors	x 1.048	x 0.913	x 1.074
	<b>Streptokinase</b>	<b>Reteplase</b>	<b>Tenecteplase</b>
Reported mortality rate (%)	7.302	7.467	6.181
<b>Adjusted rate (%)</b>	<b>7.650</b>	<b>6.816</b>	<b>6.637</b>

**TABLE 38** Calculated values of stroke rates

Trial	GUSTO I <sup>18</sup>	GUSTO III <sup>19</sup>	ASSENT-2 <sup>20</sup>
	<b>Alteplase</b>	<b>Alteplase</b>	<b>Alteplase</b>
Reported stroke rates (%)	1.549	1.788	1.661
<b>Combined rate (%)</b>	<b>1.626</b>		–
Adjustment factors	x 1.050	x 0.909	x 0.979
	<b>Streptokinase</b>	<b>Reteplase</b>	<b>Tenecteplase</b>
Reported stroke rate (%)	1.308	1.637	1.785
<b>Adjusted rate (%)</b>	<b>1.374</b>	<b>1.489</b>	<b>1.747</b>

## Reinfarction

The same method was used to calculate a set of mutually consistent reinfarction rates from the same three trials. The results are shown in *Table 39*.

Reducing the influence of GUSTO I<sup>18</sup> led to pairwise changes no greater than 0.004%, and including ASSENT-2<sup>20</sup> in the alteplase combined rate led to changes of no more than 0.010%, so that the reinfarction estimates are also robust to various assumptions.

## Congestive heart failure

The same method was used to calculate a set of mutually consistent CHF rates from the same three trials. The results are shown in *Table 40*.

Reducing the influence of GUSTO I<sup>18</sup> led to pairwise changes no greater than 0.076%. A large difference in absolute rates of CHF reported in both arms of ASSENT-2<sup>20</sup> compared to the GUSTO trials<sup>18,19</sup> points to very different criteria being employed. Thus when ASSENT-2<sup>20</sup> data for alteplase are included in the combined rate calculation, larger absolute and relative changes become evident than for the other adverse events and outcomes. The largest changes in pairwise rate differences are for those involving

streptokinase (up to 0.55%), but notwithstanding the reduced confidence in individual estimates, the relative rankings of agents are unchanged and pairwise differences not involving streptokinase change by a maximum of 0.277%.

## Major bleeding events

It is evident from the diversity of published outcomes on bleeding events that there is no recognised and consistent definition of what constitutes a 'major bleed' event. Published rates vary between 0% (White and co-workers, New Zealand<sup>59</sup> for alteplase) and nearly 20% (Central Illinois<sup>43</sup> for streptokinase). Clearly in many studies, episodes, which would elsewhere be classed as 'moderate', were recorded as 'severe' or 'life-threatening'

Using a similar methodology to those shown above, targeted on patients requiring transfusion, yields estimates of 12.25% for streptokinase, 9.90% for alteplase, 7.82% for reteplase and 7.77% for tenecteplase, based on GUSTO I,<sup>18</sup> GUSTO III<sup>19</sup> and ASSENT-2.<sup>20</sup>

However, clinical expert opinion argued that these incidence rates were not consistent with the notion of 'major bleed'. An alternative

**TABLE 39** Calculated values of reinfarction rates

Trial	GUSTO I <sup>18</sup>	GUSTO III <sup>19</sup>	ASSENT-2 <sup>20</sup>
	<b>Alteplase</b>	<b>Alteplase</b>	<b>Alteplase</b>
Reported reinfarction rates (%)	3.996	4.206	3.805
<b>Combined rate (%)</b>	<b>4.069</b>		–
Adjustment factors	× 1.018	× 0.967	× 1.069
	<b>Streptokinase</b>	<b>Reteplase</b>	<b>Tenecteplase</b>
Reported reinfarction rate (%)	3.709	4.202	4.101
<b>Adjusted rate (%)</b>	<b>3.777</b>	<b>4.065</b>	<b>4.385</b>

**TABLE 40** Calculated values of CHF rates

Trial	GUSTO I <sup>18</sup>	GUSTO III <sup>19</sup>	ASSENT-2 <sup>20</sup>
	<b>Alteplase</b>	<b>Alteplase</b>	<b>Alteplase</b>
Reported CHF rates (%)	15.203	17.496	6.998
<b>Combined rate (%)</b>	<b>16.000</b>		–
Adjustment factors	× 1.052	× 0.914	× 2.286
	<b>Streptokinase</b>	<b>Reteplase</b>	<b>Tenecteplase</b>
Reported CHF rate (%)	17.102	17.203	6.099
<b>Adjusted rate (%)</b>	<b>17.999</b>	<b>15.732</b>	<b>13.944</b>

more restrictive definition is possible, limiting attention only to the small number of episodes classed as 'severe' or 'life-threatening': this uses a weighted average of seven trials comparing alteplase with streptokinase (Central Illinois,<sup>43</sup> The European Cooperative Study Group (ECSG),<sup>45</sup> GISSI-2/ISG,<sup>46,47</sup> ISIS-3,<sup>48</sup> White and co-workers (New Zealand),<sup>59</sup> Cherng and co-workers

(Taiwan)<sup>44</sup> and TIMI 1<sup>51</sup>) to provide severe bleeding referent event rates of 0.90% for alteplase and 1.11% for streptokinase. Then results from GUSTO-III<sup>19</sup> can be rescaled to the referent rate for alteplase to yield an estimate for reteplase (0.705%), with a similar rescaling of ASSENT-2<sup>20</sup> results to obtain a revised rate for tenecteplase (0.710%).





# Appendix 11

## Supplementary references

### Clinical: included studies

Study	Reference(s)
<b>Alteplase/streptokinase</b> Central Illinois	Taylor GJ, Moses HW, Koester D, Colliver JA, Katholi RE, Dove JT, <i>et al.</i> A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study). <i>American Journal of Cardiology</i> 1993; <b>72</b> :1010–14.
Cherng <i>et al.</i>	Cherng WJ, Chiang CW, Kuo CT, Lee CP, Lee YS. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction. <i>American Heart Journal</i> 1992; <b>123</b> :841–6.
ECSCG	Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, <i>et al.</i> Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. <i>Lancet</i> 1985; <b>1</b> :842–7.
GISSI-2/ISG	<p>* Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, <i>et al.</i> GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. <i>Lancet</i> 1990;<b>336</b>:65–71.</p> <p>* Van de Werf F, Wilcox RG, Barbash GI, Diaz R, Franzosi MG, Hampton JR, <i>et al.</i> In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. <i>Lancet</i> 1990;<b>336</b>:71–5.</p> <p>Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, <i>et al.</i> Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. <i>European Heart Journal</i> 1992;<b>13</b>:1692–7.</p> <p>Fresco C, Franzosi MG, Maggioni AP, Tognoni G. The GISSI-2 trial: premises, results, epidemiological (and other) implications. <i>Clinical Cardiology</i> 1990;<b>13</b> Suppl 8:32–6.</p> <p>Glasziou PP, Bromwich S, Simes RJ. Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TAstreptokinase Group. Australian arm of International tPA/streptokinase Mortality Trial. <i>Medical Journal of Australia</i> 1994;<b>161</b>:532–6.</p> <p>Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G, <i>et al.</i> The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. <i>New England Journal of Medicine</i> 1992;<b>327</b>:1–6.</p> <p>Volpi A, De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, <i>et al.</i> Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The <i>ad hoc</i> Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base. <i>Circulation</i> 1993;<b>88</b>:416–29.</p> <p>White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, <i>et al.</i> After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. <i>Circulation</i> 1993;<b>88</b>:2097–103.</p>

continued

Clinical: included studies *contd*

Study	Reference(s)
<b>Alteplase/streptokinase contd</b> GUSTO I (accelerated alteplase)	<p>* An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. <i>New England Journal of Medicine</i> 1993;<b>329</b>:673–82.</p> <p>The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO angiographic investigators. <i>New England Journal of Medicine</i> 1993;<b>329</b>:1615–22.</p> <p>Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, et al. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. <i>Annals of Internal Medicine</i> 1996;<b>125</b>:891–900.</p> <p>Brieger DB, Mak KH, White HD, Kleiman NS, Miller DP, Vahanian A, et al. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO I trial). <i>American Journal of Cardiology</i> 1998;<b>81</b>:282–7.</p> <p>Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, et al. One-year results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO I) trial. <i>Circulation</i> 1996;<b>94</b>:1233–8.</p> <p>Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO I trial. Global Use of Strategies to Open Occluded Coronary Arteries. <i>Circulation</i> 1995;<b>92</b>:2811–18.</p> <p>Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO I trial experience. The GUSTO I investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> 1995;<b>26</b>:668–74.</p> <p>Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Circulation</i> 1994;<b>90</b>:2658–65.</p> <p>Reiner JS, Lundergan CF, Fung A, Coyne K, Cho S, Israel N, et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO I angiographic investigators. <i>Circulation</i> 1996;<b>94</b>:2441–6.</p> <p>Tsang TS, Califf RM, Stebbins AL, Lee KL, Cho S, Ross AM, et al. Incidence and impact on outcome of streptokinase allergy in the GUSTO I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. <i>American Journal of Cardiology</i> 1997;<b>79</b>:1232–5.</p> <p>Van de Werf F. Mortality results in GUSTO. <i>Australian and New Zealand Journal of Medicine</i> 1993;<b>23</b>:732–4; discussion: 735–6.</p> <p>White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy: Results from the GUSTO I trial. <i>Circulation</i> 1996;<b>94</b>:1826–33.</p> <p>Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. <i>Journal of the American Medical Association</i> 1996;<b>275</b>:777–82.</p>
ISIS-3	<p>Hunt D, Varigos J, Dienstl F, Lechleitner P, Mauel C, Dienstl A, et al. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. <i>Lancet</i> 1992;<b>339</b>:753–70.</p>
<i>continued</i>	



## Clinical: included studies contd

Study	Reference(s)
<b>Alteplase/streptokinase contd</b> KAMIT	Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, et al. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. <i>Circulation</i> 1991; <b>84</b> :540–9.
White et al.	* White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. <i>New England Journal of Medicine</i> 1989; <b>320</b> :817–21. Cross DB, Ashton NG, Norris RM, White HD. Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk. <i>Journal of the American College of Cardiology</i> 1991; <b>17</b> :1039–46.
PAIMS	Magnani B. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> 1989; <b>13</b> :19–26.
TIMI 1	* Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. <i>Circulation</i> 1987; <b>76</b> :142–54. Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. <i>American Journal of Cardiology</i> 1988; <b>62</b> :179–85. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial – phase I: hemorrhage manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. <i>Journal of the American College of Cardiology</i> 1988; <b>11</b> :1–11. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. <i>Circulation</i> 1987; <b>75</b> :817–29. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. <i>New England Journal of Medicine</i> 1985; <b>312</b> :932–6.
<b>Alteplase/tenecteplase</b>	* Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. <i>Lancet</i> 1999; <b>354</b> :716–22.
ASSENT-2 (accelerated alteplase)	Sinnaeve P, Granger C, Barbash G, Armstrong P, Ardissino D, Wallentin L, et al. Single-bolus tenecteplase and front-loaded alteplase remain equivalent after one year: follow-up results of the ASSENT-2 trial. <i>European Heart Journal</i> 2000; <b>21</b> Suppl:481.
<i>continued</i>	

Clinical: included studies *contd*

Study	Reference(s)
<b>Alteplase/reteplase</b>	
	* Topol EJ, Califf R, Ohman E, Skene A, Wilcox R, Grinfeld L, et al. A comparison of reteplase with alteplase for acute myocardial infarction. <i>New England Journal of Medicine</i> 1997; <b>337</b> :1118–23.
GUSTO III (accelerated alteplase)	Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, et al. Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. <i>Circulation</i> 2001; <b>104</b> :1229–35. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial. <i>Circulation</i> 2000; <b>102</b> :1761–5.
RAPID-2 (accelerated alteplase)	* Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. <i>Circulation</i> 1996; <b>94</b> :891–8. Lopez LM. Clinical trials in thrombolytic therapy, part 2: the open-artery hypothesis and RAPID 1 and RAPID 2. <i>American Journal of Health-System Pharmacy</i> 1997; <b>54</b> Suppl 1:S27–30. Weaver WD. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. <i>European Heart Journal</i> 1996; <b>17</b> Suppl E: 14–20.
<b>Streptokinase/reteplase</b> INJECT	* Hampton JR, Schroder R, Wilcox RG, Skene AM, Meyer-Sabellek W, Heikkila J, et al. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. <i>Lancet</i> 1995; <b>346</b> :329–36. Hampton JR. Mega-trials and equivalence trials: experience from the INJECT study. <i>European Heart Journal</i> 1996; <b>17</b> Suppl E:28–34.
<b>Dose-ranging/various regimes</b>	
COBALT (accelerated alteplase versus bolus)	Van de Werf F, Adgey A, Agnelli G, Aylward P, Biabrek A, Col J, et al. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. <i>New England Journal of Medicine</i> 1997; <b>337</b> :1124–30.
Xu et al. (accelerated streptokinase)	Xu C, Lu M, Ding W, Zhang J, Shao G, Cui L, et al. A comparative study of intravenous accelerated streptokinase dose regimen with conventional dose regimen for coronary thrombolysis. <i>Chinese Medical Sciences Journal</i> 1996; <b>11</b> :236–8.
Six et al.	Six AJ, Louwerenburg HW, Braams R, Mechelse K, Mosterd WL, Bredero AC, et al. A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. <i>American Journal of Cardiology</i> 1990; <b>65</b> :119–23.
ASSENT-1	Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of tenecteplase tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. <i>American Heart Journal</i> 1999; <b>137</b> :786–91.
TIMI 10B (accelerated alteplase)	Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. tenecteplase-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. <i>Circulation</i> 1998; <b>98</b> :2805–14.
RAPID-1	Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. <i>Circulation</i> 1995; <b>91</b> :2725–32.
* Primary reports	

## Clinical: excluded references – drugs no longer available

Study	Reference(s)
Anistreplase (APSAC)	<p>Anderson JL, Becker LC, Sorensen SG, Karagounis LA, Browne KF, Shah PK, et al. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 investigators. <i>Journal of the American College of Cardiology</i> 1992;<b>20</b>:753–66.</p> <p>Anderson JL, Sorensen SG, Moreno FL, Hackworthy RA, Browne KF, Dale HT, et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. <i>Circulation</i> 1991;<b>83</b>:126–40.</p> <p>Bassand JP, Cassagnes J, Machecourt J, Lusson JR, Anguenot T, Wolf JE, et al. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study. <i>Circulation</i> 1991;<b>84</b>:1107–17.</p> <p>Brochier ML, Quilliet L, Kulbertus H, et al. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study. <i>Drugs</i> 1987;<b>33</b> Suppl 3:140–5.</p> <p>Cannon CP, McCabe CH, Diver DJ, Herson S, Greene MRPK, Sequeira RF, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. <i>Journal of the American College of Cardiology</i> 1994;<b>24</b>:1602–10.</p> <p>Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. <i>Journal of the American College of Cardiology</i> 1995;<b>25</b>:582–9.</p> <p>Karagounis L, Moreno F, Menlove RL, Ipsen S, Anderson JL. Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. <i>American Journal of Cardiology</i> 1991;<b>68</b>:848–56.</p> <p>Karagounis LA, Anderson JL, Sorensen SG, Moreno FL. Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. <i>American Journal of Cardiology</i> 1994;<b>73</b>:16–22.</p> <p>Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). <i>Journal of the American College of Cardiology</i> 1992;<b>19</b>:885–91.</p> <p>Pacouret G, Charbonnier B, Curien ND, Monassier JP, Cribier A, Materne P, et al. Invasive reperfusion study. II. Multicentre European randomized trial of anistreplase vs. streptokinase in acute myocardial infarction. <i>European Heart Journal</i> 1991;<b>12</b>:179–85.</p> <p>Shen W, Zhang R, Zhang J, Zhang D, Zhang X, Zheng A. A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction. <i>Chinese Medical Journal</i> 1999;<b>112</b>:18–21.</p> <p>Silber H, Hausmann MJ, Katz A, Gilutz H, Zucker N, Ovsyshcher I. Short- and long-term comparative study of anistreplase versus streptokinase in acute myocardial infarction. <i>Angiology</i> 1992;<b>43</b>:572–6.</p> <p>Trent R, Adams J, Rawles J. Electrocardiographic evidence of reperfusion occurring before hospital admission – a Grampian Region Early Anistreplase Trial (GREAT) sub-study. <i>European Heart Journal</i> 1994;<b>15</b>:895–7.</p> <p>Vogt P, Monnier P, Schaller MD, Goy JJ, Beuret P, Essinger A, et al. Comparison of results of intravenous-infusion of anistreplase versus streptokinase in acute myocardial-infarction. <i>American Journal of Cardiology</i> 1993;<b>71</b>:274–80.</p>
	<i>continued</i>

**Clinical: excluded references – drugs no longer available contd**

Study	Reference(s)
Urokinase	<p>Hu D, Xu Z. Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy. <i>Chinese Medical Journal</i> 1997;<b>110</b>:839–42.</p> <p>Kanemoto N, Goto Y, Hirose K, Kawai C, Kimata S, Yui Y, et al. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction – a multicenter double-blind, randomized trial in Japan. <i>Japanese Circulation Journal</i> 1991;<b>55</b>:250–61.</p> <p>Meyer J, Bar F, Barth H, Charbonnier B, El Deeb MF, Erbel R, et al. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. <i>Lancet</i> 1989;<b>1</b>:863–8.</p> <p>Neuhaus KL, Tebbe U, Gottwik M, Weber MA, Feuerer W, Niederer W, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). <i>Journal of the American College of Cardiology</i> 1988;<b>12</b>:581–7.</p> <p>Park SJ. Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. <i>American Journal of Cardiology</i> 1998;<b>82</b>:811–13.</p> <p>Ross AM, Gao R, Coyne KS, Chen J, Yao K, Yang Y, et al. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. <i>American Heart Journal</i> 2001;<b>142</b>:244–7.</p>
Saruplase	<p>Bar FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, et al. Comparison of saruplase and alteplase in acute myocardial infarction. <i>American Journal of Cardiology</i> 1997;<b>79</b>:727–32.</p>
* Primary reports	

## Clinical: pre-hospital references

Study	Reference(s)
Anistreplase (APSAC)	<p>BEPS Collaborative Group. Prehospital thrombolysis in acute myocardial infarction: the Belgian eminase prehospital study (BEPS). <i>European Heart Journal</i> 1991;<b>12</b>:965–7.</p> <p>Boissel JP. The European Myocardial Infarction Project: an assessment of pre-hospital thrombolysis. <i>International Journal of Cardiology</i> 1995;<b>49</b> Suppl:S29–37.</p> <p>Castaigne AD, Herve C, Duval-Moulin AM, Gaillard M, Dubois-Rande JL, Boesch C, et al. Prehospital use of APSAC: results of a placebo-controlled study. <i>American Journal of Cardiology</i> 1989;<b>64</b>:30–33A; discussion: 41–42A.</p> <p>Coccolini S, Berti G, Bosi S, Pretolani M, Tumiotto G. Prehospital thrombolysis in rural emergency room and subsequent transport to a CCU: Ravenna myocardial infarction (RaMI) trial. <i>International Journal of Cardiology</i> 1995;<b>49</b> Suppl:S47–58.</p> <p>* European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. <i>New England Journal of Medicine</i> 1993;<b>329</b>:383–9.</p> <p>* GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. <i>British Medical Journal</i> 1992;<b>305</b>:548–53.</p> <p>Leizorovicz A, Haugh MC, Mercier C, Boissel JP. Pre-hospital and hospital time delays in thrombolytic treatment in patients with suspected acute myocardial infarction. Analysis of data from the EMIP study. European Myocardial Infarction Project. <i>European Heart Journal</i> 1997;<b>18</b>:248–53.</p> <p>Linderer T, Schroder R, Arntz R, Heineking M, Wunderlich W, Kohl K, et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. <i>Journal of the American College of Cardiology</i> 1993;<b>22</b>:1304–10.</p> <p>Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). <i>Journal of the American College of Cardiology</i> 1994;<b>23</b>:1–5.</p> <p>Rawles J, Light J. Loss of quality adjusted days as a trial end-point: effect of early thrombolytic treatment in suspected myocardial infarction. Grampian Region Early Anistreplase Trial (GREAT). <i>Journal of Epidemiology and Community Health</i> 1993;<b>47</b>:377–81.</p> <p>Rawles JM. Recovery of left ventricular function after acute myocardial infarction: Efficacy of domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial. <i>Coronary Artery Disease</i> 1993;<b>4</b>:801–8.</p> <p>Rawles J. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT). <i>British Medical Journal</i> 1996;<b>312</b>:212–15.</p> <p>Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). <i>Journal of the American College of Cardiology</i> 1997;<b>30</b>:1181–6.</p> <p>Rawles JM, Hennekens C. Myocardial salvage with early anistreplase treatment. <i>Clinical Cardiology</i> 1997;<b>11</b> Suppl 3:II 6–10.</p> <p>Roth A, Barbash G, Hod H, Miller H, Rath S, Modan M, et al. Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. <i>American Journal of Cardiology</i> 1990;<b>15</b>:932–6.</p>
	<i>continued</i>

## Clinical: pre-hospital references contd

Study	Reference(s)
Alteplase	<p>Barbash GI, Roth A, Hod H, Miller HI, Modan M, Rath S, et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> 1990;<b>66</b>:261–6.</p> <p>Brouwer MA, Martin JS, Maynard C, Wirkus M, Litwin PE, Verheugt FW, et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). MITI Project Investigators. <i>American Journal of Cardiology</i> 1996;<b>78</b>:497–502.</p> <p>Bouten M, Simoons M, Hartman J, van Miltenburg A, van der Does E, Pool J. Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. <i>European Heart Journal</i> 1992;<b>13</b>:925–31.</p> <p>Gibler WB, Kereiakes DJ, Dean EN, Martin L, Anderson L, Abbottsmith CW, et al. Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial. <i>American Heart Journal</i> 1991;<b>121</b>:1–11.</p> <p>Kudenchuk PJ, Maynard C, Cobb LA, Wirkus M, Martin JS, Kennedy JW, et al. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) Project. <i>Journal of the American College of Cardiology</i> 1998;<b>32</b>:17–27.</p> <p>McNeill A, Cunningham S, Flannery D, Dalzell G, Wilson C, Campbell N, et al. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. <i>British Heart Journal</i> 1989;<b>61</b>:316–21.</p> <p>Risenfors M, Gustavsson G, Ekstrom L, Hartford M, Herlitz J, Karlson B, et al. Prehospital thrombolysis in suspected acute myocardial infarction: results from the TEAHAT study. <i>Journal of Internal Medicine</i> 1991;<b>229</b>:3–10.</p> <p>Spangler DE Jr, Rogers WJ, Gore JM, Griffith M, Maske LE, Morgan TE, et al. Early tPA treatment and aeromedical transport of patients with acute myocardial infarction. <i>Journal of Interventional Cardiology</i> 1991;<b>4</b>:81–9.</p> <p>* Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, et al. Prehospital-initiated vs. hospital-initiated thrombolytic therapy: the myocardial infarction triage and intervention trial. <i>Journal of the American Medical Association</i> 1993;<b>270</b>:1211–16.</p>
Alteplase/streptokinase	<p>Grijseels EW, Bouten MJ, Lenderink T, Deckers JW, Hoes AW, Hartman JA, et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients. <i>European Heart Journal</i> 1995;<b>16</b>:1833–8.</p> <p>Lamfers E, Hooghoudt T, Uppelschoeten A, Boersma E, Simoons ML, Verheugt F. Prehospital thrombolysis for acute myocardial infarction with reteplase: the Nijmegen/Rotterdam experience. <i>European Heart Journal</i> 2001;<b>22</b> Suppl [abstract]:25.</p>
Streptokinase	<p>McAleer B, Ruane B, Burke E, Cathcart M, Costello A, Dalton G, et al. Prehospital thrombolysis in a rural community: short- and long-term survival. <i>Cardiovascular Drugs and Therapy</i> 1992;<b>6</b>:369–72.</p> <p>Rozenman Y, Gotsman M, Weiss A, Lotan C, Mosseri M, Sapoznikov D, et al. Early intravenous thrombolysis in acute myocardial infarction: the Jerusalem experience. <i>International Journal of Cardiology</i> 1995;<b>49</b> Suppl:S21–8.</p>
Reteplase	<p>Lamfers E, Hooghoudt T, Uppelschoeten A, Boersma E, Simoons ML, Verheugt F. Prehospital thrombolysis for acute myocardial infarction with reteplase: the Nijmegen/Rotterdam experience. <i>European Heart Journal</i> 2001;<b>22</b> Suppl [abstract]:25.</p> <p>Morrow D, Antman E, Syah A, Schuhwerk K, Bhargava R, Rosenberg D, et al. Pre-hospital administration of reteplase for ST segment elevation MI: preliminary results of ER-TIMI 19 trial. <i>European Heart Journal</i> 2001;<b>22</b> Suppl [abstract]:25.</p>

continued

**Clinical: pre-hospital references contd**

Study	Reference(s)
Urokinase	Mathey D, Buttner J, Geng G, Gutschmidt HJ, Herden HN, Moecke H, <i>et al.</i> Pre-hospital thrombolysis treatment of acute myocardial infarction: a randomized double-blind study. <i>Deutsche Medizinische Wochenschrift</i> 1990; <b>115</b> :803–808 [abstract]. Schofer J, Butternner J, Geng G, Gutschmidt K, Herden H, Mathey D, <i>et al.</i> Prehospital thrombolysis in acute myocardial infarction. <i>American Journal of Cardiology</i> 1990; <b>66</b> :1429–33.
* Primary reports	

## Clinical: references excluded from the review (hospital)

Reference	Reason for exclusion
Amsterdam EA. Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. <i>Pharmacotherapy</i> 1996; <b>16</b> :137–40S.	Review
Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. <i>Circulation</i> 1993; <b>87</b> :1829–39.	Outcomes
Anderson RD, Ohman EM, Holmes DR Jr, Col I, Stebbins AL, Bates ER, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> 1997; <b>30</b> :708–15.	Outcomes
Aylward P. The GUSTO trial: background and baseline characteristics. <i>Australian and New Zealand Journal of Medicine</i> 1993; <b>23</b> :728–31; discussion: 735–6.	Overview
Baardman T, Hermens Th W, Lenderink T, Molhoek GP, Grollier G, Pfisterer M, et al. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: Influence of early infarct related artery patency. The GUSTO enzyme substudy. <i>European Heart Journal</i> 1996; <b>17</b> :237–46.	Subgroup analysis
Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, et al. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. <i>Journal of the American College of Cardiology</i> 1997; <b>29</b> :770–7.	Outcomes
Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, et al. Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO I trial). <i>American Journal of Cardiology</i> 2000; <b>86</b> :24–9.	Outcomes
Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: An analysis of outcome and treatment choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT-2) studies. <i>Circulation</i> 2001; <b>103</b> :954–60.	Outcomes
Barbash GI, Modan M, Goldbourt U, White H, Van de Werf F. Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. <i>Journal of the American College of Cardiology</i> 1993; <b>21</b> :281–6.	Outcomes
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, et al. Acute myocardial infarction in the young – the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. <i>European Heart Journal</i> 1995; <b>16</b> :313–16.	Subgroup analysis
Barron H, Fox N, Berioloi S, Li X, Van de Werf F. A comparison of intracranial haemorrhage rates in patients treated with rtPA and tPA-tenecteplase: impact of gender, age and low body weight. <i>Circulation</i> 1999; <b>100</b> Suppl 1:1.	Subgroup analysis
Bassand JP. GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. <i>European Heart Journal</i> 1994; <b>15</b> :2–4.	Editorial
Berkowitz S, Granger C, Pieper K, Lee K, Gore J, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. <i>Circulation</i> 1997; <b>95</b> :2508–16.	Outcomes
Betriu A, Califf RM, Bosch X, Guerci A, Stebbins AL, Barbagelata NA, et al. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> 1998; <b>31</b> :94–102.	Outcomes
Califf RM, Pieper KS, Lee KL, Van de Werf F, Simes RJ, Armstrong PW, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. <i>Circulation</i> 2000; <b>101</b> :2231–8.	Outcomes

continued



**Clinical: references excluded from the review (hospital) contd**

Reference	Reason for exclusion
Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al. Tenecteplase-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. <i>Circulation</i> 1997; <b>95</b> :351–6.	Non-RCT
Chang WC, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, et al. Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from Canada and the United States. <i>Canadian Journal of Cardiology</i> 2000; <b>16</b> :1231–9.	Outcomes
Cohen MG, Granger CB, Ohman EM, Stebbins AL, Grinfeld LR, Cagide AM, et al. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> 1999; <b>34</b> :1729–37.	Subgroup analysis
Collins R, Peto R, Parish S, Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. <i>American Journal of Cardiology</i> 1993; <b>71</b> :1127–30.	Editorial
Cox JL, Lee E, Langer A, Armstrong PW, Naylor CD. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>Canadian Medical Association Journal</i> 1997; <b>156</b> :497–505.	Subgroup analysis
Dellborg M, Svensson AM, Johansson M, Swedberg K. Early electrocardiographic changes in acute myocardial infarction treated by streptokinase or alteplase: a randomized study with dynamic, multi-lead, electrocardiographic monitoring. <i>Cardiology</i> 1993; <b>82</b> :368–76.	Outcomes
Friedman HS. Streptokinase versus alteplase in acute myocardial infarction. <i>Journal of the Royal Society of Medicine</i> 1996; <b>89</b> :427–30.	Discussion
Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO I trial with clinical correlation. <i>Stroke</i> 1998; <b>29</b> :563–9.	Subgroup analysis
Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EB, et al. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. <i>Circulation</i> 1998; <b>97</b> :444–50.	Outcomes
Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO I trial. <i>Journal of the American College of Cardiology</i> 1998; <b>31</b> :497–505.	Outcomes
Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO I trial. <i>Circulation</i> 1996; <b>93</b> :870–8.	Outcomes
Grines CL, Nissen SE, Booth DC, Branco MC, Gurley JC, Bennett KA, et al. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. <i>Journal of the American College of Cardiology</i> 1989; <b>14</b> :573–80.	Non-RCT
Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. <i>Journal of the American College of Cardiology</i> 1998; <b>31</b> :1466–73.	Outcomes
Hasdai D, Holmes DR Jr, Topol EJ, Berger PB, Criger DA, Hochman JS, et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO III. Global Use of Strategies to Open Occluded Coronary Arteries. <i>European Heart Journal</i> 1999; <b>20</b> :128–35.	Subgroup analysis
Held PH, Teo KK, Yusuf S. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex in mortality in acute myocardial infarction. <i>Circulation</i> 1990; <b>82</b> :1668–74.	Overview

continued

## Clinical: references excluded from the review (hospital) contd

Reference	Reason for exclusion
Hochrein J, Sun F, Pieper KS, Lee KL, Gates KB, Armstrong PW, et al. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO I substudy). <i>American Journal of Cardiology</i> 1998; <b>81</b> :1078–84.	Outcomes
Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM. Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) trial. <i>Journal of the American College of Cardiology</i> 1995; <b>26</b> :1651–6.	Subgroup analysis
Krucoff MW, Green CL, Langer A, Klootwijk LJ, Trollinger KM, Sawchak ST, et al. Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. <i>Journal of Electrocardiology</i> 1993; <b>26</b> Suppl:249–55.	Subgroup analysis
Labinaz M, Sketch MH Jr., Stebbins AL, DeFranco AC, Holmes DR Jr., Kleiman NS, et al. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. <i>American Journal of Cardiology</i> 1996; <b>78</b> :1338–44.	Subgroup analysis
Langer A, Krucoff MW, Klootwijk P, Simoons ML, Granger CB, Barr A, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO I ST segment monitoring substudy. <i>Journal of the American College of Cardiology</i> 1998; <b>31</b> :783–9.	Outcomes
Langer A, Krucoff MW, Klootwijk P, Veldkamp R, Simoons ML, Granger C, et al. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. <i>Journal of the American College of Cardiology</i> 1995; <b>25</b> :1552–7.	Outcomes
Lehmann KG, Francis CK, Sheehan FH, Dodge HT. Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the thrombolysis in myocardial infarction (TIMI) trial. <i>Journal of the American College of Cardiology</i> 1993; <b>22</b> :714–19.	Outcomes
Lesnefsky EJ, Lundergan CF, Hodgson JM, Nair R, Reiner JS, Greenhouse SW, et al. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: The GUSTO I angiographic experience. <i>Journal of the American College of Cardiology</i> 1996; <b>28</b> :331–7.	Outcomes
Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> 1998; <b>32</b> :641–7.	Outcomes
Lundergan CF, Ross AM, McCarthy WF, Reiner JS, Boyle D, Fink C, et al. Predictors of left ventricular function after acute myocardial infarction: Effects of time to treatment, patency, and body mass index: The GUSTO I angiographic experience. <i>American Heart Journal</i> 2001; <b>142</b> :43–50.	Outcomes
Maggioni AP, Franzosi MG, Farina ML, Santoro E, Celani MG, Ricci S, et al. Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). <i>British Medical Journal</i> 1991; <b>302</b> :1428–31.	Placebo trial
Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO I trial. <i>Journal of the American College of Cardiology</i> 1997; <b>30</b> :1606–10.	Subgroup analysis
Mauri F, Maggioni AP, Franzosi MG, de Vita C, Santoro E, Santoro L, et al. A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-derived analysis. <i>Journal of the American College of Cardiology</i> 1994; <b>24</b> :600–7.	Outcomes
Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, et al. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of Womens Health</i> 1997; <b>6</b> :285–93.	Outcomes

continued

**Clinical: references excluded from the review (hospital) contd**

Reference	Reason for exclusion
Newby L, Rutsch WR, Califf R, Simoons M, Aylward P, Armstrong P, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. <i>Journal of the American College of Cardiology</i> 1996; <b>27</b> :1646–55.	Outcomes
Norris RM, White HD. Left ventricular function as an end-point of thrombolytic therapy. <i>European Heart Journal</i> 1990; <b>11</b> Suppl F:5–9.	Discussion
Rieves D, Wright G, Gupta G, Shacter E. Clinical trial (GUSTO I and INJECT) evidence of earlier death for men than women after acute myocardial infarction. <i>American Journal of Cardiology</i> 2000; <b>85</b> :147–53.	Subgroup analysis
Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO I angiographic investigators. Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. <i>Circulation</i> 1998; <b>97</b> :1549–56.	Outcomes
Schroder R, Wegscheider K, Schroder K, Dissmann R, Meyer-Sabellek W. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens a substudy of the international joint efficacy comparison of thrombolytics (INJECT) trial. <i>Journal of the American College of Cardiology</i> 1995; <b>26</b> :1657–64.	Outcomes
Smith BJ. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase. <i>Journal of Accident and Emergency Medicine</i> 1999; <b>16</b> :407–11.	Review
Stringer KA. TIMI grade flow, mortality, and the GUSTO III trial. <i>Pharmacotherapy</i> 1998; <b>18</b> :699–705.	Discussion
Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. <i>Lancet</i> 2001; <b>357</b> :1905–14.	Outcomes
Vaage-Nilsen M, Aurup P, Hoegholm A, Eidemark I, Rasmussen V, Jensen G. The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET study. <i>International Journal of Cardiology</i> 1993; <b>39</b> :187–93.	Placebo trial
Van de Werf F, Califf RM, Armstrong PW, Bates ER, Ross AM, Kleinman NS, et al. Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>European Heart Journal</i> 1995; <b>16</b> :1024–6.	Overview
Van de Werf FJ, Armstrong PW, Granger C, Wallentin L. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. <i>Lancet</i> 2001; <b>358</b> :605–13.	Outcomes
Wardlaw JM. Overview of Cochrane thrombolysis meta-analysis. <i>Neurology</i> 2001; <b>57</b> :S69–76.	Overview
White HD. Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction. <i>Chest</i> 1989; <b>95</b> :265–95.	Overview
Wilcox RG. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data. <i>American Journal of Cardiology</i> 1996; <b>78</b> :20–3.	Overview
Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP, Ewing DJ. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. <i>Circulation</i> 1996; <b>94</b> :432–6.	Outcomes
<i>Outcomes: reports involving outcomes, which were not considered in this review; subgroup analysis: analyses involving subset of main study population</i>	



# Health Technology Assessment Programme

## Prioritisation Strategy Group

### Members

<b>Chair,</b> <b>Professor Kent Woods,</b> Director, NHS HTA Programme, & Professor of Therapeutics University of Leicester	Professor Shah Ebrahim, Professor in Epidemiology of Ageing, University of Bristol	Dr Ron Zimmern, Director, Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge
Professor Bruce Campbell, Consultant Vascular & General Surgeon, Royal Devon & Exeter Hospital	Dr John Reynolds, Clinical Director, Acute General Medicine SDU, Oxford Radcliffe Hospital	

## HTA Commissioning Board

### Members

<b>Programme Director,</b> <b>Professor Kent Woods,</b> Director, NHS HTA Programme, & Professor of Therapeutics University of Leicester	Professor John Brazier, Director of Health Economics, University of Sheffield	Dr Alastair Gray, Director, Health Economics Research Centre, Institute of Health Sciences, University of Oxford	Dr Donna Lamping, Head, Health Services Research Unit, London School of Hygiene & Tropical Medicine
<b>Chair,</b> <b>Professor Shah Ebrahim,</b> Professor in Epidemiology of Ageing, University of Bristol	Dr Andrew Briggs, Research Fellow, Institute of Health Sciences, University of Oxford	Professor Mark Haggard, Director, MRC Institute of Hearing Research, University of Nottingham	Professor David Neal, Department of Surgery, University of Newcastle- upon-Tyne
<b>Deputy Chair,</b> <b>Professor Jon Nicholl,</b> Director, Medical Care Research Unit, University of Sheffield	Ms Christine Clark, Freelance Medical Writer, Bury, Lancs	Professor Jenny Hewison, Academic Unit of Psychiatry & Behavioural Sciences, University of Leeds	Professor Tim Peters, Social Medicine, University of Bristol
Professor Douglas Altman, Director, ICRF Medical Statistics Group, University of Oxford	Professor Martin Eccles, Professor of Clinical Effectiveness, University of Newcastle- upon-Tyne	Professor Peter Jones, University Department of Psychiatry, University of Cambridge	Professor Martin Severs, Professor in Elderly Health Care, University of Portsmouth
Professor John Bond, Director, Centre for Health Services Research, University of Newcastle-upon-Tyne	Dr Andrew Farmer, General Practitioner & NHS R&D Clinical Scientist, Institute of Health Sciences, University of Oxford	Professor Alison Kitson, Director, Royal College of Nursing Institute, London	Dr Jonathan Shapiro, Senior Fellow, Health Services Management Centre, Birmingham
	Professor Adrian Grant, Director, Health Services Research Unit, University of Aberdeen	Professor Sarah Lamb, Research Professor in Physiotherapy, University of Coventry	Dr Sarah Stewart-Brown, Director, Health Services Research Unit, University of Oxford
			Dr Gillian Vivian, Consultant in Nuclear Medicine & Radiology, Royal Cornwall Hospitals Trust, Truro

Current and past membership details of all HTA 'committees' are available from the HTA website (see inside front cover for details)

continued

## Diagnostic Technologies & Screening Panel

### Members

<p><b>Chair,</b> <b>Dr Ron Zimmern,</b> Director, Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge</p>	<p>Professor Howard Cuckle, Professor of Reproductive Epidemiology, University of Leeds</p> <p>Professor Adrian K Dixon, Professor of Radiology, Addenbrooke's Hospital, Cambridge</p>	<p>Dr Antony J Franks, Deputy Medical Director, The Leeds Teaching Hospitals NHS Trust</p> <p>Dr J A Muir Gray, Programmes Director, National Screening Committee, NHS Executive, Oxford</p> <p>Dr Peter Howlett, Executive Director – Planning, Portsmouth Hospitals NHS Trust</p> <p>Dr S M Ludgate, Medical Director, Medical Devices Agency, London</p> <p>Professor Jennie Popay, Professor of Sociology &amp; Public Health, Institute for Health Research, University of Lancaster</p>	<p>Dr Susan Schonfield, CPHM Specialist Commissioning, Public Health Directorate, Croydon Primary Care Trust</p> <p>Mrs Kathlyn Slack, Professional Support, Diagnostic Imaging &amp; Radiation Protection Team, Department of Health, London</p> <p>Mr Tony Tester, Chief Officer, South Bedfordshire Community Health Council, Luton</p> <p>Dr Andrew Walker, Senior Lecturer in Health Economics, University of Glasgow</p> <p>Professor Martin J Whittle, Head of Division of Reproductive &amp; Child Health, University of Birmingham</p>
<p>Mrs Stella Burnside, Chief Executive, Altnagelvin Hospitals Health &amp; Social Services Trust, Londonderry</p>	<p>Dr David Elliman, Consultant in Community Child Health, St. George's Hospital, London</p>		
<p>Dr Paul O Collinson, Consultant Chemical Pathologist &amp; Senior Lecturer, St George's Hospital, London</p>	<p>Dr Tom Fahey, Senior Lecturer in General Practice, University of Bristol</p> <p>Dr Andrew Farmer, General Practitioner &amp; NHS R&amp;D Clinical Scientist, Institute of Health Sciences, University of Oxford</p>		
<p>Dr Barry Cookson, Director, Laboratory of Hospital Infection, Public Health Laboratory Service, London</p>	<p>Professor Jane Franklyn, Professor of Medicine, University of Birmingham</p>		

## Pharmaceuticals Panel

### Members

<p><b>Chair,</b> <b>Dr John Reynolds,</b> Clinical Director, Acute General Medicine SDU, Oxford Radcliffe Hospital</p>	<p>Dr Christopher Cates, GP &amp; Cochrane Editor, Bushey Health Centre, Bushey, Herts</p> <p>Dr Karen A Fitzgerald, Pharmaceutical Adviser, Bro Taf Health Authority, Cardiff</p>	<p>Mrs Sharon Hart, Managing Editor, <i>Drug &amp; Therapeutics Bulletin</i>, London</p> <p>Dr Christine Hine, Consultant in Public Health Medicine, Bristol South &amp; West Primary Care Trust</p> <p>Mrs Jeannette Howe, Deputy Chief Pharmacist, Department of Health, London</p> <p>Professor Robert Peveler, Professor of Liaison Psychiatry, Royal South Hants Hospital, Southampton</p> <p>Dr Frances Rotblat, CPMP Delegate, Medicines Control Agency, London</p>	<p>Dr Eamonn Sheridan, Consultant in Clinical Genetics, St James's University Hospital, Leeds</p> <p>Mrs Katrina Simister, New Products Manager, National Prescribing Centre, Liverpool</p> <p>Professor Terence Stephenson, Professor of Child Health, University of Nottingham</p> <p>Dr Richard Tiner, Medical Director, Association of the British Pharmaceutical Industry, London</p> <p>Professor Jenifer Wilson- Barnett, Head of Florence Nightingale School of Nursing &amp; Midwifery, King's College, London</p>
<p>Professor Tony Avery, Professor of Primary Health Care, University of Nottingham</p>	<p>Dr Felicity J Gabbay, Managing Director, Transcrip Ltd, Milford-on-Sea, Hants</p>		
<p>Professor Iain T Cameron, Professor of Obstetrics &amp; Gynaecology, University of Southampton</p>	<p>Mr Peter Golightly, Director, Trent Medicines Information Services, Leicester Royal Infirmary</p> <p>Dr Alastair Gray, Director, Health Economics Research Centre, Institute of Health Sciences, University of Oxford</p>		
<p>Mr Peter Cardy, Chief Executive, Macmillan Cancer Relief, London</p>			

## Therapeutic Procedures Panel

### Members

<b>Chair,</b> <b>Professor Bruce Campbell,</b> Consultant Vascular & General Surgeon, Royal Devon & Exeter Hospital	Dr Carl E Counsell, Senior Lecturer in Neurology, University of Aberdeen	Dr Duncan Keeley, General Practitioner, Thame, Oxon	Dr John C Pounsford, Consultant Physician, Frenchay Healthcare Trust, Bristol
Professor John Bond, Professor of Health Services Research, Centre for Health Services Research, University of Newcastle- upon-Tyne	Dr Keith Dodd, Consultant Paediatrician, Derbyshire Children's Hospital, Derby	Dr Phillip Leech, Principal Medical Officer for Primary Care, Department of Health, London	Professor Mark Sculpher, Professor of Health Economics, Institute for Research in the Social Services, University of York
Ms Judith Brodie, Head of Cancer Support Service, Cancer BACUP, London	Mr John Dunning, Consultant Cardiothoracic Surgeon, Papworth Hospital NHS Trust, Cambridge	Mr George Levy, Chief Executive, Motor Neurone Disease Association, Northampton	Dr Ken Stein, Senior Lecturer in Public Health, Peninsular Technology Assessment Group, University of Exeter
Ms Tracy Bury, Head of Research & Development, Chartered Society of Physiotherapy, London	Mr Jonothan Earnshaw, Consultant Vascular Surgeon, Gloucestershire Royal Hospital, Gloucester	Professor James Lindesay, Professor of Psychiatry for the Elderly, University of Leicester	
Mr Michael Clancy, Consultant in A & E Medicine, Southampton General Hospital	Professor Gene Feder, Professor of Primary Care R&D, St Bartholomew's & the London, Queen Mary's School of Medicine & Dentistry, University of London	Professor Rajan Madhok, Medical Director & Director of Public Health, North & East Yorkshire & Northern Lincolnshire Strategic Health Authority, York	
Professor Collette Clifford, Professor of Nursing & Head of Research, School of Health Sciences, University of Birmingham	Professor Richard Johanson, Consultant & Senior Lecturer, North Staffordshire Infirmary NHS Trust, Stoke-on-Trent (deceased Feb 2002)	Dr Mike McGovern, Senior Medical Officer, Heart Team, Department of Health, London	

continued

## Expert Advisory Network

### Members

Mr Gordon Aylward,  
Chief Executive,  
Association of British  
Health-Care Industries,  
London

Mr Shaun Brogan,  
Chief Executive,  
Ridgeway Primary Care Group,  
Aylesbury, Bucks

Mr John A Cairns,  
Reader in Health Economics,  
Health Economics  
Research Unit,  
University of Aberdeen

Professor Nicky Cullum,  
Director of Centre for  
Evidence-Based Nursing,  
University of York

Dr Katherine Darton,  
Information Unit,  
MIND – The Mental  
Health Charity, London

Professor Carol Dezateux,  
Professor of  
Paediatric Epidemiology,  
Institute of Child Health,  
London

Professor Pam Enderby,  
Dean of Faculty of Medicine  
Institute of General Practice  
& Primary Care,  
University of Sheffield

Mr Leonard R Fenwick,  
Chief Executive,  
Freeman Hospital,  
Newcastle-upon-Tyne

Professor David Field,  
Professor of  
Neonatal Medicine,  
The Leicester Royal  
Infirmary NHS Trust

Mrs Gillian Fletcher,  
Antenatal Teacher &  
Tutor & President,  
National Childbirth  
Trust, Henfield,  
West Sussex

Ms Grace Gibbs,  
Deputy Chief Executive  
Director for Nursing,  
Midwifery & Clinical  
Support Services,  
West Middlesex  
University Hospital,  
Isleworth, Middlesex

Dr Neville Goodman,  
Consultant Anaesthetist,  
Southmead Hospital, Bristol

Professor Robert E Hawkins,  
CRC Professor & Director  
of Medical Oncology,  
Christie Hospital NHS Trust,  
Manchester

Professor F D Richard Hobbs,  
Professor of Primary Care  
& General Practice,  
University of Birmingham

Professor Allen Hutchinson,  
Director of Public Health &  
Deputy Dean of SchARR,  
University of Sheffield

Professor David Mant,  
Professor of General Practice,  
Institute of Health Sciences,  
University of Oxford

Professor Alexander Markham,  
Director,  
Molecular Medicine Unit,  
St James's University Hospital,  
Leeds

Dr Chris McCall,  
General Practitioner,  
The Hadleigh Practice,  
Corfe Mullen, Dorset

Professor Alistair McGuire,  
Professor of Health Economics,  
London School of Economics,  
University of London

Dr Peter Moore,  
Freelance Science Writer,  
Ashtead, Surrey

Dr Andrew Mortimore,  
Consultant in Public  
Health Medicine,  
Southampton City Primary  
Care Trust

Dr Sue Moss,  
Associate Director,  
Cancer Screening  
Evaluation Unit,  
Institute of Cancer Research,  
Sutton, Surrey

Mrs Julietta Patnick,  
National Coordinator,  
NHS Cancer  
Screening Programmes,  
Sheffield

Professor Chris Price,  
Director of Clinical Research,  
Bayer Diagnostics Europe,  
Stoke Poges, Berks

Ms Marianne Rigge,  
Director, College of Health,  
London

Dr William Rosenberg,  
Senior Lecturer &  
Consultant in Medicine,  
University of Southampton

Professor Ala Szczepura,  
Director, Centre for  
Health Services Studies,  
University of Warwick

Dr Ross Taylor,  
Senior Lecturer,  
Department of General  
Practice & Primary Care,  
University of Aberdeen

Mrs Joan Webster,  
Consumer member,  
HTA – Expert  
Advisory Network





### **Feedback**

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (<http://www.nchta.org>) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

***We look forward to hearing from you.***

Copies of this report can be obtained from:

The National Coordinating Centre for Health Technology Assessment,  
Mailpoint 728, Boldrewood,  
University of Southampton,  
Southampton, SO16 7PX, UK.  
Fax: +44 (0) 23 8059 5639    Email: [hta@soton.ac.uk](mailto:hta@soton.ac.uk)  
<http://www.nchta.org>